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A B S T R A C T
Background
Decision aids prepare people to participate in ’close call’ decisions that involve weighing benefits, harms, and scientific uncertainty.
Objectives
To conduct a systematic review of randomised controlled trials (RCTs) evaluating the efficacy of decision aids for people facing difficult
treatment or screening decisions.
Search strategy
We searched MEDLINE (Ovid) (1966 to July 2006); Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane
Library; 2006, Issue 2); CINAHL (Ovid) (1982 to July 2006); EMBASE (Ovid) (1980 to July 2006); and PsycINFO (Ovid) (1806 to
July 2006). We contacted researchers active in the field up to December 2006. There were no language restrictions.
Selection criteria
We included published RCTs of interventions designed to aid patients’ decision making by providing information about treatment or
screening options and their associated outcomes, compared to no intervention, usual care, and alternate interventions. We excluded
studies in which participants were not making an active treatment or screening decision, or if the study’s intervention was not available
to determine that it met the minimum criteria to qualify as a patient decision aid.
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Data collection and analysis
Two review authors independently screened abstracts for inclusion, and extracted data from included studies using standardized forms.
The primary outcomes focused on the effectiveness criteria of the International Patient Decision Aid Standards (IPDAS) Collaboration:
attributes of the decision and attributes of the decision process. We considered other behavioural, health, and health system effects as
secondary outcomes. We pooled results of RCTs using mean differences (MD) and relative risks (RR) using a random effects model.
Main results
This update added 25 new RCTs, bringing the total to 55. Thirty-eight (69%) used at least one measure that mapped onto an IPDAS
effectiveness criterion: decision attributes: knowledge scores (27 trials); accurate risk perceptions (11 trials); and value congruence with
chosen option (4 trials); and decision process attributes: feeling informed (15 trials) and feeling clear about values (13 trials).
This review confirmed the following findings from the previous (2003) review. Decision aids performed better than usual care inter-
ventions in terms of: a) greater knowledge (MD 15.2 out of 100; 95% CI 11.7 to 18.7); b) lower decisional conflict related to feeling
uninformed (MD -8.3 of 100; 95% CI -11.9 to -4.8); c) lower decisional conflict related to feeling unclear about personal values (MD
-6.4; 95% CI -10.0 to -2.7); d) reduced the proportion of people who were passive in decision making (RR 0.6; 95% CI 0.5 to 0.8);
and e) reduced proportion of people who remained undecided post-intervention (RR 0.5; 95% CI 0.3 to 0.8). When simpler decision
aids were compared to more detailed decision aids, the relative improvement was significant in knowledge (MD 4.6 out of 100; 95%
CI 3.0 to 6.2) and there was some evidence of greater agreement between values and choice.
In this review, we were able to explore the use of probabilities in decision aids. Exposure to a decision aid with probabilities resulted in
a higher proportion of people with accurate risk perceptions (RR 1.6; 95% CI 1.4 to 1.9). The effect was stronger when probabilities
were measured quantitatively (RR 1.8; 95% CI 1.4 to 2.3) versus qualitatively (RR 1.3; 95% CI 1.1 to 1.5).
As in the previous review, exposure to decision aids continued to demonstrate reduced rates of: elective invasive surgery in favour of
conservative options, decision aid versus usual care (RR 0.8; 95% CI 0.6 to 0.9); and use of menopausal hormones, detailed versus
simple aid (RR 0.7; 95% CI 0.6 to 1.0). There is now evidence that exposure to decision aids results in reduced PSA screening, decision
aid versus usual care (RR 0.8; 95% CI 0.7 to 1.0) . For other decisions, the effect on decisions remains variable.
As in the previous review, decision aids are no better than comparisons in affecting satisfaction with decision making, anxiety, and health
outcomes. The effects of decision aids on other outcomes (patient-practitioner communication, consultation length, continuance,
resource use) were inconclusive.
There were no trials evaluating the IPDAS decision process criteria relating to helping patients to recognize a decision needs to be
made, understand that values affect the decision, or discuss values with the practitioner.
Authors’ conclusions
Patient decision aids increase people’s involvement and are more likely to lead to informed values-based decisions; however, the size of
the effect varies across studies. Decision aids have a variable effect on decisions. They reduce the use of discretionary surgery without
apparent adverse effects on health outcomes or satisfaction. The degree of detail patient decision aids require for positive effects on
decision quality should be explored. The effects on continuance with chosen option, patient-practitioner communication, consultation
length, and cost-effectiveness need further evaluation.
P L A I N L A N G U A G E S U M M A R Y
Decision aids to help people who are facing health treatment or screening decisions
Making a decision about the best option to manage health can be difficult. Getting information on the options and the possible benefits
and harms in the form of decision aids may help. Decision aids, such as pamphlets and videos that describe options, are designed
to help people understand the options, consider the personal importance of possible benefits and harms, and participate in decision
making. They are used when there is more than one medically reasonable option - no option has a clear advantage in terms of health
outcomes, each has benefits and harms that people value differently. The updated review of trials found that decision aids improve
people’s knowledge of the options, create accurate risk perceptions of their benefits and harms, reduce difficulty with decision making,
and increase participation in the process. They may have a role in preventing use of options that informed patients don’t value without
adversely affecting health outcomes. They did not seem to have an effect on satisfaction with decision making or anxiety.
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B A C K G R O U N D
Many health treatment and screening decisions have no single
’best’ choice. These types of decisions are considered ’close calls’
because there is scientific uncertainty about outcomes or there is
a need to trade off known benefits and harms. In 2005, Clinical
Evidence classified 47% of treatments as having insufficient evi-
dence and 8% of its treatments as ’tradeoffs between benefits and
harms’ (Godlee 2005).
To prepare people to discuss close call decisions with their practi-
tioner, patient decision aids have been developed (Deber 1994a;
Deber 1994b; Gafni 1998 Deber 1994a; Deber 1994b; Martin
2002; RTI 1997). Decision aids differ fromusual health education
materials because of their detailed, specific, and personalized fo-
cus on options and outcomes for the purpose of preparing people
for decision making. In contrast, health education materials are
broader in perspective, helping people to understand their diag-
nosis, treatment, and management in general terms, but not nec-
essarily helping them to participate in decision making.
According to the International Patient Decision Aids Standards
(IPDAS) Collaboration (Elwyn 2006; IPDAS 2005a; Elwyn
2006), patient decision aids are evidence-based tools designed to
prepare clients to participate in making specific and deliberated
choices among healthcare options in ways they prefer. Patient de-
cision aids supplement (rather than replace) clinician’s counselling
about options. The specific aims of decision aids and the type of
decision support they provide may vary slightly, but in general
they:
1. provide evidence-based information about a health
condition, the options, associated benefits, harms, probabilities,
and scientific uncertainties;
2. help patients to recognize the values-sensitive nature of the
decision and to clarify, either implicitly or explicitly, the value
they place on the benefits, harms, and scientific uncertainties.
Strategies that may be included in the decision aid are: describing
the options in enough detail that clients can imagine what it is
like to experience the physical, emotional, and social effects; and
guiding clients to consider which benefits and harms are most
important to them; and
3. provide structured guidance in the steps of decision making
and communication of their informed values with others
involved in the decision (e.g. clinician, family, friends).
Decision aids can be used before, during, or after the clinical en-
counter to enable patients to become active, informedparticipants.
Decision aids are being developed in several centres, primarily in
North America, Europe, and Australia. Since 1999, there has been
a rapid proliferation of patient decision aids; in 2006, decision
aids from large scale producers were accessed over 8 million times
(O’Connor 2007). In response to concerns about variability in
quality of patient decision aids, the IPDAS Collaboration reached
agreement on criteria for judging their quality (Elwyn 2006).More
than 100 researchers, practitioners, patients, and policy makers
from 14 countries participated. Participants addressed three do-
mains of quality: clinical content, development process, and eval-
uation of a patient decision aid’s effectiveness.
The ultimate goal of patient decision aids is to improve decision
making. Over the past decade, there has been considerable debate
about the definition of a ’good decision’, when there is no single
’best’ therapeutic action and choices depend on how patients value
benefits versus harms (Briss 2004; O’Connor 2003a; O’Connor
1997b; Ratliff 1999; Sepucha 2004). IPDAS reached agreement
on criteria for judging “the things that you would need to observe
in order to say that after using a patient decision aid, the way
the decision was made was good, and that the choice that was
made was good” (Elwyn 2006; IPDAS 2005b). The criteria were
as follows:
• Decision: There is evidence that the patient decision aid
improves the match between the chosen option and the features
that matter most to the informed patient.
• Decision process: There is evidence that the patient
decision aid helps patients to: recognize that a decision needs to
be made; know options and their features; understand that values
affect the decision; be clear about the option features that matter
most; discuss values with their practitioner; and become involved
in preferred ways.
Several individual trials examining the efficacy of decision aids
have been published. There are annotated bibliographies, reports,
and general reviews of decision aids (Bekker 1999; Bekker 2003;
RTI 1997 Estabrooks 2000; Molenaar 2000; O’Connor 1997a;
O’Connor 1999c; RTI 1997; Whelan 2002; Bekker 2003). We
published the first systematic review of 17 randomised trials of
decision aids in 1999 (O’Connor 1999b), followed by an update
on 35 trials in 2003 (O’Connor 2003b).
O B J E C T I V E S
To conduct a systematic review of randomised controlled trials
evaluating the efficacy of decision aids for people facing difficult
treatment or screening decisions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included all published studies using a randomised controlled
trial (RCT) design comparing decision aids to no intervention,
usual care, alternative interventions, or a combination.
Types of participants
We included studies involving people who were making decisions
about screening or treatment options for themselves, for a child,
or for an incapacitated significant other. We excluded studies in
which participants were making hypothetical choices.
Types of interventions
Decision aids were defined as interventions designed to help peo-
ple make specific and deliberative choices among options (includ-
ing the status quo) by providing (at the minimum) information
on the options and outcomes relevant to a person’s health status
and implicit methods to clarify values. The aid also may have
included: information on the disease/condition; costs associated
with options; probabilities of outcomes tailored to personal health
risk factors; an explicit values clarification exercise; information on
others’ opinions; a personalized recommendation on the basis of
clinical characteristics and expressed preferences; and guidance or
coaching in the steps of decision making and in communicating
with others.
We excluded studies if interventions focused on: decisions about
lifestyle changes, clinical trial entry, or general advance directives
(e.g. do not resuscitate); education programs not geared to a spe-
cific decision; and interventions designed to promote adherence
to or to elicit informed consent regarding a recommended option.
We also excluded studies whose interventions were not available
to determine that they provided the minimum criteria to qualify
as a patient decision aid.
Types of outcome measures
Evaluation of outcomes depends on the framework used to de-
velop the decision aids (RTI 1997 Charles 1997; Entwistle 1998;
Llewellyn-Thomas’95; Makoul 2006; Mulley 1995; O’Connor
1998b; Rothert 1987; RTI 1997; Ruland 2002; Stacey 2007;
Whitney 2003). To ascertain whether the decision aids achieved
their objectives, we examined a broad range of positive or nega-
tive effects. Although the decision aids focused on diverse clinical
decisions, many had similar objectives such as improving knowl-
edge, accurate risk perceptions and participation in decision mak-
ing. Many of these evaluation criteria mapped onto the IPDAS
criteria for evaluating the effectiveness of decision aids. A total list
of outcomes, specified in advance of the review, included:
Primary outcomes
Evaluation criteria which map onto the IPDAS criteria
• Attributes of the decision: There is evidence that the patient
decision aid improves the match between the chosen option and
the features that matter most to the informed patient (including
outcomes such as knowledge, accurate risk perceptions, and
value congruence with chosen option).
• Attributes of the decision process: There is evidence that
the patient decision aid helps patients to: recognize that a
decision needs to be made; know the options and their features;
understand that values affect the decision; be clear about the
option features that matter most; discuss values with their
practitioner; and become involved in preferred ways.
Other decision making process variables
• Decisional conflict.
• Patient-practitioner communication.
• Participation in decision making.
• Satisfaction.
Secondary outcomes
Behaviour
• Decisions (proportion undecided, option selected).
• Adherence to chosen option.
Health outcomes
• Health status and quality of life (generic and condition-
specific).
• Anxiety, depression, emotional distress, regret, confidence.
Healthcare system
• Patients’ and physicians’ satisfaction.
• Costs, cost effectiveness.
• Consultation length.
• Litigation rates.
Search methods for identification of studies
Our search strategy for the review included:
1. searching electronic medical and social science databases;
and
2. contacting known developers and evaluators through a
shared decision making list-serve and e-mail contacts up to
December 2006.
We searched the following electronic databases: MEDLINE
(Ovid) (1966 to July 2006); Cochrane Central Register of Con-
trolled Trials (CENTRAL, The Cochrane Library; 2006, Issue 2);
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CINAHL (Ovid) (1982 to July 2006); EMBASE (Ovid) (1980 to
July 2006); and PsycINFO (Ovid)(1806 to July 2006).We present
the search strategies in Appendices.
Data collection and analysis
This update differed from our previous Cochrane reviews (
O’Connor 2001b; O’Connor 2003b) by focusing on the new IP-
DAS criteria. Moreover, we used new systematic review software,
TrialStat SRS, to manage the search and data extraction; there-
fore our search, screen and data collection procedures were redone
completely. Two review authors (CB, SK,DS,AO, orVF) screened
all reports of RCTs and extracted data independently using Tri-
alStat SRS 3.0 software. No review author screened or extracted
data from any of their own studies. We resolved inconsistencies by
discussion and consensus. Wherever possible, we obtained miss-
ing data from the authors. Risk of bias was assessed by two review
authors independently (CB, SK, DS, AO, or VF) using the Jadad
scale (Jadad 1996) plus the criterion of allocation concealment.
We described study results individually. There were planned com-
parisons between groups receiving: a) usual care versus decision
aids; and b) simpler versus detailed decision aids. For studies in
which there was more than one intervention group and one con-
trol group, we extracted data from the two groups that provided
the strongest contrast. For example, the group that used the most
detailed decision aid was compared with those who used the least
detailed decision aid, or received usual care.
We pooled results across studies in cases where: a) similar outcome
measures were used; and b) the effects were expected to be in-
dependent of the type of decision studied. For example, decision
aids were expected to improve knowledge of options, benefits and
harms; to create realistic expectations of benefits/harms; to reduce
decisional conflict; and to enhance active participation in deci-
sion making. Therefore, we pooled data from the RCTs for these
outcomes, if comparable measures were used. When analysing the
effects of decision aids on choices, we pooled outcomes on more
homogenous subgroups of decisions (preference for major surgery
versus conservative options; PSA testing or not; menopause hor-
mone therapy or not; etc.). In addition, we analysed studies com-
paring usual care to decision aids separately from studies compar-
ing simple to more detailed decision aids.
We used Review Manager 4.2 (2003) to estimate a weighted treat-
ment effect (with 95% confidence intervals). For continuous mea-
sures, we usedmeandifferences (MD); for dichotomous outcomes,
we calculated pooled relative risks (RR). We analysed all data with
a random effects model because of the diverse nature of the studies
being combined.
Due to statistically significant heterogeneity for most of the out-
comes, we performed post hoc sub-analyses to explore potential
sources of heterogeneity. Focusing on the IPDAS effectiveness cri-
teria, we explored heterogeneity according to the following fac-
tors: type of decision (treatment versus screening), type of media
of the decision aid (video/computer versus audio booklet/pam-
phlet), and possibility of a ceiling effect based on usual-care scores
(removal of studies with lower knowledge and realistic perceptions
scores; removal of studies with higher decisional conflict scores for
subscales feeling uninformed and unclear values). We analysed the
effect of removing the biggest outlier(s) (defined by visual inspec-
tion of forest plots). Additionally, we performed a post hoc analysis
to examine the effect of excluding trials of lower methodological
quality, and excluding trials that were outliers and contributing to
heterogeneity.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
We identified 22,778 unique citations from the electronic database
searches. Of these, only 1,293 citations focused on people’s deci-
sion making.
Of the 1,293 citations identified, 130 appeared to be evaluations
of interventions.We excluded 64 of these Sixty-four were excluded
upon close perusal of the paper. The reasons for exclusion were:
a) the study was not focused on making a choice (n = 33); b)
the study was not a randomised controlled trial (n = 14); c) the
intervention offered no decision support in the form of a decision
aid (n = 8); d) the decision was hypothetical with participants not
actually at a point of decision making (n = 6); e) no outcome data
were provided (n = 2); and protocol only (n = 1).
We identified 15ongoingRCTs (1 through the database search and
14 through personal contact) (see references to Ongoing studies,
and table Characteristics of ongoing studies).
Included studies
The remaining 66 citations provided data on 55 trials which
met our inclusion criteria. The 55 RCTs, presenting results from
seven countries (Australia, Canada, China, Finland, Netherlands,
United States, and the United Kingdom), evaluated 23 different
screening or treatment decisions.
The current version of our review updates our 2003 version (
O’Connor 2003b, which included 34 efficacy trials) with 25 new
trials (Auvinen 2004; Bekker 2004; Deschamps 2004; Frosch
2003;Gattellari 2003;Gattellari 2005;Green 2004;Hunter 2005;
Johnson 2006; Lalonde 2006; Laupacis 2006; Legare 2003; Leung
2004; McAlister 2005; Miller 2005; Montgomery 2003; Myers
2005a; Oakley 2006; Partin 2004; Shorten 2005; vanRoosmalen
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2004; Vuorma 2003; Whelan 2003; Whelan 2004; Wong 2006).
Four trials (Davison 1999; Maisels 1983; Michie 1997; Thornton
1995) that were included in the 2003 review were excluded from
this update, as the decision support intervention was not available
to determine whether it met the inclusion criteria - a requirement
for this update of the new IPDAS standards.
Unit of randomisation
All but four trials randomised individual patients. Goel 2001 ran-
domised 57 surgeons; Legare 2003 randomised 40 family physi-
cians; Whelan 2004 randomised 27 surgeons; andMcAlister 2005
randomised 102 primary care practices. For two studies (Goel
2001; Whelan 2004) the cluster effect was taken into account in
the published outcome data and the meta-analysis used published
results. For McAlister 2005, meta-analysis was done applying the
design effect (based on the published intracluster correlation co-
efficient (ICC)). For Legare 2003 the authors stated that for the
Decisional Conflict Scale results “Clustering had no impact on
individual scores of women and therefore, we present the results
without adjustment”. We were unable to obtain an ICC from
the authors so we conducted sensitivity analyses, varying the ICC
from 0.02 to a conservative 0.2 to calculate a design effect. There
was no substantial change in pooled estimate, so we have chosen
to present the outcome data as published.
Decision aids and comparisons
The 55 included RCTs evaluated 51 separate decision aids (Ad-
ditional Table 1). The decision aids used a variety of formats and
were compared to a variety of control interventions. We noted the
nature of usual care when reported. We describe briefly below the
types of decisions covered and comparisons that were made in the
included studies.
Table 1. Decision aids evaluated in the RCTs
Study Topic Availability Source Contact Information
Auvinen 2004 Prostate cancer treatment Yes Auvinen, Helsinki, Fin-
land, 1993
included in publication
Barry 1997 Benign prostate disease
treatment
Yes Foundation for Informed
Medical Decision Making
(FIMDM), Hanover NH,
US, 2001
www.healthdialog.com
Bekker 2004 Prenatal screening Yes Bekker, Leeds, UK, 2003 included in publication
Bernstein 1998 Ischaemic heart disease
treatment
Yes FIMDM, Hanover NH,
US, 2002
www.healthdialog.com
Clancy 1988 Hepatitis B Vaccine No Clancy, Richmond VA,
US, 1983
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Table 1. Decision aids evaluated in the RCTs (Continued)
Davison 1997 Prostate cancer treatment No Davison, Manitoba CA,
1992-1996
Deschamps 2004 Hormone replacement
therapy
No O’Connor, Ottawa, CA,
1996
Deyo 2000 Back surgery Yes FIMDM, Hanover NH,
US, 2001
www.healthdialog.com
Dodin 2001 Hormone replacement
therapy
No O’Connor, Ottawa, CA,
1996
Dolan 2002 Colon cancer screening No Dolan, RochesterNY,US,
1999
Dunn 1998 Infant vaccination sched-
ule
No Dunn, East Lansing MI,
US, 1998
Frosch 2003 Prostate cancer screening Yes FIMDM, Hanover NH,
1999
www.healthdialog.com
Gattellari 2003 Prostate cancer screening Yes Gatellari , Sydney, AU,
2003
included in publication
Gattellari 2005 Prostate cancer screening Yes Gatellari , Sydney, AU,
2003
included in publication
Goel 2001 Breast cancer surgery Yes Goel/Sawka, Toronto
CAN, 2001 www.breastcancersurgery.cancer.ca
Green 2001a Breast cancer genetic test-
ing
Yes Green, Hershey PA, US,
2000
1-800-757-4868
dwc@mavc.com
Green 2004 Breast cancer genetic test-
ing
Yes Green, Hershey PA, US,
2000
1-800-757-4868
dwc@mavc.com
Herrera 1983 Infant male circumcision No Herrera, Baltimore MD,
US, 1983
Hunter 2005 Prenatal screening No Hunter, Ottawa, CA,
2000
Johnson 2006 Endodontic treatment Yes Johnson, Chicago, US,
2004
Included in publication
Kennedy 2002 Abnormal uterine bleed-
ing treatment
No Kennedy/Coulter,
London UK, 1996
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Table 1. Decision aids evaluated in the RCTs (Continued)
Lalonde 2006 Cardiovascular health
treatment
Yes Lalonde, Ottawa, CA,
2002
www.decisionaid.ohri.ca
Laupacis 2006 Pre-operative autologous
blood donation
Yes Laupacis, Ottawa, CA,
2001
www.decisionaid.ohri.ca
Legare 2003 Hormone replacement
therapy
No O’Connor, Ottawa, CA,
1996
Lerman 1997 Breast cancer genetic test-
ing
No Lerman/Schwartz, Wash-
ington DC, US, 1997
Leung 2004 Prenatal screening No Leung, Hong Kong,
China, 2001
Man-Son-Hing 1999 Atrial fibrillation treat-
ment
Yes McAlister/Laupacis, Ot-
tawa CAN, 2000
www.decisionaid.ohri.ca
McAlister 2005 Atrial fibrillation treat-
ment
Yes McAlister/Laupacis, Ot-
tawa CAN, 2000
www.decisionaid.ohri.ca
McBride 2002 Hormone replacement
therapy
Yes, update in progress Sigler/Bastien, Durham
NC, US, 1998
basti001@mc.duke.edu
Miller 2005 BRCA1 BRCA2 gene
testing
No Miller, Fox Chase PA, US
Montgomery 2003 Hypertension treatment Yes Montgomery, UK, 2000 Included in publication
Morgan 2000 Ischaemic heart disease
treatment
Yes FIMDM, Hanover NH,
US, 2002
www.healthdialog.com
Murray 2001a Benign prostate disease
treatment
Yes FIMDM, Hanover NH,
US, 2001
www.healthdialog.com
Murray 2001b Hormone replacement
therapy
No, update in progress FIMDM, Hanover NH,
US,
www.healthdialog.com
Myers 2005a Prostate cancer screening Yes Myers, Philadelphia PA,
US, 1999
Included in publication
O’Connor 1998a Hormone replacement
therapy
No O’Connor, Ottawa CA,
1996
O’Connor 1999a Hormone replacement
therapy
No O’Connor, Ottawa CA,
1996
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Table 1. Decision aids evaluated in the RCTs (Continued)
Oakley 2006 Osteoporosis treatment Yes Cranney, Ottawa CA,
2002
www.decisionaid.ohri.ca
Partin 2004 Prostate cancer screening Yes FIMDM, Hanover NH,
US, 2001
www.healthdialog.com
Phillips 1995 Dental orthognathic
surgery
Yes, commercial Phillips, Chapel Hill NC,
US, 1995 Ceib˙Phillips@DENTISTRY.UNC.EDU
Pignone 2000 Colon cancer screening Yes Pignone, ChapelHill NC,
US, 1999
www.med.unc.edu/
medicine/edusrc/
colon.htm
Rostom 2002 Hormone replacement
therapy
No O’Connor, Ottawa CA,
1996
Rothert 1997 Hormone replacement
therapy
No, update in progress Rothert, East Lansing MI,
US, 1999
Schapira 2000 Prostate specific antigen
testing
Yes Schapira, Milwaukee WI,
US, 1995
mschap@mcw.edu
Schwartz 2001 Breast cancer genetic test-
ing
No Schwartz/Lerman, Wash-
ington DC, US, 1997
Shorten 2005 Birthing options after
previous caesarean
Yes (updated 2006) Shorten, Wollongong,
AU, 2000
Street 1995 Breast cancer surgery No Street, College Station
TX, US, 1995
vanRoosmalen 2004 BRCA1/2mutation: pro-
phylactic surgery
Yes vanRoosmalen,
Netherlands, 1999
see publication
Volk 1999 Prostate specific antigen
testing
Yes FIMDM, Hanover NH,
US, 1999
www.healthdialog.com
Vuorma 2003 Menorrhagia treatment No Vuorma, Helsinki Fin-
land, 1996
Whelan 2003 Breast cancer chemother-
apy
Yes Whelan, Hamilton CA,
1995
included in publication
Whelan 2004 Breast cancer surgery Yes Whelan, Hamilton CA,
1997
http://
www.fhs.mcmaster.ca/
slru/sccru/
decisionboard.html
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Table 1. Decision aids evaluated in the RCTs (Continued)
Wolf 1996 Prostate specific antigen
testing
Yes Wolf, Charlottesville VA,
US, 1996
Script in publication
Wolf 2000 Colon cancer screening Yes Wolf, Charlottesville VA,
US, 2000
Script in publication
Wong 2006 Pregnancy termination No Wong, Nottingham UK,
2002
a) Prostate specific antigen (PSA) screening
Three of the eight PSA studies compared a decision aid to usual
care: Volk 1999 used a 20 minute video plus a brochure on PSA
screening;Wolf 1996 used scripted information onPSA screening;
and Gattellari 2003 used a 32-page pamphlet.
Gattellari 2005 used the same 32-page pamphlet in a later study,
comparing it to both usual care and a group receiving a 20-minute
video on testing for prostate cancer. Partin 2004 compared a 23-
minute video to both usual care and an information pamphlet.
Schapira 2000 compared a detailed decision aid that included
quantitative and qualitative information on the risks and benefits
of screening with a simple decision aid that had similar content
but did not include this information. Frosch 2003 compared a
23-minute video to an internet-based decision aid which mirrored
the content of the video. Myers 2005a compared an informa-
tion booklet and a decision education intervention (that included
values clarification, guidance and coaching) to the informational
booklet alone.
b) Prenatal screening
Two of three studies compared a detailed to a simple decision aid:
Hunter 2005 compared an audio-guided decision aid to individ-
ual counselling and group counselling; and Leung 2004 compared
a interactive multimedia decision aid to a video and pamphlet.
Bekker 2004 compared routine consultation augmented with de-
cision analysis to routine counselling alone.
c) Colon cancer screening
All three studies compared a decision aid to usual care. Pignone
2000 provided the decision aid group with a videocassette, Wolf
2000 used scripted information read to the participants, andDolan
2002 used an analytic hierarchy process via computer.
d) Genetic testing
Green 2001a compared three groups: decision aid with coun-
selling, counselling alone, and usual care (women on a waiting list
served as a control group). In a later study, Green 2004 compared
two groups: the decision aid with counselling versus counselling
alone. Lerman 1997 compared a decision aid group (discussion
and counselling about BRCA1 gene testing) to usual care (women
on a waiting list who served as a control group). Schwartz 2001
compared general breast cancer information (usual care) to a book-
let decision aid about genetic testing. Miller 2005 compared an
enhanced educational intervention to provision of general infor-
mation about cancer risk (standard care).
e) Hepatitis B vaccination/screening
Clancy 1988 compared a handout and personal decision analysis
to usual care.
f) Prostate cancer treatment
Davison 1997 compared a consultation, audiotape, and five hand-
outs about prostate cancer treatment options to usual care recipi-
ents who were provided with general information. Auvinen 2004
compared a pamphlet decision aid to standard care by a clinical
guideline.
g) Benign prostate disease treatment
Barry 1997 and Murray 2001a compared an interactive videodisc
about benign prostate disease treatment with usual care. In Barry
1997 men in the control group were provided with general infor-
mation, while men in the Murray 2001a trial usual care group did
not receive written information.
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h) Hormone replacement therapy (HRT)
Two of the nine HRT trials (McBride 2002; Murray 2001b) com-
pared a decision aid to usual care, with McBride 2002 using a
booklet format and Murray 2001b using an interactive videodisc.
SevenHRTtrials compared a detailed decision aid that included all
of the design elements (options/outcomes, clinical problem, prob-
abilities of outcomes, values clarification, other’s opinions, and
guidance in decision making and/or communicating) to a simple
decision aid that briefly outlined options and outcomes along with
some information about the clinical problem. O’Connor 1998a
and Dodin 2001 provided the detailed decision aid group with an
audio-guided workbook; O’Connor 1999a compared an audio-
guided decision aid with values clarification and others’ opinions
to one without values clarification; Rothert 1997 used a combina-
tion of a group lecture, handouts and a personal decision exercise;
Rostom 2002 compared an audio booklet to a computer version
with the same information that also provided feedback to correct
misunderstanding of information; Legare 2003 compared and au-
dio-guided decision aid to a general information pamphlet on the
benefits and side effects of HRT; and Deschamps 2004 compared
an audio-guided decision aid to a 40-minute pharmacist consul-
tation.
i) Ischaemic heart disease
Both studies of ischaemic heart disease compared a decision aid to
a usual care. Morgan 2000 used an interactive videodisc with the
decision aid group and Bernstein 1998 used a videocassette.
j) Male newborn circumcision
Herrera 1983 compared a pamphlet with a discussion to usual
care.
k) Back surgery
Deyo 2000 compared a detailed decision aid (an interactive video
plus booklet) to a simple decision aid (booklet alone) for back
surgery.
l) Breast cancer surgery
Two studies compared a detailed to a simple decision aid. Street
1995 provided the decision aid group with an interactive multi-
media presentation and Goel 2001 used an audio-guided work-
book. A third study, Whelan 2004, compared a decision board to
usual care.
m) Prophylactic surgery for BRCA1/2 mutation
vanRoosmalen 2004 compared a video and brochure with and
without values clarification for women who have tested positive
for the BRCA1/2 gene, considering prophylactic surgery.
n) Breast cancer chemotherapy
Whelan 2003 compared a decision board to a general information
booklet on adjuvant chemotherapy for women with breast cancer.
o) Atrial fibrillation treatment
Both Man-Son-Hing 1999 and McAlister 2005 compared an au-
dio-guided workbook decision aid to usual care.
p) Dental orthognathic surgery
Phillips 1995 compared a video imaging of facial reconstruction
outcomes to usual care.
q) Dental endodontic treatment
Johnson 2006 compared a decision board to usual care.
r) Infant vaccination schedules
Dunn 1998 compared a video plus pamphlet on vaccination
schedule choices for infants to usual care recipients who were pro-
vided with general information.
s) Treatment for abnormal uterine bleeding
In the context of treatment for abnormal uterine bleeding,
Kennedy 2002 compared three interventions: a) video plus book-
let and coaching by a nurse; b) video plus booklet alone; and c)
usual care. Vuorma 2003 compared a booklet decision aid to usual
care.
t) Obstetrical decisions
Shorten 2005 compared a booklet decision aid to usual care for
women considering birthing options after a previous cesarean sec-
tion. Wong 2006 compared a decision aid leaflet to a placebo
leaflet for women considering pregnancy termination methods.
u) Cardiovascular risk management
For patients newly diagnosed with hypertension considering drug
therapy, Montgomery 2003 compared four group: decision analy-
sis and informational video and leaflet, decision analysis alone, in-
formational video and leaflet, and usual care. Lalonde 2006 com-
pared a booklet and personal worksheet decision aid to a personal
risk profile and informational book in patients diagnosed with hy-
pertension or dyslipidaemia considering drug therapy or lifestyle
changes.
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v) Osteoporosis treatment
Oakley 2006 compared an audio-guided decision aid to usual care
for treatment options to prevent further bone loss.
w) Pre-operative autologous blood donation
For patients undergoing open heart surgery and considering pre-
operative autologous blood donation, Laupacis 2006 compared
an audio-guided decision aid booklet to usual care.
By definition, all of the patient decision aids included information
about the options and outcomes and implicit values clarification.
Most patient decision aids included information on the clinical
problem (95%) as well as outcome probabilities (85%). Fewer pa-
tient decision aids included examples of others’ experiences (62%),
and less than half included explicitmethods to clarify values (49%)
or provided extra guidance in the steps of decision making (47%).
(see table Characteristics of included studies).
The comparison interventions ranged from no intervention
through to usual care, and general information through to simpler
decision aids that varied in their number of elements. However,
most simple decision aids provided information about the clini-
cal problem, options, and outcomes. (see table Characteristics of
included studies).
Risk of bias in included studies
Weused the Jadad scale (Jadad1996) and the criterionof allocation
concealment to assess study quality. The Jadad scale allocates two
points to randomisation, two points to blinding, and one point to
the description of withdrawals. Allocation concealment provides
an assessment of howwell the allocation schedule was hidden. The
break down of the quality scores for each study can be found in the
table Characteristics of included studies. All included studies were
described as RCTs (mean randomisation score = 1.6 out of 2, SD
= 0.6). None of the studies were blinded which would be expected
given the nature of the interventions. Documentation of loss to
follow up was generally good (mean follow-up score = 0.7 out of
1, SD = 0.5). The overall mean quality score for the 55 included
studies was 2.2 out of 5 (SD = 0.9). If blinding were eliminated
from the total score, the overall mean quality score would be 2.2
out of 3.
Effects of interventions
At additional Table 2 we provide a summary of the pooled data
from the RCTs; see also Additional tables 1 to 6 for outcome data
not pooled, and the Data and analyses section.
Table 2. Summary of pooled outcomes
Outcome Type of Com-
parison
Number of
Studies
N for Main In-
tervention
N for Compari-
son
Effect size (95%
CI)
Statistical Sig-
nificance
Knowledge
Knowledge
(0 to 100 scale) (
Analysis 1.1)
DA vs usual care 18 1708 1783 MD 15.18
(11.66 to 18.69)
P < 0.00001*
Knowledge
(0 to 100 scale) (
Analysis 2.1)
Detailed vs sim-
ple DA
9 627 634 MD 4.63 (3.02
to 6.24)
P < 0.00001*
Decisional conflict: DA versus usual care
Decisional Con-
flict (0 to 100
scale) - Total (
Analysis 1.2.6)
DA vs usual care 10 918 932 MD-6.12 (-8.62
to -3.63)
P < 0.00001*
Decisional Con-
flict - Uncer-
tainty subscale (
Analysis 1.2.1)
DA vs usual care 12 1149 1184 MD-0.94 (-3.29
to 1.40)
P = 0.43
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Table 2. Summary of pooled outcomes (Continued)
Decisional
Conflict - Unin-
formed subscale
(Analysis 1.2.2)
DA vs usual care 10 906 933 MD -8.31 (-
11.85 to -4.78)
P < 0.00001*
Decisional Con-
flict - Unclear
values subscale (
Analysis 1.2.3)
DA vs usual care 8 710 723 MD -6.35 (-
10.02 to -2.67)
P = 0.0007*
Decisional Con-
flict - Unsup-
ported subscale (
Analysis 1.2.4)
DA vs usual care 8 712 721 MD -5.97 (-
10.40 to -1.55)
P = 0.008*
Decisional Con-
flict - Ineffective
choice subscale (
Analysis 1.2.5)
DA vs usual care 11 1005 1060 MD-5.69 (-8.93
to -2.46)
P = 0.0006*
Decisional conflict: Detailed vs simple DA
Decisional Con-
flict (0 to100
scale) - Total (
Analysis 2.2.6)
Detailed vs sim-
ple DA
7 526 497 MD-1.34 (-3.33
to 0.64)
P = 0.19
Decisional Con-
flict - Uncer-
tainty subscale (
Analysis 2.2.1)
Detailed vs sim-
ple DA
7 443 422 MD-2.43 (-8.58
to 3.72)
P = 0.44
Decisional
Conflict - Unin-
formed subscale
(Analysis 2.2.2)
Detailed vs sim-
ple DA
5 322 290 MD-1.32 (-5.27
to 2.62)
P = 0.51
Decisional Con-
flict - Unclear
values subscale (
Analysis 2.2.3)
Detailed vs sim-
ple DA
5 319 290 MD-1.05 (-4.81
to 2.70)
P = 0.58
Decisional Con-
flict - Unsup-
ported subscale (
Analysis 2.2.4)
Detailed vs sim-
ple DA
5 324 290 MD-0.80 (-3.77
to 2.17)
P = 0.6
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Table 2. Summary of pooled outcomes (Continued)
Decisional Con-
flict - Ineffective
choice subscale (
Analysis 2.2.5)
Detailed vs sim-
ple DA
5 324 289 MD-0.04 (-3.93
to 3.86)
P = 0.99
Participation in decision making
Participation
in decision mak-
ing (DM) - Pa-
tient controlled (
Analysis 1.3.1)
DA vs usual care 7 550 556 RR 1.65 (1.02 to
2.65)
P = 0.04*
Participation in
DM - Shared (
Analysis 1.3.2)
DA vs usual care 7 550 565 RR 0.99 (0.78 to
1.25)
P = 0.93
Participation
in DM - Practi-
tioner controlled
(Analysis 1.3.3)
DA vs usual care 8 630 647 RR 0.61 (0.45 to
0.82)
P = 0.0009*
Behaviour: Remaining undecided
Remain-
ing undecided (
Analysis 1.6)
DA vs usual care 4 516 516 RR 0.51 (0.34 to
0.75)
P = 0.0006*
Remain-
ing undecided (
Analysis 2.5)
Detailed vs sim-
ple
2 148 144 RR 1.04 (0.66 to
1.62)
P = 0.87
Preference or uptake of option: DA versus usual care
Preference or up-
take of option
- Surgery (ITT
analysis, Analysis
1.7.2)
DA vs usual care 8 1028 1041 RR 0.75 (0.60 to
0.94)
P = 0.01*
Preference or up-
take of option -
Prostate Specific
Antigen testing (
Analysis 1.8)
DA vs usual care 5 726 716 RR 0.80 (0.66 to
0.98)
P = 0.03*
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Table 2. Summary of pooled outcomes (Continued)
Preference or up-
take of option -
Colon
cancer screening
(Analysis 1.9)
DA vs usual care 3 435 300 RR 1.14 (0.70 to
1.85)
P = 0.59
Preference or up-
take of option
- Breast cancer
genetic testing (
Analysis 1.10)
DA vs usual care 4 448 501 RR 1.01 (0.83 to
1.22)
P = 0.94
Preference or uptake of option: Detailed versus simple DA
Preference or up-
take of option
- Surgery (ITT
analysis, Analysis
2.5.2)
Detailed vs sim-
ple DA
2 220 233 RR 0.78 (0.57 to
1.07)
P = 0.12
Preference or up-
take of option -
Prostate Specific
Antigen testing (
Analysis 2.6)
Detailed vs sim-
ple DA
3 336 341 RR 0.97 (0.81 to
1.17)
P = 0.78
Preference or up-
take of option
- Hormone re-
place-
ment therapy (
Analysis 2.7)
Detailed vs sim-
ple DA
3 181 176 RR 0.73 (0.55 to
0.98)
P = 0.04*
Preference or up-
take of option
- Prenatal diag-
nostic testing (
Analysis 2.8)
Detailed vs sim-
ple DA
2 216 227 RR 0.94 (0.85 to
1.04)
P = 0.22
Accurate risk perceptions
Accurate
risk perceptions (
Analysis 3.1)
DA with out-
comes and prob-
abilities vs no
outcome proba-
bilities
11 1504 1449 RR 1.61 (1.35 to
1.92)
P < 0.00001*
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Table 2. Summary of pooled outcomes (Continued)
Accurate
risk perceptions (
Analysis 3.2)
- Numbers 8 994 1017 RR 1.81 (1.43 to
2.29)
P < 0.00001*
Accurate
risk perceptions (
Analysis 3.3)
- Words 3 510 432 RR 1.27 (1.09 to
1.48)
P = 0.002*
MD: mean difference.
RR: relative risk.
CI: confidence interval.
IPDAS attributes of the decision: whether the patient
decision aid improves the match between the chosen
option and the features that matter most to the
informed patient.
The RCTs used three measures which correspond to this defini-
tion: knowledge test results, accuracy of risk perceptions, and value
congruence with the chosen option.
Knowledge
Twenty-seven of the 55 studies examined the effects of decision
aids on knowledge; 18 of these compared decision aids to usual
care and 9 compared detailed decision aids to simple decision aids.
The studies’ knowledge tests were based on information contained
in the decision aid, thereby establishing content validity. The pro-
portion of accurate responses was transformed to a percentage scale
ranging from 0% (no correct responses) to 100% (perfectly accu-
rate responses). The results are reported separately for the com-
parison of decision aids to usual care and the comparison of deci-
sion aids with detailed information to simpler decision aids. One
additional study, Partin 2004, used a previously validated 10-item
prostate cancer knowledge index to assess patient’s prostate cancer
screening knowledge. Patients in the decision aid group scored
moderately higher on the index than control group patients (see
Table 3).
Table 3. Other outcome measures
Study Scale Used Timing N Decision
Aid
DA - mean N Compari-
son
Comparison -
mean
Notes
Knowledge
Partin 2004 10-item
knowledge in-
2 weeks 308 7.44 290 6.9 P = 0.001
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Table 3. Other outcome measures (Continued)
dex score
Expectations
Phillips 1995 Ex-
pectations 18-
item scalewith
response range
-3 to +3
2 weeks 37 78% 37 62% DA sig (P =
0.045) higher
self-image ex-
pectation. No
difference (P >
0.13) for oral
function, gen-
eral well-
being, general
health. Hav-
ing a higher
expectation
was not neces-
sarily correct.
Laupacis 2006 Re-
alistic expecta-
tion of out-
comes 8-item
questionnaire
(0 to 100)
average 10
days
47 21.5 (18.1
SD)
50 7.0 (7.6 SD) P = 0.001
Street 1995 Optimism
8-item instru-
ment (range 8
to 40)
post-
intervention
30 34.1 (change
from baseline
+0.3)
30 33.8 (change
from baseline
+0.8)
No difference.
The more
women know
about their
treat-
ment options,
the more posi-
tive they were.
Value congruence with chosen option
Rothert 1997 Correlation
between ex-
pected utilities
and their like-
lihood of tak-
ing hormones
------ ------ ------ ------ ------ Simple DA
showed
lower correla-
tions between
expected value
of hormones
and likelihood
of taking hor-
mones
than did more
detailed DA
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Table 3. Other outcome measures (Continued)
O’Connor
1999a
De-
gree to which
personal val-
ues discrimi-
nated between
the choices
women made
immediately
after
101 65%
(48.7%SD)
100 67% (48.5%
SD)
No difference
between
groups in dis-
crimination of
personal val-
ues amongst
choices;
in small group
accepting
HRT, there
was a non-sig-
nificant trend
toward bet-
ter discrimina-
tion (P = 0.06)
in the values
clarification
group (40%)
than the con-
trol (0%)
Dodin 2001 Congru-
ence between
personal val-
ues and de-
cision 4-items
using a 0 to 10
scale
post DA 52 23% 49 14% P = 0.003
Lerman 1997 Association
between val-
ues and choice
No difference;
between
group differ-
ences were not
reported
Decisional Conflict Score - Patient/Physician Agreement
Legare 2003 DCS / Dolan’s
Provider De-
cision Process
Assessment
Instrument
immediately
post
97 ICC 0.44 (0.9
SD)
87 ICC 0.28 (1.0
SD)
Decision Making Preference
Barry 1997 15-item sub-
scale of Au-
tonomy Pref-
erence Index
6, 12 months 104 40.4 (6
months), 39.0
(12 months)
123 40.4 (6
months), 39.3
(12 months)
No difference
(P = 0.69)
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Table 3. Other outcome measures (Continued)
to measure in-
terest in par-
ticipating
Satisfaction
Miller 2005 Satisfac-
tionwithCan-
cer Informa-
tion Service 1-
item (1 to 5;
low to high)
2 weeks 4.37 (0.84
SD)
4.38 (0.86
SD)
no difference
6 months 4.51 (0.75
SD)
4.51 (0.64
SD)
no difference
Deschamps
2004
Satisfaction
with Prepara-
tion for De-
cision Making
(10-item)
Post-physician
consult
48 28 (6.1 SD) 42 27(5.5 SD) ns
Oakley 2006 Satisfaction
with Informa-
tion about
Medicines (0-
17; low-high)
4 months post 16 10.4 (2.9 SD) 17 10.1 (2.2 SD) ns
Hunter 2005 Sat-
isfaction with
genetic coun-
selling
11-item short
form (range 4
to 44; low to
high)
immediately
post
116 37.27 (5.74
SD)
126 40.48 (4.26
SD)
P < 0.001
Satisfaction - Decision Making Process
Deyo 2000 7-item scale (5
point
response)
3 months 171 separate
responses pro-
vided with no
total
172 separate
responses pro-
vided with no
total
No difference
ex-
cept DA more
likely to re-
port they had
as much infor-
mation as they
wanted
and less likely
to report hav-
ing re-
lied too much
19Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Other outcome measures (Continued)
on physician’s
opinion
Man-Son-
Hing 1999
6-item
survey using a
5-point Likert
scale
1 to 4 days 146 83.75%
(14.79)
138 84.75%
(13.04)
No difference
Laupacis 2006 informa-
tion subscale
4-item (0 to
100; low to
high)
average 10
days
54 76 (15.5 SD) 56 59 (23.3 SD) P = 0.001
Laupacis 2006 practitioner
treatment sub-
scale 4-item (0
to 100; low to
high)
average 10
days
54 69 (25.3 SD) 56 54 (26.7 SD) P = 0.004
Green 2004 Ef-
fectiveness of
consultation -
patient assess-
ment.
Single item 1
(not at all ef-
fective) to 7
(extremely ef-
fective)
106 6.6 105 6.6 No difference
Green 2004 Ef-
fectiveness of
consultation -
counsellor as-
sessment. Sin-
gle item 1 to 7
5.9 5.8 No difference
Satisfaction - Decision
Deschamps
2004
6-item 3 months 46 85.0 (12.5) 41 82.5 (15.0) ns
Rothert 1997 6-item scale
(measured on
1 to 5)
1 day 83 4.0 (0.56) 89 3.8 (0.66) No difference
6 months 63 3.8 (0.63) 75 3.8 (0.67) No difference
12 months 62 3.9 (0.62) 74 3.9 (0.67) No difference
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Table 3. Other outcome measures (Continued)
Laupacis 2006 1-item (0 to
100; low to
high)
average 10
days
54 73 (21.7) 56 61 (25.4) P = 0.015
Deschamps
2004
6-item 3 months 46 85.0 (12.5) 41 82.5 (15.0) ns
Volk 1999 6-item 1 year 70 24.3 (2.8) 67 23.8 (3.8) ns
Confidence
McBride 2002 Confidence
with ability to
understand
outcomes
of HRT, make
a decision, en-
gage in discus-
sion with
practitioner 3-
items (0 to 10;
low to high
confidence)
1 month post 273 78% (18%
SD)
284 70% (19%
SD)
P < 0.0001
9 months post 261 80%
(17%SD)
278 75% (20%
SD)
P = 0.0004
Rothert 1997 8-items
(1 to 10; low
to high confi-
dence)
post DA 83 78% (16%
SD)
89 80% (19%
SD)
No difference
12 months
post
63 78% (15%
SD)
74 80% (19%
SD)
No difference
Gattellari
2003
Perceived abil-
ity to make an
informed
choice 1-item;
5-point Likert
scale
3 days post 106 108 P = 0.008; DA
group
more likely to
agree that they
could make an
informed
choice about
PSA screening
Gattellari
2005
Perceived abil-
ity to make an
informed
choice 1-item;
5-point Likert
scale
Immediately
post
131 136 No difference
Healthcare system effects
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Table 3. Other outcome measures (Continued)
Deyo 2000 Healthcare use 1 year 171 ------ 172 ------ No difference
in most ser-
vices; DA
less surgery for
herniated disk
Bekker 2004 Consul-
tation length
(minutes)
50 32.2 (13.0
SD)
56 26.3 (11.5
SD)
P = 0.01
Green 2004 Consul-
tation length
(minutes)
106 82 105 90 P = 0.03
Whelan 2003 Consul-
tation length
(minutes)
50 68.3 50 65.7 P = 0.53
In the comparison of patient decision aids to usual care (Barry
1997; Bekker 2004; Bernstein 1998; Dunn 1998; Gattellari 2003;
Gattellari 2005; Green 2001a; Johnson 2006; Laupacis 2006;
Lerman 1997;Man-Son-Hing 1999;Montgomery 2003;Morgan
2000; Schwartz 2001; Shorten 2005; Volk 1999; Whelan 2003;
Wong 2006), people exposed to decision aids had higher average
knowledge scores (MD 15.2%; 95% CI 11.7 to 18.7; Analysis
1.1). The nine studies comparing detailed to simpler patient de-
cision aids (Dodin 2001; Goel 2001; Hunter 2005; O’Connor
1998a; Rostom 2002; Deyo 2000; Rothert 1997; Street 1995;
Schapira 2000) showed a smaller statistically significant beneficial
effect (MD 4.6%; 95% CI 3.0 to 6.2; Analysis 2.1).
Accurate risk perceptions (i.e. perceived probabilities of
outcomes)
Eleven of 55 studies examined the effects of including probabilities
in decision aids on the accuracy of patients’ perceived probabilities
of outcomes. Eight studies measured perceived probabilities as
percentages (Dodin 2001; Gattellari 2003; Man-Son-Hing 1999;
McAlister 2005;McBride 2002; O’Connor 1998a;Whelan 2003;
Whelan 2004) and three gauged probabilities in words (Lerman
1997; Schapira 2000; Wolf 2000).
Perceived outcome probabilities were classified according to the
percentage of individuals whose judgments corresponded to the
scientific evidence about the chances of an outcome for simi-
lar people. In three out of four studies that elicited expectations
for multiple outcomes (Dodin 2001; McAlister 2005; O’Connor
1998a), the proportion of realistic expectations was averaged; in
the remaining study (Man-Son-Hing 1999), the most conserva-
tive result was chosen for meta-analysis.
People who received a detailed patient decision aid with descrip-
tions of outcomes and probabilities were more likely to have ac-
curate risk perceptions than those who did not receive this infor-
mation; the pooled relative risk (RR) of having accurate risk per-
ceptions was 1.6 (95% CI 1.4 to 1.9; Analysis 3.1). There was a
trend towards a stronger effect when probabilities were measured
quantitatively versus qualitatively. The pooledRR for probabilities
described as numbers was 1.8 (95% CI 1.4 to 2.3; Analysis 3.2).
The pooled RR for probabilities described in words was 1.3 (95%
CI 1.1 to 1.5; Analysis 3.3).
Value congruence with chosen option
Four of 55 studies measured value congruence with chosen op-
tion; however, Lerman (Lerman 1997) did not calculate differ-
ences between interventions. The three trials comparing interven-
tions were similar in that they: a) focused on the decision to take
menopausal hormone replacement therapy (HRT); and b) com-
pared two active interventions. However, these trials used differ-
entmeasures of value congruence.Holmes-Rovner (Rothert 1997)
measured the correlation between the subjective expected value of
hormones and women’s likelihood of taking HRT, converted here
to percent of variance in likelihood explained by values. Dodin
2001 measured the percentage of variance in decisions explained
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by values. O’Connor 1999a used logistic regression to estimate
the percentage agreement between values and choice.
Patient decision aids improved value congruence with chosen op-
tion in two of three studies. In Dodin 2001, 24% of the variance
in HRT decisions was explained by personal values when a de-
tailed decision aid with explicit values clarification was used; in
contrast 14% of the variance in decisions was explained when a
simpler decision aid was used (P = 0.003). In the study byHolmes-
Rovner (Rothert 1997), the percentage of variance in likelihood of
choosing HRT that was explained by women’s expected values was
greater when a more detailed decision aid was used (13 to 14%)
than when a simpler decision aid was used (0.1 to 2%). O’Connor
(O’Connor 1999a) found that the addition of an explicit values
clarification exercise in a decision aid did not improve agreement
between values and chosen option. However, in the subgroup of
women who chose HRT, women who used the decision aid with
explicit values clarification had a trend toward better agreement
(40%) than those who used an identical decision aid without ex-
plicit values clarification (0%), P = 0.06.
IPDAS attributes of the decision process: whether the
patient decision aid helps patients to: recognize that a
decision needs to be made; know the options and
their features; understand that values affect the
decision; be clear about the option features that
matter most; discuss values with their practitioner;
and become involved in preferred ways.
In relation to the IPDAS decision process criteria, no trials eval-
uated the extent to which patient decision aids helped patients
to: recognize that a decision needs to be made, understand that
values affect the decision, or discuss values with their practitioner.
Although eight trials evaluated the effects on patient participation,
none focused on helping patients become involved in preferred
ways.
Some studies measured patients’ self-reports about feeling in-
formed and clear about personal values. The measures used to
evaluate these two criteria were two subscales of the previously
validated Decisional Conflict Scale (DCS) (O’Connor 1995).
Decisional conflict
Seventeen studies evaluated decisional conflict using the DCS (
O’Connor 1995). The DCS is reliable, discriminates between
those who make or delay decisions, is sensitive to change, and
discriminates between different decision support interventions (
Morgan 2000; O’Connor 1995; O’Connor 1998a). The scale
measures the constructs of uncertainty and factors contributing
to uncertainty (such as feeling uninformed, unclear about values,
and unsupported in decision making). A final subscale measures
perceived effective decision making. The scores were standardized
to range from zero (no decisional conflict) to 100 points (extreme
decisional conflict). Scores of 25 or lower are associated with fol-
low-through with decisions, whereas scores that exceed 38 are as-
sociated with delay in decision making (O’Connor 1998a).When
decision aids are compared to usual care, a negative score indicates
a reduction in decisional conflict, which is in favour of the deci-
sion aid.
Analysis 1.2.6 summarizes the decisional conflict results for the
10 studies that compared decision aids to usual care (Dolan
2002; Laupacis 2006; Man-Son-Hing 1999; McAlister 2005;
Montgomery 2003;Morgan 2000;Murray 2001a;Murray 2001b;
Shorten 2005; Whelan 2004) and Analysis 2.2.6 summarises the
results for the 7 studies that compared detailed to simple deci-
sion aids (Dodin 2001; Goel 2001; Hunter 2005; Lalonde 2006;
Legare 2003; O’Connor 1998a; O’Connor 1999a).
Among the 17 studies, the decision aids were significantly bet-
ter at reducing total decisional conflict in 8 studies: 7 compar-
ing decision aids to usual care (Laupacis 2006; McAlister 2005;
Montgomery 2003;Murray 2001a;Murray 2001b; Shorten 2005;
Whelan 2004) and 1 comparing detailed to simple decision aids
(O’Connor 1998a). Reductions ranged from -2.5 to -17.1 out of
100. Smaller reductions ranging from -1.5 to -5.0 out of 100 were
noted in 5 trials but were not statistically significant: 2 comparing
decision aids to usual care (Dolan 2002; Man-Son-Hing 1999)
and 3 comparing detailed versus simple decision aids (Goel 2001;
Hunter 2005; Legare 2003). Morgan 2000 showed no difference
between decision aids and usual care andDodin 2001 and Lalonde
2006 showed no difference between detailed and simple decision
aids. When a decision aid with values clarification was compared
to the same decision aid without values clarification (O’Connor
1999a), there was a small increase of 2.5 in total decisional conflict
but it was not statistically significant. The overallMDwas -6.1 out
of 100 points for decision aid/usual care comparisons (95% CI -
8.6 to -3.6; Analysis 1.2.6) and -1.3 for detailed/simple decision
aid comparisons (95% CI -3.3 to 0.6; Analysis 2.2.6).
Fifteen trials used the DCS subscale for feeling informed and 13
trials used the DCS subscale for feeling clear abut values. Because
this DCS subscale measures self-reported comfort with knowledge
and not actual knowledge, we elected to consider it a process mea-
sure and to reserve the gold standard of objective knowledge tests
in assessing decision quality.
TheMD in feeling uninformed about options, benefits, and harms
was -8.3 (95% CI -11.9 to -4.8; Analysis 1.2.2) in the ten trials
that compared patient decision aids to usual care (Bekker 2004;
Dolan 2002; Laupacis 2006; Man-Son-Hing 1999; McAlister
2005; Montgomery 2003; Morgan 2000; Murray 2001a; Murray
2001b; Wong 2006). The five trials that compared detailed with
simpler patient decision aids (Dodin 2001; Goel 2001; Lalonde
2006; O’Connor 1998a; O’Connor 1998a) had a MD in feeling
uninformed of -1.3 (95% CI -5.3 to 2.6; Analysis 2.2.2).
Eight trials comparing patient decision aids to usual care (Dolan
2002; Laupacis 2006; Man-Son-Hing 1999; McAlister 2005;
Montgomery 2003;Morgan 2000;Murray 2001a;Murray 2001b)
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had a MD of -6.4 (95% CI -10.0 to -2.7) for feeling clear about
values (Analysis 1.2.3). Five trials compared detailed to simpler
decision aids (Dodin 2001; Goel 2001; Lalonde 2006; O’Connor
1998a; O’Connor 1999a). For these trials, theMD in feeling clear
about values was -1.1 (95% CI -4.8 to 2.7; Analysis 2.2.3).
Two trials measured the longer term effect of decision aids (com-
pared to usual care) on total decisional conflict, overall uncertainty,
factors contributing to uncertainty, and perceived effective deci-
sion making. In both trials, the statistically significant differences
observed at three months post intervention were maintained at
nine months (Murray 2001a; Murray 2001b).
Patient-practitioner communication
Legare 2003 measured agreement between physicians and women
on decisional conflict scores and found that the agreementmeasure
was higher for the decision aid group than for the controls.
Participation in decision making
Eight studies (Auvinen 2004; Davison 1997; Dolan 2002; Man-
Son-Hing 1999; Morgan 2000; Murray 2001a; Murray 2001b;
Whelan 2003) compared the effects of decision aids to usual care
in terms of participation in decision making (Analysis 1.3) and
one study (Deschamps 2004) compared a detailed decision aid to
a simpler one (Analysis 2.3). The Davison paper used the Control
Preferences Scale (Degner 1992). The scale measures the preferred
or actual role in decision making using five response statements:
two represent an active or patient controlled role, one a shared or
collaborative role, and two response statements represent a passive
or practitioner controlled role. The eight other studies used com-
parable response statements that could be classified within each of
the three groupings of the Control Preferences Scale. We present
data on actual role in decision making in this review.
Seven of these 9 studies showed a 16 to 70% reduction in the pro-
portion of people who assumed a passive (practitioner-controlled)
role in decisionmaking; in two trials this reductionwas statistically
significant (Auvinen 2004; Davison 1997) and in five it was not
(Deschamps 2004; Man-Son-Hing 1999; Morgan 2000; Murray
2001b; Whelan 2003). The other two studies showed a non-sig-
nificant increase (Dolan 2002; Murray 2001a). The pooled RR
comparing decision aids to usual care was 0.6 (95% CI 0.5 to
0.8; Analysis 1.3.3). A mirrored pattern emerged for individuals
assuming an active (patient-controlled) role in decision making.
Three of the nine studies (Auvinen 2004; Davison 1997; Murray
2001a) reported RRs ranging from 3.4 to 7.6, indicating a sig-
nificant impact on the assumption of the patient-controlled role,
three indicated an increase that was not statistically significant,
and there was a non-significant decrease for the other two studies.
The pooled RR for decision aid versus usual care was 1.7 (95%
CI 1.0 to 2.7; Analysis 1.3.1). The proportion adopting a shared
decision making role was more variable (decision aid versus usual
care pooled RR 1.0; 95% CI 0.8 to 1.3; Analysis 1.3.2).
One study (Barry 1997) found no significant difference between
the decision aid and usual care, using a 15-item decision-making
preference subscale of the previously validated Autonomy Prefer-
ence Index (Ende 1989) (see Table 3).
Satisfaction
Six out of 11 studies found improvements in satisfaction with: the
decision; process of decision making; opportunities to participate
in decision making; and/or outcomes.
Satisfaction with the decision making process was measured in
6 trials. Three trials comparing the decision aid to usual care (
Barry 1997; Bernstein 1998; Morgan 2000) used the 12-item val-
idated questionnaire (Barry 1997) (Analysis 1.4). The scores were
standardized to a 0 to 100 point scale, with higher scores reflect-
ing greater satisfaction. One of these three studies (Barry 1997)
demonstrated that decision aids significantly improved satisfac-
tion with the decision making process by 5 points out of 100.
Morgan 2000 showed an improvement of 2 points out of 100 and
Bernstein 1998 showed a worsening of satisfaction by 3 points of
100 but neither of these results were statistically significant.
Three other studies (Deyo 2000; Laupacis 2006; Man-Son-Hing
1999) evaluated satisfaction with the process of decision making,
using differentmeasures (see Table 3). Deyo 2000 foundmixed re-
sults, with separate itemsmeasuring satisfaction; results for two out
of the nine items were statistically significantly different, with the
decision aid group reporting higher levels of satisfaction. Laupacis
2006 found statistically significant greater satisfaction with deci-
sion aids over usual care, on two scales measuring satisfaction with
information and satisfaction with practitioner treatment. Man-
Son-Hing 1999 found no statistically significant difference be-
tween groups (MD 1% ).
Nine trials measured satisfaction with the decision. Three trials (
Barry 1997; Bernstein 1998; Morgan 2000) used the three-item
validated Satisfaction with Decision Made questionnaire (Barry
1997) (Analysis 1.5). The scores were standardized to a 0 to 100
point scale, with higher scores reflecting greater satisfaction. The
differences between decision aids and usual care for individual’s
satisfaction with the decision ranged from 2.5 to -5.0 out of 100
and were not statistically significantly different. In 4 of 6 other tri-
als using different measures to evaluate satisfaction with the deci-
sion (see Table 3), there were no statistically significant differences
between decision aids and comparison interventions (Deschamps
2004; Deyo 2000; Rothert 1997; Volk 1999). McBride 2002 and
Laupacis 2006 found that the decision aid group was statistically
significantly more satisfied (5% and 12% MD respectively).
Kennedy 2002 measured satisfaction with opportunities to par-
ticipate in decision making and with overall results of treatment,
using two single item questions. Compared to usual care, women
who received the decision aid followed by nurse coaching were
statistically significantly more satisfied with the opportunities to
participate in decision making (OR 1.5; 95% CI 1.1 to 2.0) and
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more satisfied with their results of treatment (OR 1.4; 95% CI
1.0 to 2.0). Deschamps 2004 evaluated satisfaction with prepa-
ration for decision making using a 10-item scale. There was no
statistically significant difference between the decision aid group
or the control group participants who received a 40-minute phar-
macist consultation. Oakley 2006 and Miller 2005 used specific
measures of satisfaction with information and found no difference
between groups. Lastly, Hunter 2005, found a small but statisti-
cally significant higher satisfaction with genetic counselling score
for those who received individual counselling versus a decision aid.
(See Table 3).
Behaviour
Proportion undecided
Four studies comparing decision aids to usual care reported on
the proportion of people who remained undecided post interven-
tion. Three of these studies (Man-Son-Hing 1999;Murray 2001b;
Vuorma 2003) showed statistically significantly lower proportion
in the decision aid group (Analysis 1.6). For individuals consid-
ering warfarin post atrial fibrillation, 1% of those in the decision
aid group remained undecided, compared to 6% of those who re-
ceived usual care (Man-Son-Hing 1999). For women considering
HRT, 14% in the decision aid group, versus 26% in the usual care
group, remained undecided three months after using the decision
aid. A similar pattern was observed at the nine month follow-up,
with 6% versus 14% remaining undecided (Murray 2001b). In
Vuorma 2003 evaluating themenorrhagia decision aid, 4% of par-
ents in the decision aid group were undecided, versus 11% in the
usual care group. In Shorten 2005 for women considering vagi-
nal birth after previous cesarean section, 14% of women in the
decision aids group remained undecided versus 22% in the usual
care group. The pooled RR was 0.5 (95% CI 0.3 to 0.8). The tri-
als (Leung 2004; Deschamps 2004) comparing detailed decision
aids to simpler ones found no statistically significant differences
(pooled RR 1.0; 95% CI 0.7 to 1.6; Analysis 2.4).
Decisions: preferences and uptake of options
Forty-two trials assessed the effects of decision aids on the par-
ticipants’ preferred options (n = 19) or their uptake of options
(n = 23). Preferences or uptake of options were reported as the
percentage of individuals stating a preference for, or actually im-
plementing, the most intensive or most invasive option.
Ten trials focused on choices regarding major elective surgery.
Eight (Auvinen 2004; Barry 1997; Bernstein 1998; Kennedy
2002;Morgan 2000;Murray 2001a;Vuorma 2003;Whelan2004)
compared decision aids to usual care (Analysis 1.7) and two (
Deyo 2000; Street 1995) compared detailed to simple decision
aids (Analysis 2.5). Using intention-to-treat analysis, three trials
showed a statistically significant reductions in surgery rates: 29%
for cardiac revascularization (Morgan 2000); 74% formastectomy
(Whelan2004); and33%for prostatectomy (Auvinen 2004). Four
out of ten trials (Barry 1997; Bernstein 1998;Deyo2000;Kennedy
2002) showed reductions in uptake of the more intensive surgical
treatment by 18% to 42%, but the results were not statistically sig-
nificant.One study (Vuorma 2003) showed non-significant higher
rates of hysterectomy in the decision aid group (53%) compared
to usual care (49%) at 1 year post-intervention. Another study (
Murray 2001a), having less than 1% weight in the pooled results,
reported a non-significant 5-fold increase in uptake of prostatec-
tomy. There was no difference in the uptake rate of mastectomy in
Street 1995. There was a statistically significant reduction inmajor
elective surgery for decision aid compared to usual care (RR 0.8;
95% CI 0.6 to 0.9; Analysis 1.7.2) but the reduction for detailed
compared to simple decision aids was not statistically significant
(RR 0.8; 95% CI 0.6 to 1.1; Analysis 2.5.2). Using as-treated
analysis, the reduction in surgical rates were similar for decision
aid compared to usual care (RR 0.8; 95% CI 0.6 to 0.9; Analysis
1.7.1) and for detailed compared to simple decision aids (RR 0.8;
95% CI 0.6 to 1.0; Analysis 2.5.1).
Three trials evaluated the effect of decision aids versus usual care
on minor elective surgical decisions. Decision aids did not signifi-
cantly influence circumcision rates (Herrera 1983), surgical abor-
tion rates (Wong 2006), or preferences for dental orthognathic
surgery (Phillips 1995).
The effects of eight decision aids on Prostate Specific Antigen
(PSA) screening decisions were variable. In two out of five studies
comparing decision aids with usual care, there were significant
reductions in preference for screening by 23% and 42% (Volk
1999; Wolf 1996) (Analysis 1.8). Two studies (Gattellari 2005;
Partin 2004) showed reductions of 9% and 10% respectively, and
one study (Gattellari 2003) showed an increase of 10%; however,
these results were not statistically significant. The pooled RR was
0.8 (95% CI 0.7 to 1.0). Of the three studies that compared
a detailed and simpler decision aid (Analysis 2.6), there was a
statistically significant reduction of PSA screening by 11% in one
study (Frosch 2003); a non-significant reduction of 2% in a second
study (Schapira 2000); and a non-significant increase of 89% in
the third study (Myers 2005a). The pooled RR was 1.0 (95% CI
0.8 to 1.2).
In one of three studies of colon cancer screening, the decision aid
significantly increased uptake of screening by 64% (Pignone 2000)
compared to usual care. However, there was no significant impact
on preferences in another study (Wolf 2000), in which the relative
increment was 9%. In the third study, Dolan 2002, there was a
decrease in screening by 73% that was not statistically significant.
The pooled RR was not statistically significant (RR 1.1; 95% CI
0.7 to 1.9) (Analysis 1.9).
Preferences for breast cancer gene screening were not statistically
significantly affected when a decision aid was compared to usual
care. One study reported an increased uptake of screening by 14%
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(Lerman 1997), a second study reported an increase of 18% (
Green 2001a), a third study reported a decrease in uptake by 29%
(Schwartz 2001), the last study reported no difference (Green
2004). The pooled RRwas 1.0 (95%CI 0.8 to 1.2; Analysis 1.10).
The uptake of prenatal testing was not affected by a decision aid
compared to usual care (Bekker 2004, RR 1.1, 95% CI 0.9 to 1.2)
nor by a more complex decision aid compared to a simple decision
aid (Hunter 2005; Leung 2004; pooled RR 0.9, 95% CI 0.9 to
1.0; Analysis 2.8).
Preferences regarding hormone replacement therapy were affected
when a detailed decision aid was compared to a simple decision
aid, with a statistically significant decrease of 36% (Dodin 2001),
a decrease of 25% (Deschamps 2004) and an increase of 12% that
were not statistically significant (O’Connor 1998a). There was a
statistically significant reduction of 27% in uptake of hormone
replacement therapy of when these studies were pooled (RR 0.7;
95% CI 0.6 to 1.0; Analysis 2.7). In a single trial comparing a
decision aid to usual care (Murray 2001b), there was a decrease of
8% which was not statistically significant.
Two trials evaluated the effect of a decision aid on use of anti-
thrombotic therapy for atrial fibrillation versus usual care. One
trial demonstrated a non-significant reduction of uptake of war-
farin of 25% (Man-Son-Hing 1999). The second trial evaluated
the proportion of patients choosing the option that was appropri-
ate relative to their level of risk, and found no significant difference
between the groups (McAlister 2005).
Montgomery 2003 found no significant effect of decision aids
over usual care on the uptake of medication for hypertension, and
Whelan 2003 also found no significant effect on preference for
adjuvant chemotherapy for breast cancer.
In three other studies comparing decision aids to usual care, there
was a statistically significant increase in uptake of Hepatitis B
vaccinationby 76%(Clancy 1988), but no effect onpreferences for
vaginal birth following previous cesarean section (Shorten 2005)
or on the uptake of pre-operative autologous blood donation (
Laupacis 2006).
Continuance (adherence) with chosen option
Five studies measured continuance with the chosen option or ad-
herence. Three of these studies compared decision aids to usual
care (Man-Son-Hing 1999;Oakley2006;Montgomery 2003) and
two compared detailed to simpler decision aids (Deschamps 2004;
Rothert 1997). Man-Son-Hing 1999, comparing an audiotape
booklet decision aid to usual care, measured continuance with the
chosen option (warfarin versus aspirin) at six months and found
no significant difference between the groups. Oakley 2006 com-
pared an audiotape booklet decision aid to usual care; there was
no difference between the groups in adherence to oral bisphos-
phonate medication at 4 months. Montgomery 2003 compared
four groups: decision analysis plus informational video and leaflet;
decision analysis; informational video; and usual care. There was
no difference for any of the interventions in adherence to blood
pressure medication at three years. The two studies which com-
pared a detailed to a simpler decision aid measured adherence to
hormone replacement therapy at 12 months: Rothert 1997 com-
pared an informational lecture and personal decision exercise to a
pamphlet and Deschamps 2004 compared an audiotape booklet
decision aid to a pharmacist consultation. Neither study found a
difference between the decision aid and comparison group (Table
4).
Table 4. Continuance (adherence) with chosen option
Reference Timing N Decision Aid Mean (SD) Deci-
sion Aid
N Comparison Mean (SD)Com-
parison
Notes
DA versus usual care
Oakley 2006 4 months 16 10.4% (32) [im-
provement from
baseline]
17 2% (26) [improve-
ment from base-
line]
Not significant
Man-Son-Hing
1999
6 months 129 95.35% 134 93.28% P = 0.44
Montgomery
2003
~ 3 years No difference
Detailed versus simpler DA
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Table 4. Continuance (adherence) with chosen option (Continued)
Rothert 1997 12 months 62 ~89% 74 ~89% No difference
Deschamps
2004
12 months 16 ~72% 20 ~72% No difference
Health outcomes
General health outcomes
Seven studies compared a decision aid to usual care in terms of
general health outcomes. Six of these (Barry 1997; Bernstein 1998;
Kennedy 2002; Morgan 2000; Murray 2001a; Murray 2001b)
used the previously validated Medical Outcomes Study 36-item
Short-Form Health Survey (SF-36) or the 12-item Short-form
Health Survey (SF-12) (Stewart 1992); and, one study (Vuorma
2003) used the RAND-36 (Hays 1993). As shown in Table 5,
there were no significant differences for mental health function
or social function in all seven studies. In one study (Barry 1997),
general health and physical function outcome scores were signifi-
cantly better in the decision aid group compared to usual care for
men considering treatments for benign prostatic disease. Of the
two studies evaluating the effect of a decision aid for women con-
sidering treatment for abnormal uterine bleeding, Kennedy 2002
found a statistically significant improvement in role physical func-
tion and Vuorma 2003 found a statistically significant improve-
ment in emotional role functioning for women.
Table 5. General health outcomes
Reference Timing N Decision
Aid
Mean DA
(SD)
Change
from Base-
line
N Compar-
ison
Mean Com-
parison
(SD)
Change
from Base-
line
Notes
General health
Barry 1997
(SF-36)
Baseline 104 67.2 (19.0) 123 71.1 (17.6) P = 0.02
3 months -0.96 (1.41) -3.59 (1.57)
6 months -1.46 (1.41) -4.93 (1.45)
12 months 0.61 (1.58) -4.99 (1.44)
Morgan
2000 (SF-
36)
6 months
post
72 62 (23) +4.0 88 65 (20) +7.0 No
difference
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Table 5. General health outcomes (Continued)
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
Vuorma
2003
(RAND-36)
1 year 156 2.2 159 2.8 No
difference
Physical function
Barry 1997
(SF-36)
Baseline 104 81.9 (20.0) 123 83.0 (18.9) P = 0.02
3 months -0.34 (1.61) -1.81 (1.07)
6 months 0.10 (1.28) -3.26 (1.37)
12 months 0.15 (1.40) -3.74 (1.18)
Bernstein
1998 (SF-
12)
3 months
post
61 38 (12.1) +0.6 48 37.6 (10.6) +3.8 No
difference
Morgan
2000 (SF-
36)
6 months
post
72 67 (29) +7.0 88 71 (24) +10.0 No
difference
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
Vuorma
2003
(RAND-36)
1 year 156 2.4 159 2.2 No
difference
Social function
Barry 1997
(SF-36)
Baseline 104 90.6 (15.5) 123 91.7 (15.7) P = 0.17
3 months 0.34 (1.58) -2.26 (1.36)
6 months -0.05 (1.92) -2.46 (1.45)
12 months -1.46 (1.85) -3.52 (1.71)
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
28Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. General health outcomes (Continued)
Vuorma
2003
(RAND-36)
1 year 156 5.2 159 7.1 No
difference
Mental function
Bernstein
1998 (SF-
12)
3 months
post
61 49.1 (11.4) 0.0 48 48.9 (10.8) +0.9 No
difference
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
Vuorma
2003
(RAND-36)
1 year 156 4.7 159 5.3 No
difference
Role function
Morgan
2000 (SF-
36)
6 months
post
72 62 (44) +20.0 88 58 (43) +15.0 No
difference
Kennedy
2002 (SF-
36)
2 years 176 157 P = 0.04
Vuorma
2003
(RAND-36)
1 year 9.2 6.3 No
difference
Bodily pain
Morgan
2000 (SF-
36)
6 months
post
72 81 (22) +6.0 88 77 (24) +5.0 No
difference
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
Vuorma
2003
(RAND-36)
1 year 156 6.5 159 6.2 No
difference
Role emotional
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Table 5. General health outcomes (Continued)
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
Vuorma
2003
(RAND-36)
1 year 156 12.6 159 1.9 P = 0.01
Energy/vitality
Kennedy
2002 (SF-
36)
2 years 176 157 No
difference
Vuorma
2003
(RAND-36)
1 year 156 8.9 159 8.8 No
difference
SF-36 all dimensions
Murray
2001b (SF-
36)
9 months 93 94 No
difference
Murray
2001a (SP-
36)
9 months 54 48 No
difference
Functional status
Deyo 2000
(Roland
Disability
Question-
naire)
1 year 171 20.4 +5.4 173 20.9 +5.7 No
difference
Health Utilities
Murray
2001a (Eu-
roqol EQ-
5D)
No
difference
Murray
2001b (Eu-
roqol EQ-
5D)
No
difference
Depression
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Table 5. General health outcomes (Continued)
Davison
1997 (20-
item Centre
for Epi-
demiology
Studies De-
presion
Scale (CES-
D))
5 to 6 weeks 30 29.8 -0.6 30 29.5 +1.3 No
difference
Whelan
2004 (20-
item CES-
D)
1 week post
DA
94 13.8 (1.0) 107 13.4 (1.1) No
difference
6 months
post DA
94 15.1 (1.1) 107 14.2 (1.2) No
difference
12 months
post DA
94 13.2 (1.3) 107 12.8 (1.2) No
difference
Deyo 2000, using the previously validated Roland Disabil-
ity Questionnaire (Roland 1983) to measure functional status in
patients with back pain, found no difference between the detailed
decision aid and simple decision aid groups.
In two studiesmeasuring health utilities using the Euroqol EQ-5D
(Murray 2001a; Murray 2001b), there was no difference between
the decision aid and usual care groups.
Condition-specific health outcomes
Seven studies (see Table 6) used various measures to assess con-
dition-specific health outcomes. Six of these compared decision
aids to usual care (Barry 1997; Bernstein 1998; Morgan 2000;
Murray 2001a; Murray 2001b; Vuorma 2003) and one compared
a detailed decision aid to a simple decision aid (Deyo 2000). Out-
comes included urinary symptoms (Barry 1997; Murray 2001a),
angina (Bernstein 1998; Morgan 2000), back pain (Deyo 2000),
menopausal symptoms (Murray 2001b), andmenstrual symptoms
(Vuorma 2003). Five of the 7 studies (Bernstein 1998; Morgan
2000; Murray 2001a; Murray 2001b; Vuorma 2003) found no
significant effects on condition-specific health outcomes. Deyo
2000 found no significant differences according to most measures
except for back pain severity for which improvement was shown,
one year later, in the decision aid group. Barry 1997 showed an
improvement in urinary symptoms in favour of the decision aid
group, but it was not statistically significant.
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Table 6. Condition-specific health outcomes
Study Outcome Scale Used Timing N Decision
Aid
DA mean
change
NCompari-
son
Compari-
son mean
change
Notes
Barry 1997 Urinary
symptoms
AUA Symp-
tom Index
(0 to 100)
3 months 104 -4.80%
(1.74)
117 -1.40%
(1.37)
No differ-
ence; trend
toward DA
Urinary
symptoms
AUA 6 months 104 -3.66%
(2.06)
117 -3.17%
(1.77)
No
difference
Urinary
symptoms
AUA 12 months 104 -2.51%
(2.11)
117 -4.14%
(1.66)
No differ-
ence; trend
toward con-
trol
Impact of
symptoms
BPU Impact
Index (0 to
100)
3 months 104 -6.58%
(1.10)
117 -3.00%
(1.05)
No differ-
ence; trend
toward DA
Impact of
symptoms
BPU 6 months 104 -4.37%
(1.32)
117 -3.89%
(1.16)
No differ-
ence; trend
toward DA
Impact of
symptoms
BPU 12 months 104 -5.53%
(1.32)
117 -2.63%
(1.32)
No differ-
ence; trend
toward DA
Bernstein
1998
Satisfaction Seattle
Angina
Question-
naire (SAQ)
(0 to 100)
3 months 61 +6.2% 48 +10.5% Control sig-
nif-
icantly more
satisfied
Angina sta-
bility
SAQ 3 months 61 +17.2% 48 +28.3% No
difference
Angina fre-
quency
SAQ 3 months 61 +5.5% 48 +15.3% No
difference
Disease Per-
ception
SAQ 3 months 61 +14.1% 48 +18.8% No
difference
Physical Ca-
pacity
SAQ 3 months 61 -0.5% 48 +7.1% No
difference
Deyo 2000 % working 1 year 171 +17.3% 173 +18.3% No
difference
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Table 6. Condition-specific health outcomes (Continued)
%missed 1+
day
work within
past month
1 year 171 -38.4% 173 -35.2% No
difference
Back pain
severity
1 year 171 -22.4% 173 -22% 1 year scores:
DA 27.6%
signifi-
cantly better
than control
37.2%
Leg pain
severity
1 year 171 -42.1% 173 -43.9% No
difference
Seek-
ing compen-
sation
1 year 171 -2.9% 173 -5.9% No
difference
Satisfied
with symp-
toms
1 year 171 +32.1% 173 +32.4% No
difference
Morgan
2000
No Angina Canadian
Cardiovas-
cular Angina
(CCVA)
6 months 72 +49% 88 +48% No
difference
Class I
Angina
CCVA 6 months 72 -1% 88 +6% No
difference
Class II
Angina
CCVA 6 months 72 -23% 88 -26% No
difference
Class III
Angina
CCVA 6 months 72 -26% 88 -28% No
difference
Class IV
Angina
CCVA 6 months 72 0% 88 0% No
difference
Murray
2001a
Urinary
symptoms
AUA symp-
tom Index
(0 to100)
No
difference
Murray
2001b
Menopausal
symptoms
MenQol No
difference
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Table 6. Condition-specific health outcomes (Continued)
Vuorma
2003
Inconve-
nience due
to menstrual
bleeding
(5 to 25) 1 year 156 10.4 159 10.5 No
difference
Menstrual
pain
(0 to 12) 1 year 156 4.7 159 4.6 No
difference
Anxiety
Thirteen studies measured state anxiety using the previously
validated 20-item State Anxiety Inventory (Spielberger 1970).
Eleven of these studies (Bekker 2004; Davison 1997; Green 2004;
Hunter 2005;Montgomery 2003;Murray 2001a; Murray 2001b;
Vuorma 2003; Whelan 2003; Whelan 2004; Wong 2006) in-
volved decision aid/usual care comparisons, and two (Goel 2001;
vanRoosmalen 2004) involved detailed/simple decision aid com-
parisons (Table 7). None of these studies demonstrated signifi-
cant differences in effects on people’s state anxiety. The study by
Johnson 2006 measured anxiety by response to a single seven-
point Likert scaled question and found no significant difference
between a group administered a decision board versus usual care (
Table 7).
Table 7. Anxiety
Study Timing N
Decision
Aid
Mean
DA (SD)
Change
from Base-
line
N
Compari-
son
MeanCom-
parison
(SD)
Change
from Base-
line
Notes
State Anxiety Inventory: <30 days post-intervention
Goel 2001;
breast can-
cer surgery
1 to 3 days
post DA
74 51.2 (14.2) -0.7 43 50.7 (14.8) -0.1 No
difference
Mont-
gomery
2003; hy-
pertension
immediately
post DA
44 35.45
(10.52)
50 37.67
(13.92)
No
difference
Whelan
2004; breast
cancer
surgery
7 days post
DA
94 42.3 (1.3) 107 41.9 (1.3) No
difference
34Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Anxiety (Continued)
Whelan
2003; breast
chemother-
apy
7 days post
DA
82 45.6 +2.2 93 47.4 +0.8 No
difference
Green 2004;
breast can-
cer screen-
ing (low risk
group)
Immedi-
ately post
56 29 -4 61 30 -3 P = 0.04 (for
difference in
change
score)
Green 2004;
breast can-
cer screen-
ing (high
risk group)
Immedi-
ately post
50 30 -3 44 33 -5 P = 0.04 (for
difference in
change
score)
Hunter
2005; pre-
natal screen-
ing
Immedi-
ately post
116 45.50 (9.69) -1.17 126 47.98
(10.14)
-0.37 No
difference
Wong 2006;
pregnancy
termination
Immedi-
ately post
154 54 (15.8) 159 54 (16.1)
Bekker
2004; pre-
natal screen-
ing
Immedi-
ately post
50 58.9 (16.6) 56 61.2 (13.7) No
difference
State Anxiety Inventory: 1 month post-intervention
Davison
1997;
prostate
cancer treat-
ment
5 to 6 weeks
post DA
30 35.5 -9.0 30 34.5 -2.5 No
difference
vanRoos-
malen
2004
1 month
post DA
43 35.4 (11.7) 43 37.4 (10.7) No
difference
Bekker
2004; pre-
natal screen-
ing
1 month
post DA
29 35.3 (12.5) 39 34.7(14.8) No
difference
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Table 7. Anxiety (Continued)
State Anxiety Inventory: 3 months post-intervention
Murray
2001a; BPH
3 months
post DA
55 36.36
(14.99)
+2.4 48 32.08
(9.836)
+0.7 No
difference
Murray
2001b;
HRT
3 months
post DA
93 38.42
(10.83)
-0.5 95 40.53
(12.96)
+1.8 No
difference
Vuorma
2003; men-
orrhagia
treatment
3 months
post DA
184 37.1 +1.0 179 35.9 -1.0 No
difference
Whelan
2003; breast
chemother-
apy
3 months
post DA
82 36.0 93 37.8 No
difference
State Anxiety Inventory: 6 months post-intervention
Goel 2001;
breast can-
cer surgery
6 months
post DA
59 36.6 (12.9) -15.3 39 34.3 (11.6) -16.5 No
difference
Whelan
2004; breast
cancer
surgery
6 months
post DA
94 39.3 (1.3) 107 38.9 (1.6) No
difference
Whelan
2003; breast
chemother-
apy
6 months
post DA
82 38.2 93 38.2 No
difference
State Anxiety Inventory: 12 months post-intervention
Whelan
2004; breast
cancer
surgery
12 months
post DA
94 37.5 (1.4) 107 36.6 (1.5) No
difference
Whelan
2003; breast
chemother-
apy
12 months
post DA
82 39.2 93 40.2 No
difference
Trait Anxiety
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Table 7. Anxiety (Continued)
Davison
1997;
prostate
cancer treat-
ment
5 to 6 weeks
post DA
30 34.5 -0.5 30 33.0 +2.5 No
difference
Single question 7-point Likert scale
Johnson
2006;
endodontic
treatment
Immedi-
ately post
32 3.2 (1.7) 35 3.8 (2.1) P = 0.27
Depression
Davison 1997 found no significant difference between groups for
depression at 5 to 6 weeks post-intervention, measured on the
previously validated 20-item Centre for Epidemiologic Studies
Depression Scale (Radloff 1977); nor didWhelan 2004 at 1 week,
6 months and 12 months post-intervention (Table 5).
Regret
One study (Goel 2001), comparing a simple decision aid to a de-
tailed decision aid, measured decisional regret on the 5-itemDeci-
sional Regret scale (O’Connor 2001a). There were no significant
differences between the groups (Table 8).
Table 8. Decisional regret
Author Item Decision Aid (n = 63) Control (n = 44) Notes
Goel 2001 Right decision 58 (92.06%) 42 (95.45%) No difference
Regret choice 8 (12.70%) 5 (11.36%) No difference
Would make same choice 54 (85.71%) 40 (90.91%) No difference
Choice did me harm 7 (11.11%) 3 (6.82%) No difference
Decision was wise 54 (85.71%) 41 (93.18%) No difference
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Confidence
Four trials measured the effect of decision aids on confidence
levels (Table 3). One trial measured participants’ confidence re-
lated to personal ability to understand the outcomes of HRT,
make a decision, and engage in discussion with their practitioner
(McBride 2002). The second trial measured confidence related
to actively participating in discussions with one’s practitioner (
Rothert 1997). The other two trials measured participants’ per-
ceived ability to make an informed choice regarding PSA screen-
ing (Gattellari 2003; Gattellari 2005). In McBride 2002, women
who used the decision aid had higher confidence scores at one
month post-intervention (78% versus 70%) than those who re-
ceived usual care. This difference was statistically significant. Fur-
thermore, the women in the decision aid group who were con-
fident were more likely to remain confident in their decision at
the nine month follow-up. Rothert 1997 found no difference in
women’s level of confidence when comparing more detailed to
simple decision aids. Gattellari 2003 found that menwho received
a decision aid regarding PSA screening were significantly more
likely to indicate that they were more able to make an informed
decision then men who received general information. However,
Gattellari 2005 found no difference between groups.
Healthcare system effects
Cost and resource use
Four trials evaluated the impact of decision aids compared to usual
care on cost and resource use (Kennedy 2002; Murray 2001a;
Murray 2001b; Vuorma 2003). Both trials by Murray involved a
cost-minimization economic analysis from the perspective of the
healthcare system decision-maker, with less than 4% of resource
use items being replaced by conditionalmeans due tomissing data.
There was no significant difference between the groups in terms of
health service resource use. There was a difference in costs, when
expensive interactive videodisc equipment was considered in the
analysis. However, if one substituted low cost internet access to
the decision aids, there was no significant difference in the cost.
The cost analysis in the Kennedy 2002 trial was also conducted
from the healthcare system perspective using 1999 to2000 US
dollars and calculated over 2 years. The decision aid with nurse
coaching had the lowest mean cost ($1566) compared to decision
aid alone ($2026) or usual care ($2751).
In the Vuorma 2003 trial, despite the statistically insignificant
trend for lower diagnostic procedures (55 versus 89, P = 0.07) and
lower uterine saving surgery procedures(16 versus 26, P = 0.08) in
the intervention group, there was no difference between the inter-
vention and control group when treatment cost and productivity
losses were analysed at the one year follow-up.
Consultation length
Three trials (Bekker 2004; Green 2004; Whelan 2003) evaluated
the effect of a decision aid on consultation length, with varied
results. Bekker 2004 found that, on average, consultation times
were about 6 minutes longer for women receiving decision anal-
ysis versus women receiving routine consultation for prenatal di-
agnostic testing. Green 2004 found that the average consultation
length was 8 minutes shorter for women who received a decision
aid prior to genetic counselling for breast cancer screening com-
pared to women who received routine genetic counselling. Both
of these results were statistically significant. Whelan 2003 did not
find a statistically significant difference in consultation length for
women considering adjuvant therapy for breast cancer who re-
ceived a decision board (68 minutes) versus standard counselling
(66 minutes; P = 0.5). (See Table 3).
Two trials evaluated the effect of decision aids on the quality of
the consultation session. Green 2004 evaluated both the practi-
tioner’s and the patient’s evaluation of consultation effectiveness
with a single seven-point Likert question. There was no differ-
ence between treatment and control groups with regard to both
the physician and the patient evaluations. Bekker 2004 evaluated
the perceived usefulness and directiveness of the consultation and
found no difference between intervention and control groups on
either of these outcomes.
None of the studies examined the effect of decision aids on litiga-
tion. As well, preference-linked health outcomes-that is, whether
the patients experienced the outcomes they preferred and avoided
the outcomes they did not prefer-were not evaluated.
Post hoc analysis
Effects of study quality
To examine the potential bias from including trials of lowmethod-
ological quality, the 13 trials (Barry 1997;Deschamps 2004;Green
2001a; Herrera 1983; Lerman 1997; McBride 2002; O’Connor
1998a; Oakley 2006; Phillips 1995; Rothert 1997; Schapira 2000;
Street 1995; Wolf 2000) with Jadad scores of 0 or 1 were excluded
from the analysis. Overall, the results remained the same. There
was a significant improvement in knowledge scores for the com-
parison of patient decision aids to usual care controls (MD 13.9%;
95% CI 10.2 to17.6) and for the comparison of detailed to sim-
pler patient decision aids (MD 5.5%; 95% CI 2.4 to 8.6). The
proportion of patients having accurate risk perceptions was greater
for patients receiving patient decision aids with information on
outcome probabilities (RR 2.0; 95% CI 1.4 to 2.8). However, we
no longer had pooled results for the comparison of detailed versus
simple decision aids for the following outcomes: uptake of major
elective surgery, and uptake of hormone replacement therapy.
Heterogeneity
There was statistically significant heterogeneity when patient de-
cision aids were compared to usual care for four of the IPDAS
effectiveness criteria: knowledge test scores; realistic risk percep-
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tions; feeling uninformed; and feeling unclear regarding personal
values. It should be noted that the heterogeneity of the effect was
not in the direction but in the size.
When we explored the potential factors contributing to hetero-
geneity (Table 9), we found that none of the factors eliminated het-
erogeneity for the outcomes of knowledge scores. When grouped
into treatment and screening decisions, the MD for knowledge
scores was slightly higher for the treatment group (16.5% versus
13.1%), but there was still statistically significant heterogeneity.
For the outcomes of accurate risk perceptions, heterogeneity was
not significant when we removed three studies with lower accu-
rate risk perception scores in the usual control group (P = 0.3) (
Gattellari 2003; Man-Son-Hing 1999; McAlister 2005). For the
outcome of feeling uninformed, heterogeneity was no longer sig-
nificant with: a) removal of three studies with higher uninformed
scores in the usual care control group (P = 0.11); b) inclusion
of only audio booklet/pamphlet decision aids (P = 0.06); and c)
removal of an outlier (Montgomery 2003) (P = 0.06). None of
the factors eliminated heterogeneity for the outcomes of unclear
values scores.
Table 9. Heterogenity
Outcome Overall Effect Treatment
Decision
Screening
Decision
Video/Com-
puter DA
Audio/
Pamphlet DA
Base Risk
Control
Removal of
Outliers*
Knowledge 15.2 (11.7 to
18.7)
16.5 (11.9 to
21.2)
13.1 (7.7 to
18.5)
21.3 (16.3 to
26.2)
11.9 (8.3 to
15.6)
15.5 (11.3 to
19.8)
17.3 (13.6 to
20.9) (*
Bekker 2004,
Gattellari
2003,
Johnson
2006)
Accurate Risk
Perceptions
1.6 (1.4 to
1.9)
1.6 (1.4 to
1.9)
1.6 (1.1 to
2.3)
No data 1.6 (1.4 to
1.9)
1.3 (1.2 to
1.5) (P = 0.3)
1.5
(1.3 to 1.7) (*
Gattellari
2003)
Uninformed
subscale of the
DCS
-8.4 (-11.9 to -
4.8)
-9.4 (-13.3 to -
5.5)
-3.5 (-12.9 to
5.8)
-12.6 (-19.5 to
-5.8)
-4.9 (-7.6 to -
2.3) (P = 0.06)
-5.4 (-7.7 to -
3.2) (P = 0.11)
-6.2 (-8.4 to -
4.1) (P = 0.06)
(*
Montgomery
2003)
Unclear values
subscale of the
DCS
-6.3 (-10.0 to -
2.7)
-6.0 (-9.8 to -
2.3)
Insufficient
data
-8.0 (-15.1 to -
1.0)
-4.5 (-8.4 to -
0.6)
-3.6 (-6.8 to -
0.5)
-4.0 (-
6.7 to -1.3) (*
Montgomery
2003)
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D I S C U S S I O N
The addition of 25 trials in this updated review has confirmed
many of the observations of the previous review (O’Connor
2003b). Decision aids do a better job than usual care interven-
tions in improving people’s knowledge regarding options, reduc-
ing their decisional conflict related to feeling uninformed and un-
clear about personal values, decreasing the proportion of people
remaining undecided, and stimulating people to take amore active
role in decision making. Compared to simpler versions, detailed
decision aids improved knowledge only marginally, but had other
benefits. For example, if probabilities of outcomes were included,
there were more accurate risk perceptions, especially if they were
presented quantitatively. There was also some evidence of better
congruence between values and chosen option.
The impact of decision aids on increasing or decreasing prefer-
ences for particular options continues to be variable. As noted
previously, most trials appear to dampen women’s preferences for
menopausal hormones; moreover, people’s enthusiasm for major
elective surgery is decreased in favour of more conservative op-
tions. In this review, the preference for PSA testing was also de-
creased with exposure to decision aids.
Decision aids do not better than alternative interventions on peo-
ple’s satisfactionwith decisionmaking, anxiety, or health outcomes
such as general quality of life, or condition-specific quality of life.
There continue to be too few studies to determine the effects of
decision aids on persistence with the chosen therapy, costs, or re-
source use.
Study limitations
Study quality ratings of all trials included in the review were low
because they all lost 2 points for lack of blinding. While not an a
priori exclusion criterion for this review, in the future we may con-
sider using study quality ratings for the selection of included trials
through conducting a Risk of Bias assessment. The conclusions of
this review are limited by: a) inadequate power to detect important
differences in effectiveness in subgroups; andb) thewide variability
in the decision contexts, the elements within the patient decision
aids, the type of comparison interventions, the targeted outcomes,
and the evaluation procedures. The small number of studies for
most outcomes did not allow for analysis of publication bias due
to failure to publish negative studies. Moreover, there may have
been publication bias due to failure to report all negative findings
in a published study. Lastly, several of the outcomes demonstrated
statistically significant heterogeneity. It reflects differences across
clinically diverse studies; therefore, the pooled effect size and CI
should be interpreted as a range across conditions, which may not
be applicable to a specific condition.
Main effects of decision aids
The largest and most consistent benefits of decision aids, relative
to usual care, are better knowledge of options and outcomes and
more accurate perceptions of outcome probabilities. These obser-
vations are clinically important for two reasons. First, the usual
care group’s knowledge and understanding of probable outcomes
were less than adequate for informed decision making. Second,
participants often changed from their initial decision once their
knowledge and risk perceptions improved. Taken together, these
effects on knowledge and risk perceptions suggest that current
’usual care’ may not be good enoughwhen informing people about
these complex, value-laden decisions. People need to comprehend
the options and probable outcomes in order to consider and com-
municate to their practitioners the personal value they place on
the benefits versus the harms.
Decision aids compared to usual care also help people feel more
comfortable with their choices. This is revealed by the reduced
scores for the decisional conflict subscales. People who use deci-
sion aids generally feel more informed about options and clearer
regarding their personal values.
Compared to usual care strategies, decision aids improve individ-
uals’ involvement in decision making. This observation suggests
that the IPDAS criterion of helping patients participate ‘in ways
that they prefer’, needs to be assessed after a patient has adequate
information about what involvement means. People may have
a mistaken preference for passivity because they believe that the
best choice relies on the expertise of the clinician (which option
is medically reasonable?) rather than the opinions of the person
who will experience the outcomes (which outcomes matter most
to me?).
Variable effects of decision aids
There may be several reasons for the variable impact of decision
aids on actual choices. First, most studies were underpowered to
detect important differences in actual choices. Second, in the five
studies reporting actual choices at baseline and post decision aid,
some options may have been underused and others overused, rel-
ative to the actual choices individuals would make if they were
more fully informed. Under these circumstances, one could ex-
pect to observe directional effects on actual choices once people
become better informed and more involved in decision making.
Examples of relatively underused options at baseline were colon
cancer screening and hepatitis B vaccination. Another illustration
lies in the non-significant 5-fold increase in rates of surgery in the
UK trial. At the time there was a shortage of urologists and low
referrals for benign prostatic hyperplasia. This situation may have
resulted in under-use of an option, which was corrected with expo-
sure to a decision aid. In contrast, the other surgical decision aid
trials had higher uptake rates in the control group. The procedure
may have been over-used due to people’s inflated perceptions of
the probabilities of benefits, lack of appreciation of the probabil-
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ities of harms, and lack of awareness of alternatives. Exposure to
the decision aid reduced preferences for surgery in favour of more
conservative alternatives.
Limited effects of decision aids
The limited effects of decision aids on reported satisfaction with
the decision making process and with the actual choice made may
indicate that decision aids have a limited effect on satisfaction.
The null effectsmay also be due tomeasurement insensitivity. This
is especially likely when satisfaction with usual care is already quite
high and when choices are inherently difficult to make because of
competing benefits and harms. As well, satisfaction could be more
strongly affected by the relationship with the practitioner than
the decision aid. Furthermore, once the decision is made, people
may find it psychologically more comforting to say that they are
satisfied rather than entertain doubts about what they have chosen
(Gruppen 1994).
It is not surprising that decision aids had limited effects on health
outcomes. The reason for using a decision aid is that there is no
option with a clear health outcome advantage. If health outcomes
are used in future investigations of decision aids, the key question
to pose is: Do patients experience the health outcomes they prefer
and avoid the outcomes to which they are averse?
The small differences in knowledge and decisional conflict scores
between detailed and simpler versions of decision aids are likely
due to the overlapping information presented in the two inter-
ventions. This raises questions about the minimum information
needed for the decision aid to be effective. It was clear from Goel
2001 that, for their population of women with a strong prior pref-
erence for lumpectomy, a simple pamphlet describing options and
outcomes of mastectomy versus lumpectomy was comparable to a
detailed audio-workbook. A post-hoc analysis, however, revealed
that women who were uncertain about their choice at baseline or
leaning toward mastectomy, appeared to benefit more from the
detailed aid. There is a need to establish the ’essential ingredients’
in decision aids and to identify the people who are most likely
to benefit from detailed versions. To do this, it is recommended
that future trials assess baseline predispositions toward options
(strongly leaning toward optionA, unsure, strongly leaning toward
option B) and stage of decision making (not thinking about op-
tions, actively weighing options, close to selecting an option, have
made a choice but willing to re-consider, have made a choice and
unwilling to reconsider). As the body of available research grows,
it will become easier and more important to assess the usefulness
of different components of decision support for different clinical
contexts, decision problems, and groups of people.
Unknown effects of decision aids
The effects of patient decision aids on other outcomes (consulta-
tion length, adherence) are inconclusive. For consultation length,
this variable is likely dependent on the type of practice and more
studies in the same context are needed. The adherence results are
difficult to interpret due to incomplete data, varying length of fol-
low-up (4 to 36 months), and small sample size (n = 33 in one
study). Moreover, studies such as Man-Son-Hing 1999 had very
little variation in choice (over 90% of long term aspirin users de-
cided to stay on aspirin). It would be important to examine adher-
ence: a) separating those choosing to change versus remain with
status quo; and b) in the early phase, when presumably the issue
is decisional (e.g. filling the prescription; picking up the prescrip-
tion; refilling the prescription) rather than management of side
effects.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The positive effects of decision aids in facilitating active partici-
pation and informed decision making may provide sufficient ev-
idence for using them in clinical practice. However, several con-
ditions may be necessary for successful implementation: a) good
quality decision aids to meet the needs of the population; b) prac-
titioners willing to use decision aids in their practice; c) effective
systems for delivering decision support; and d) practitioners and
healthcare consumers who are skilled in shared decision making.
Although some strides have been made in achieving these condi-
tions (O’Connor 2007), the use of patient decision aids will not
occur without adequate attention to the barriers to implementa-
tion (Gravel 2006).
Implications for research
Studies are needed to deepen our understanding of: interactions
between patient decision aid use and the patterns of patient-prac-
titioner communication; format issues such as web-based delivery
of patient decision aids; timing issues regarding most effective use
of decision aids before, during or after a consultation; and down-
stream effects on adherence to a chosen option, decisional regret,
cost, resource use, and litigation rates.
More studies are needed to evaluate the effects of patient decision
aids on congruence between values and chosen options. Moreover
themethods for quantifying value congruence should be explored.
With the addition of more trials to the systematic review, it may
be possible to tease out the reasons for heterogeneity of results
including variability in: a) study quality; b) comparison interven-
tion; c) elements within patient decision aids; d) decision type;
and e) format of decision aid (e.g., video, Internet, booklet). The
degree of detail in patient decision aids that is required for positive
effects on IPDAS criteria should also be explored.
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Research is needed to ensure that decision aids are accessible to
people with low literacy. We also need to examine ways of fa-
cilitating the introduction and uptake of patient decision aids in
various clinical settings, and to explore different practice models
supporting their implementation.
A C K N OW L E D G E M E N T S
The Cochrane Consumers and Communication Review Group
(editors, academic and consumer referees) provided peer review
and advice regarding the protocol and review and checked all ex-
tracted data for newly included trials. Jessie McGowan, a librar-
ian from the University of Ottawa, assisted with literature search-
ing. Joan Peterson assisted with the screening and data extraction.
George Wells and Dean Fergusson provided consultation on the
statistical analysis.
R E F E R E N C E S
References to studies included in this review
Auvinen 2004 {published data only}
∗ Auvinen A, Hakama M, Ala-Opas M, Vornanen T, Leppilahti M,
Salminen P, et al.A randomized trial of choice of treatment in
prostate cancer: the effect of intervention on the treatment chosen.
BJU International 2004;93(1):52–6.
Auvinen A, Vornanen T, Tammela T L, Ala-Opas M, Leppilahti M,
Salminen P, et al.A randomized trial of the choice of treatment in
prostate cancer: design and baseline characteristics. BJU
International 2001;88(7):708–15.
Barry 1997 {published and unpublished data}
Barry MJ, Cherkin DC, Chang Y, Fowler FJ, Skates S. A
randomized trial of a multimedia shared decision-making program
for men facing a treatment decision for benign prostatic hyperplasia.
Disease Management and Clinical Outcomes 1997;1(1):5–14.
Bekker 2004 {published data only}
∗ Bekker HL, Hewison J, Thornton JG. Applying decision analysis
to facilitate informed decision making about prenatal diagnosis for
Down syndrome: a randomised controlled trial. Prenatal Diagnosis
2004;24(4):265–75.
Bekker HL, Hewison J, Thornton JG. Understanding why decision
aids work: linking process with outcome. Patient Education &
Counseling 2003;50(3):323–9.
Bernstein 1998 {published and unpublished data}
Bernstein SJ, Skarupski K A, Grayson CE, Starling M R, Bates ER,
Eagle KA. A randomized controlled trial of information-giving to
patients referred for coronary angiography: effects on outcomes of
care. Health Expectations 1998;1(1):50–61.
Clancy 1988 {published data only}
Clancy CM, Cebul RD, Williams SV. Guiding individual
decisions: a randomized, controlled trial of decision analysis.
American Journal of Medicine 1988;84(2):283–8.
Davison 1997 {published data only}
Davison BJ, Degner LF. Empowerment of men newly diagnosed
with prostate cancer. Cancer Nursing 1997;20(3):187–96.
Deschamps 2004 {published and unpublished data}
Deschamps MA, Taylor JG, Neubauer SL, Whiting S, Green K.
Impact of pharmacist consultation versus a decision aid on decision
making regarding hormone replacement therapy. International
Journal of Pharmacy Practice 2004;12(1):21–8.
Deyo 2000 {published and unpublished data}
∗ Deyo RA, Cherkin DC, Weinstein J, Howe J, Ciol M, Mulley
AG. Involving patients in clinical decisions: impact of an
interactive video program on use of back surgery. Medical Care
2000;38(9):959–69.
Phelan EA, Deyo RA, Cherkin DC, Weinstein JN, Ciol MA,
Kreuter W, et al.Helping patients decide about back surgery: a
randomized trial of an interactive video program. Spine 2001;26
(2):206–12.
Dodin 2001 {published and unpublished data}
Dodin S, Legare F, Daudelin G, Tetroe J, O’Connor A. Making a
decision about hormone replacement therapy. A randomized
controlled trial [Prise de decision en matière d’hormonothérapie de
remplacement]. Canadian Family Physician 2001;47:1586–93.
Dolan 2002 {published data only}
Dolan JG, Frisina S. Randomized controlled trial of a patient
decision aid for colorectal cancer screening. Medical Decision
Making 2002;22(2):125–39.
Dunn 1998 {published and unpublished data}
Dunn RA, Shenouda PE, Martin DR, Schultz AJ. Videotape
increases parent knowledge about poliovirus vaccines and choices of
polio vaccination schedules. Pediatrics 1998;102(2):1–6.
42Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Frosch 2003 {published data only}
Frosch DL, Kaplan RM, Felitti VJ. A randomized controlled trial
comparing internet and video to facilitate patient education for
men considering the prostate specific antigen test. Journal of
General Internal Medicine 2003;18(10):781–7.
Gattellari 2003 {published data only}
Gattellari M, Ward JE. Does evidence-based information about
screening for prostate cancer enhance consumer decision-making?
A randomised controlled trial. Journal of Medical Screening 2003;10
(1):27–39.
Gattellari 2005 {published data only}
Gattellari M, Ward JE. A community-based randomised controlled
trial of three different educational resources for men about prostate
cancer screening. Patient Education & Counseling 2005;57(2):
168–82.
Goel 2001 {published and unpublished data}
Goel V, Sawka CA, Thiel EC, Gort EH, O’Connor AM.
Randomized trial of a patient decision aid for choice of surgical
treatment for breast cancer. Medical Decision Making 2001;21(1):
1–6.
Green 2001a {published data only}
Green MJ, Biesecker BB, McInerney AM, Mauger D, Fost N. An
interactive computer program can effectively educate patients about
genetic testing for breast cancer susceptibility. American Journal of
Medical Genetics 2001;103(1):16–23.
Green 2004 {published data only}
Green MJ, Peterson SK, Baker MW, Friedman LC, Harper GR,
Rubinstein WS, Peters JA, Mauger DT. Use of an educational
computer program before genetic counseling for breast cancer
susceptibility: effects on duration and content of counseling
sessions. Genetics in Medicine 2005;7(4):221–9.
∗ Green MJ, Peterson SK, Baker MW, Harper GR, Friedman LC,
Rubinstein WS, et al.Effect of a computer-based decision aid on
knowledge, perceptions, and intentions about genetic testing for
breast cancer susceptibility: a randomized controlled trial. JAMA
2004;292(4):442–52.
Herrera 1983 {published data only}
Herrera AJ, Cochran B, Herrera A, Wallace B. Parental information
and circumcision in highly motivated couples with higher
education. Pediatrics 1983;71(2):133–4.
Hunter 2005 {published data only}
Hunter AG, Cappelli M, Humphreys L, Allanson JE, Chiu TT,
Peeters C, et al.A randomized trial comparing alternative
approaches to prenatal diagnosis counseling in advanced maternal
age patients. Clinical Genetics 2005;67(4):303–13.
Johnson 2006 {published data only}
Johnson BR, Schwartz A, Goldberg J, Koerber A. A chairside aid
for shared decision making in dentistry: a randomized controlled
trial. Journal of Dental Education 2006;70(2):133–41.
Kennedy 2002 {published data only}
Kennedy AD, Sculpher MJ, Coulter A, Dwyer N, Rees M, Abrams
KR, et al.Effects of decision aids for menorrhagia on treatment
choices, health outcomes, and costs: a randomized controlled trial.
JAMA 2002;288(21):2701–8.
Lalonde 2006 {published data only}
Lalonde L, O’Connor AM, Duguay P, Brassard J, Drake E, Grover
SA. Evaluation of a decision aid and a personal risk profile in
community pharmacy for patients considering options to improve
cardiovascular health: The OPTIONS pilot study. International
Journal of Pharmacy Practice 2006;14(1):51–62.
Laupacis 2006 {published data only}
Laupacis A, O’Connor AM, Drake ER, Rubens FD, Robblee JA,
Grant FC, et al.A decision aid for autologous pre-donation in
cardiac surgery - a randomized trial. Patient Education & Counseling
2006;61(3):458–66.
Legare 2003 {published data only}
Legare F, O’Connor AM, Graham ID, Wells GA, Jacobsen MJ,
Elmslie T, et al.The effect of decision aids on the agreement
between women’s and physicians’ decisional conflict about
hormone replacement therapy. Patient Education & Counseling
2003;50(2):211–21.
Lerman 1997 {published data only}
Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-
Caminero A, Hughes C, et al.Controlled trial of pretest education
approaches to enhance informed decision-making for BRCA1 gene
testing. Journal of the National Cancer Institute 1997;89(2):148–57.
Leung 2004 {published data only}
Leung KY, Lee CP, Chan HY, Tang MH, Lam YH, Lee A.
Randomised trial comparing an interactive multimedia decision aid
with a leaflet and a video to give information about prenatal
screening for Down syndrome. Prenatal Diagnosis 2004;24(8):
613–8.
Man-Son-Hing 1999 {published and unpublished data}
Man-Son-Hing M, Laupacis A, O’Connor AM, Biggs J, Drake E,
Yetisir E, et al.A patient decision aid regarding antithrombotic
therapy for stroke prevention in atrial fibrillation: a randomized
controlled trial. JAMA 1999;282(8):737–43.
McAlister 2005 {published data only}
McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson
D, Majumdar SR, et al.Impact of a patient decision aid on care
among patients with nonvalvular atrial fibrillation: a cluster
randomized trial. CMAJ 2005;173(5):496–501.
McBride 2002 {published data only}
Bastian LA, McBride CM, Fish L, Lyna P, Farrell D, Lipkus IM, et
al.Evaluating participants’ use of a hormone replacement therapy
decision-making intervention. Patient Education & Counseling
2002;48(3):283–91.
∗ McBride CM, Bastian LA, Halabi S, Fish L, Lipkus IM, Bosworth
HB, et al.A tailored intervention to aid decisionmaking about
hormone replacement therapy. American Journal of Public Health
2002;92(7):1112–4.
Miller 2005 {published data only}
Miller SM, Fleisher L, Roussi P, Buzaglo JS, Schnoll R, Slater E, et
al.Facilitating informed decision making about breast cancer risk
and genetic counseling among women calling the NCI”s Cancer
Information Service. Journal of Health Communication 2005;10
(Suppl 1):119–36.
Montgomery 2003 {published and unpublished data}
Emmett CL, Montgomery AA, Peters TJ, Fahey T. Three-year
follow-up of a factorial randomised controlled trial of two decision
43Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
aids for newly diagnosed hypertensive patients. British Journal of
General Practice 2005;55(516):551–3.
∗ Montgomery AA, Fahey T, Peters TJ. A factorial randomised
controlled trial of decision analysis and an information video plus
leaflet for newly diagnosed hypertensive patients. British Journal of
General Practice 2003;53(491):446–53.
Morgan 2000 {published and unpublished data}
Morgan MW. A randomized trial of the ischemic heart disease
shared decision making program: an evaluation of a decision aid.
Master’s Thesis. University of Toronto. 1997.
∗ Morgan MW, Deber RB, Llewellyn-Thomas HA, Gladstone P,
Cusimano RJ, O’Rourke K, et al.Randomized, controlled trial of an
interactive videodisc decision aid for patients with ischemic heart
disease. Journal of General Internal Medicine 2000;15(10):685–93.
Murray 2001a {published and unpublished data}
Murray E, Davis H, Tai SS, Coulter A, Gray A, Haines A.
Randomised controlled trial of an interactive multimedia decision
aid on benign prostatic hypertrophy in primary care. BMJ 2001;
323(7311):493–6.
Murray 2001b {published and unpublished data}
Murray E, Davis H, Tai SS, Coulter A, Gray A, Haines A.
Randomized controlled trial of an interactive multimedia decision
aid on hormone replacement therapy in primary care. BMJ 2001;
323(7311):490–3.
Myers 2005a {published data only}
Myers RE, Daskalakis C, Cocroft J, Kunkel EJ, Delmoor E,
Liberatore M, et al.Preparing African-American men in community
primary care practices to decide whether or not to have prostate
cancer screening. Journal of the National Medical Association 2005;
97(8):1143–54.
O’Connor 1999a {published data only}
O’Connor AM, Wells GA, Tugwell P, Laupacis A, Elmslie T, Drake
E. The effects of an ’explicit’ values clarification exercise in a
women’s decision aid regarding postmenopausal hormone therapy.
Health Expectations 1999;2:21–32.
O’Connor 1998a {published and unpublished data}
O’Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E,
Hollingworth G, et al.Randomized trial of a portable, self-
administered decision aid for postmenopausal women considering
long-term preventive hormone therapy. Medical Decision Making
1998;18:295–303.
Oakley 2006 {published data only}
Oakley S, Walley T. A pilot study assessing the effectiveness of a
decision aid on patient adherence with oral bisphosphonate
medication. Pharmaceutical Journal 2006;276(7399):536–8.
Partin 2004 {published and unpublished data}
Partin MR, Nelson D, Radosevich D, Nugent S, Flood AB, Dillon
N, et al.Randomized trial examining the effect of two prostate
cancer screening educational interventions on patient knowledge,
preferences, and behaviors. Journal of General Internal Medicine
2004;19(8):835–42.
Phillips 1995 {published data only}
Phillips C, Hill BJ, Cannac C. The influence of video imaging on
patients’ perceptions and expectations. Angle Orthodontist 1995;65
(4):263–70.
Pignone 2000 {published data only}
Pignone M, Harris R, Kinsinger L. Videotape-based decision aid
for colon cancer screening. A randomized, controlled trial. Annals
of Internal Medicine 2000;133(10):761–9.
Rostom 2002 {published data only}
Rostom A, O’Connor A, Tugwell P, Wells G. A randomized trial of
a computerized versus an audio-booklet decision aid for women
considering post-menopausal hormone replacement therapy.
Patient Education & Counseling 2002;46(1):67–74.
Rothert 1997 {published and unpublished data}
Holmes-Rovner M, Kroll J, Rovner DR, Schmitt N, Rothert M,
Padonu G, et al.Patient decision support intervention: increased
consistency with decision analytic models. Medical Care 1999;37
(3):270–84.
∗ Rothert ML, Holmes-Rovner M, Rovner D, Kroll J, Breer L,
Talarczyk G, et al.An educational intervention as decision support
for menopausal women. Research in Nursing & Health 1997;20(5):
377–87.
Schapira 2000 {published data only}
Schapira MM, VanRuiswyk J. The effect of an illustrated pamphlet
decision-aid on the use of prostate cancer screening tests. Journal of
Family Practice 2000;49(5):418–24.
Schwartz 2001 {published data only}
Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson
A, Johnson L. Impact of educational print materials on knowledge,
attitudes, and interest in BRCA1/BRCA2: testing among
Ashkenazi Jewish women. Cancer 2001;92(4):932–40.
Shorten 2005 {published and unpublished data}
Shorten A, Shorten B, Keogh J, West S, Morris J. Making choices
for childbirth: a randomized controlled trial of a decision-aid for
informed birth after cesarean. Birth 2005;32(4):252–61.
Street 1995 {published data only}
Street RLJ, Voigt B, Geyer CJ, Manning T, Swanson GP. Increasing
patient involvement in choosing treatment for early breast cancer.
Cancer 1995;76(11):2275–85.
vanRoosmalen 2004 {published and unpublished data}
van Roosmalen MS, Stalmeier PF, Verhoef LC, Hoekstra-Weebers
JE, Oosterwijk JC, Hoogerbrugge N, et al.Randomised trial of a
decision aid and its timing for women being tested for a BRCA1/2
mutation. British Journal of Cancer 2004;90(2):333–42.
∗ van Roosmalen MS, Stalmeier PF, Verhoef LC, Hoekstra-Weebers
JE, Oosterwijk JC, Hoogerbrugge N, et al.Randomized trial of a
shared decision-making intervention consisting of trade-offs and
individualized treatment information for BRCA1/2 mutation
carriers. Journal of Clinical Oncology 2004;22(16):3293–301.
Volk 1999 {published and unpublished data}
∗ Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of
shared decision making for prostate cancer screening. Archives of
Family Medicine 1999;8(4):333–40.
Volk RJ, Spann SJ, Cass AR, Hawley ST. Patient education for
informed decision making about prostate cancer screening: a
randomized controlled trial with 1-year follow-up. Annals of Family
Medicine 2003;1(1):22–8.
Vuorma 2003 {published data only}
∗ Vuorma S, Rissanen P, Aalto AM, Hurskainen R, Kujansuu E,
Teperi J. Impact of patient information booklet on treatment
44Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
decision - a randomized trial among women with heavy
menstruation. Health Expectations 2003;6(4):290–7.
Vuorma S, Teperi J, Aalto AM, Hurskainen R, Kujansuu E,
Rissanen P. A randomized trial among women with heavy
menstruation - impact of a decision aid on treatment outcomes and
costs. Health Expectations 2004;7(4):327–37.
Whelan 2003 {published and unpublished data}
Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, et
al.Helping patients make informed choices: a randomized trial of a
decision aid for adjuvant chemotherapy in lymph node-negative
breast cancer. Journal of the National Cancer Institute 2003;95(8):
581–7.
Whelan 2004 {published and unpublished data}
Whelan T, Levine M, Willan A, Gafni A, Sanders K, Mirsky D, et
al.Effect of a decision aid on knowledge and treatment decision
making for breast cancer surgery: a randomized trial. JAMA 2004;
292(4):435–41.
Wolf 1996 {published data only}
∗ Wolf AM, Nasser JF, Wolf AM, Schorling JB. The impact of
informed consent on patient interest in prostate-specific antigen
screening. Archives of Internal Medicine 1996;156(12):1333–6.
Wolf AM, Schorling JB. Preferences of elderly men for prostate-
specific antigen screening and the impact of informed consent.
Journals of Gerontology Series A-Biological Sciences & Medical Sciences
1998;53(3):M195–200.
Wolf 2000 {published and unpublished data}
Wolf AM, Schorling JB. Does informed consent alter elderly
patients’ preferences for colorectal cancer screening? Results of a
randomized trial. Journal of General Internal Medicine 2000;15(1):
24–30.
Wong 2006 {published data only}
Wong SS, Thornton JG, Gbolade B, Bekker HL. A randomised
controlled trial of a decision-aid leaflet to facilitate women’s choice
between pregnancy termination methods. BJOG: An International
Journal of Obstetrics & Gynaecology 2006;113(6):688–94.
References to studies excluded from this review
Adab 2003 {published data only}
Adab P, Marshall T, Rouse A, Randhawa B, Sangha H, Bhangoo N.
Randomised controlled trial of the effect of evidence based
information on women’s willingness to participate in cervical cancer
screening. Journal of Epidemiology & Community Health 2003;57
(8):589–93.
Armstrong 2005 {published data only}
Armstrong K, Weber B, Ubel PA, Peters N, Holmes J, Schwartz JS.
Individualized survival curves improve satisfaction with cancer risk
management decisions in women with BRCA1/2 mutations.
Journal of Clinical Oncology 2005;23(36):9319–28.
Brown 2004 {published data only}
Brown RF, Butow PN, Sharrock MA, Henman M, Boyle F,
Goldstein D, et al.Education and role modelling for clinical
decisions with female cancer patients. Health Expectations 2004;7
(4):303–16.
Brundage 2001 {published data only}
Brundage MD, Feldman-Stewart D, Cosby R, Gregg R, Dixon P,
Youssef Y, et al.Phase I study of a decision aid for patients with
locally advanced non-small-cell lung cancer. Journal of Clinical
Oncology 2001;19(5):1326–35.
Chadwick 1991 {published data only}
Chadwick DJ, Gillatt DA, Gingell JC. Medical or surgical
orchidectomy: The patients’ choice. BMJ 1991;302(6776):572.
Chewning 1999 {published data only}
Chewning B, Mosena P, Wilson D, Erdman H, Potthoff S, Murphy
A, et al.Evaluation of a computerized contraceptive decision aid for
adolescent patients. Patient Education & Counseling 1999;38(3):
227–39.
Colella 2004 {published data only}
Colella KM, DeLuca G. Shared decision making in patients with
newly diagnosed prostate cancer: a model for treatment education
and support. Urologic Nursing 2004;24(3):187-91, 195-6.
Coulter 2003 {published data only}
Coulter A. Patient information and shared decision-making in
cancer care. British Journal of Cancer 2003;89(Suppl 1):S15–6.
Crang-Svalenius 1996 {published data only}
Crang-Svalenius E, Dykes AK, Jorgensen C. Women’s informed
choice of prenatal diagnosis: early ultrasound examination-routine
ultrasound examination-age-independent amniocentesis. Fetal
Diagnosis & Therapy 1996;11(1):20–5.
Davison 1999 {published data only}
Davison BJ, Kirk P, Degner LF, Hassard TH. Information and
patient participation in screening for prostate cancer. Patient
Education & Counseling 1999;37(3):255–63.
Flood 1996 {published data only}
Flood AB, Wennberg JE, Nease RF Jr, Fowler FJ Jr, Ding J, Hynes
LM. The importance of patient preference in the decision to screen
for prostate cancer. Prostate Patient Outcomes Research Team.
Journal of General Internal Medicine 1996;11(6):342–9.
Frosch 2001 {published data only}
Frosch DL, Kaplan RM, Felitti V. Evaluation of two methods to
facilitate shared decision making for men considering the prostate-
specific antigen test. Journal of General Internal Medicine 2001;16
(6):391–8.
Graham 2000 {published data only}
Graham W, Smith P, Kamal A, Fitzmaurice A, Smith N, Hamilton
N. Randomised controlled trial comparing effectiveness of touch
screen system with leaflet for providing women with information
on prenatal tests. BMJ 2000;320(7228):155–60.
Green 2001b {published data only}
Green MJ, McInerney AM, Biesecker BB, Fost N. Education about
genetic testing for breast cancer susceptibility: patient preferences
for a computer program or genetic counselor. American Journal of
Medical Genetics 2001;103(1):24–31.
Greenfield 1985 {published data only}
Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement
in care. Effects on patient outcomes. Annals of Internal Medicine
1985;102(4):520–8.
Gruppen 1994 {published data only}
Gruppen LD, Margolin J, Wisdom K, Grum CM. Outcome bias
and cognitive dissonance in evaluating treatment decisions.
Academic Medicine 1994;69(10 Suppl):S57–9.
45Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Healton 1999 {published data only}
Healton C, Taylor S, Messeri P, Weinberg G, Bamji M. Effects of
ZDV-based patient education on intentions toward ZDV use, HIV
testing and reproduction among a US cohort of women. AIDS
Care 1999;11(6):675–86.
Hewison 2001 {published data only}
Hewison J, Cuckle H, Baillie C, Sehmi I, Lindow S, Jackson F, et
al.Use of videotapes for viewing at home to inform choice in Down
syndrome screening: a randomised controlled trial. Prenatal
Diagnosis 2001;21(2):146–9.
Hickish 1995 {published data only}
Hickish TF, Smith IE, Middleton G, Nicolson M. Patient
preference for extended palliative chemotherapy for non-small cell
lung cancer. Lancet 1995;345(8953):857–8.
Hochlehnert 2006 {published data only}
Hochlehnert A, Richter A, Bludau HB, Bieber C, Blumenstiel K,
Mueller K, et al.A computer-based information-tool for chronic
pain patients Computerized information to support the process of
shared decision-making. Patient Education & Counseling 2006;61
(1):92–8.
Holloway 2003 {published data only}
Holloway RM, Wilkinson C, Peters TJ, Russell I, Cohen D, Hale J,
et al.Cluster-randomised trial of risk communication to enhance
informed uptake of cervical screening. British Journal of General
Practice 2003;53(493):620–5.
Hunt 2005 {published data only}
Hunt LM, de Voogd KB, Castaneda H. The routine and the
traumatic in prenatal genetic diagnosis: does clinical information
inform patient decision-making?. Patient Education and Counseling
2005;56(3):302–12.
Hunter 1999 {published data only}
Hunter M, O’Dea I. An evaluation of a health education
intervention for mid-aged women: five year follow-up of effects
upon knowledge, impact of menopause and health. Patient
Education & Counseling 1999;38(3):249–55.
Jorm 2003 {published data only}
Jorm AF, Griffiths KM, Christensen H, Korten AE, Parslow RA,
Rodgers B. Providing information about the effectiveness of
treatment options to depressed people in the community: a
randomized controlled trial of effects on mental health literacy,
help-seeking and symptoms. Psychological Medicine 2003;33(6):
1071–9.
LaCroix 1999 {published data only}
LaCroix AZ, Newton KM, Buist DSM, Curry SJ, Scholes D,
Anderson LA, et al.Population-based strategy for improving
informed decision making about hormone replacement therapy in
managed care settings. Women’s Health Issues 1999;9(6):306–18.
Lazcano Ponce 2000 {published data only}
Lazcano Ponce EC, Sloan NL, Winikoff B, Langer A, Coggins C,
Heimburger A, et al.The power of information and contraceptive
choice in a family planning setting in Mexico. Sexually Transmitted
Infections 2000;76(4):277–81.
Lewis 2003 {published data only}
Lewis CL, Pignone MP, Sheridan SL, Downs SM, Kinsinger LS. A
Randomized Trial of Three Videos that Differ in the Framing of
Information about Mammography in Women 40 to 49 Years Old.
Journal of General Internal Medicine 2003;18(11):875–83.
Maisels 1983 {published data only}
Maisels MJ, Hayes B, Conrad S, Chez RA. Circumcision: the effect
of information on parental decision making. Pediatrics 1983;71(3):
453–5.
Manns 2005 {published data only}
Manns B J, Taub K, Vanderstraeten C, Jones H, Mills C, Visser M,
et al.The impact of education on chronic kidney disease patients”
plans to initiate dialysis with self-care dialysis: a randomized trial.
Kidney International 2005;68(4):1777–83.
Markham 2003 {published data only}
Markham R, Smith A. Limits to patient choice: Example from
anaesthesia. BMJ 2003;326(7394):863–4.
Maslin 1998 {published data only}
∗ Maslin AM, Baum M, Walker JS, A’Hern R, Prouse A. Shared
decision-making using an interactive video disk system for women
with early breast cancer. NT Research 1998;3(6):444–55.
Maslin AM, Baum M, Walker JS, A’Hern R, Prouse A. Using an
interactive video disk in breast cancer patient support. Nursing
Times 1998;94(44):4–10.
Mazur 1994 {published data only}
Mazur DJ, Hickam DH. The effect of physician’s explanations on
patients’ treatment preferences: five-year survival data. Medical
Decision Making 1994;14(3):255–8.
McGinley 2002 {published data only}
McGinley AM. Effect of Web-based computer-tailoring on
women’s intention to continue or begin to use hormone
replacement therapy to lower their risk for osteoporosis. University
of Pennsylvania 2002;Doctoral Dissertation:166 p.
McInerney-Leo 2004 {published data only}
McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG,
Giambarresi TR, Johnson E, et al.BRCA1/2 testing in hereditary
breast and ovarian cancer families: effectiveness of problem-solving
training as a counseling intervention. American Journal of Medical
Genetics. Part A 2004;130(3):221–7.
Michie 1997 {published data only}
Michie S, Smith D, McClennan A, Marteau TM. Patient decision
making: An evaluation of two different methods of presenting
information about a screening test. British Journal of Health
Psychology 1997;2(4):317–26.
Molenaar 2001 {published data only}
Molenaar S, Sprangers MA, Rutgers EJ, Luiten EJ, Mulder J,
Bossuyt PM, et al.Decision support for patients with early-stage
breast cancer: effects of an interactive breast cancer CDROM on
treatment decision, satisfaction, and quality of life. Journal of
Clinical Oncology 2001;19(6):1676–87.
Mulley 2006 {published data only}
Mulley AG Jr. Developing skills for evidence-based surgery:
Ensuring that patients make informed decisions. Surgical Clinics of
North America 2006;86(1):181–92.
Myers 2005b {published data only}
Myers RE. Decision counseling in cancer prevention and control.
Health Psychology 2005;24(4 Suppl):S71–7.
46Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Newton 2001 {published data only}
Newton KM, LaCroix AZ, Buist DS, Delaney KM, Anderson LA.
Women’s responses to a mailed hormone replacement therapy
workbook. Menopause 2001;8(5):361–7.
O’Cathain 2002 {published data only}
O’Cathain A, Walters SJ, Nicholl JP, Thomas KJ, Kirkham M. Use
of evidence based leaflets to promote informed choice in maternity
care: randomised controlled trial in everyday practice. BMJ 2002;
324(7338):643–6.
O’Connor 1996 {published data only}
O’Connor AM, Pennie RA, Dales RE. Framing effects on
expectations, decisions, and side effects experienced: the case of
influenza immunization. Journal of Clinical Epidemiology 1996;49
(11):1721–6.
Pearson2005 {published data only}
Pearson S, Maddern GJ, Hewett P. Interacting effects of
preoperative information and patient choice in adaptation to
colonoscopy. Diseases of the Colon & Rectum 2005;48(11):2047–54.
Peele 2005 {published data only}
Peele PB, Siminoff LA, Xu Y, Ravdin PM. Decreased use of
adjuvant breast cancer therapy in a randomized controlled trial of a
decision aid with individualized risk information. Medical Decision
Making 2005;25(3):301–7.
Proctor 2006 {published data only}
Proctor A, Jenkins TR, Loeb T, Elliot M, Ryan A. Patient
satisfaction with 3 methods of postpartum contraceptive
counseling: a randomized, prospective trial. Journal of Reproductive
Medicine 2006;51(5):377–82.
Rimer 2001 {published data only}
Rimer BK, Halabi S, Sugg Skinner C, Kaplan EB, Crawford Y,
Samsa GP, et al.The short-term impact of tailored mammography
decision-making interventions. Patient Education & Counseling
2001;43(3):269–85.
Rimer 2002 {published data only}
Rimer BK, Halabi S, Sugg Skinner C, Lipkus IM, Strigo TS,
Kaplan EB, et al.Effects of a mammography decision-making
intervention at 12 and 24 months. American Journal of Preventive
Medicine 2002;22(4):247–57.
Rovner 2004 {published data only}
Rovner DR, Wills CE, Bonham V, Williams G, Lillie J, Kelly-Blake
K, et al.Decision aids for benign prostatic hyperplasia: Applicability
across race and education. Medical Decision Making 2004;24(4):
359–66.
Ryser 2004 {published data only}
Ryser FG. Breastfeeding attitudes, intention, and initiation in low-
income women: the effect of the best start program. Journal of
Human Lactation 2004;20(3):300–5.
Sheridan 2004 {published data only}
Sheridan SL, Felix K, Pignone MP, Lewis CL. Information needs of
men regarding prostate cancer screening and the effect of a brief
decision aid. Patient Education & Counseling 2004;54(3):345–51.
Sorenson 2004 {published data only}
Sorenson JR, Lakon C, Spinney T, Jennings-Grant T. Assessment of
a decision aid to assist genetic testing research participants in the
informed consent process. Genetic Testing 2004;8(3):336–46.
Steiner 2003 {published data only}
Steiner MJ, Dalebout S, Condon S, Dominik R, Trussell J.
Understanding risk: a randomized controlled trial of
communicating contraceptive effectiveness. Obstetrics & Gynecology
2003;102(4):709–17.
Street 1998 {published data only}
Street RL Jr, Van Order A, Bramson R, Manning T. Preconsultation
education promoting breast cancer screening: does the choice of
media make a difference?. Journal of Cancer Education 1998;13(3):
152–61.
Tabak 1995 {published data only}
Tabak N. Decision making in consenting to experimental cancer
therapy. Cancer Nursing 1995;18(2):89–96.
Thomson 2006 {published data only}
Thomson P, Dowding D, Swanson V, Bland R, Mair C, Morrison
A, et al.A computerised guidance tree (decision aid) for
hypertension, based on decision analysis: Development and
preliminary evaluation. European Journal of Cardiovascular Nursing
2006;5(2):146–9.
Thornton 1995 {published data only}
Thornton JG, Hewison J, Lilford RJ, Vail A. A randomised trial of
three methods of giving information about prenatal testing. BMJ
1995;311(7013):1127–30.
Valdez 2001 {published data only}
Valdez A, Banerjee K, Fernandez M, Ackerson L. Impact of a
multimedia breast cancer education intervention on use of
mammography by low-income Latinas. Journal of Cancer Education
2001;16(4):221–4.
Wagner 1995 {published data only}
Wagner EH, Barrett P, Barry MJ, Barlow W, Fowler FJ Jr. The
effect of a shared decisionmaking program on rates of surgery for
benign prostatic hyperplasia. Pilot results. Medical Care 1995;33
(8):765–70.
Wallston 1991 {published data only}
Wallston KA, Smith RA, King JE, Smith MS, Rye P, Burish TG.
Desire for control and choice of antiemetic treatment for cancer
chemotherapy. Western Journal of Nursing Research 1991;13(1):
12–23.
Wang 2004 {published data only}
Wang C, Gonzalez R, Milliron KJ, Strecher VJ, Merajver SD.
Genetic counseling for BRCA1/2: a randomized controlled trial of
two strategies to facilitate the education and counseling process.
American Journal of Medical Genetics. Part A 2005;134(1):66–73.
Willemsen 2006 {published data only}
Willemsen MC, Wiebing M, van Emst A, Zeeman G. Helping
smokers to decide on the use of efficacious smoking cessation
methods: a randomized controlled trial of a decision aid. Addiction
2006;101(3):441–9.
Wroe 2005 {published data only}
Wroe AL, Turner N, Owens RG. Evaluation of a decision-making
aid for parents regarding childhood immunizations. Health
Psychology 2005;24(6):539–47.
Zapka 2004 {published data only}
Zapka JG, Lemon SC, Puleo E, Estabrook B, Luckmann R, Erban
S. Patient education for colon cancer screening: a randomized trial
47Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of a video mailed before a physical examination. Annals of Internal
Medicine 2004;141(9):683–92.
References to ongoing studies
Connelly {unpublished data only}
Alternative approaches to support HRT decision making. Ongoing
study Trial complete.
Cranny osteoporosis {unpublished data only}
Osteoporosis treatment options decision aid. Ongoing study May
2001.
Hamm/Volk prostate {unpublished data only}
Prostate cancer screening. Ongoing study Ongoing.
Krist/Woolf prostate {unpublished data only}
Prostate cancer screening. Ongoing study Ongoing.
Kupperman prenatal {unpublished data only}
Prenatal diagnostic testing. Ongoing study Ongoing.
Leigh breast mets {unpublished data only}
Breast Cancer Metastatic Decision Aid. Ongoing study Sept. 2002.
Leighl colon mets {unpublished data only}
Colon Cancer Metastatic Decision Aid. Ongoing study Dec. 2002.
Molewijk aneurysms {unpublished data only}
Asymptomatic aorta aneurysm decision aid. Ongoing study
Ongoing.
Nagle 2006 {published data only}
Nagle C, Lewis S, Meiser B, Metcalfe S, Carlin JB, Bell R, et
al.Evaluation of a decision aid for prenatal testing of fetal
abnormalities: a cluster randomised trial [ISRCTN22532458].
BMC Public Health 2006;6:96.
Schapira HRT {unpublished data only}
Menopause options. Ongoing study Trial complete.
Scheid breastscreen {unpublished data only}
Breast screening decision aid. Ongoing study Ongoing.
Taylor prostate screening {unpublished data only}
Prostate cancer screening decision aid. Ongoing study Ongoing.
Tiller ovarian prevention {unpublished data only}
High risk ovarian cancer prevention. Ongoing study June 2001 to
December 2003.
VanSteenkiste cholesterol {unpublished data only}
Decision aid to enhance implementation of cholesterol guideline in
general practice. Ongoing study Trial complete.
Whelan mixed formats {unpublished data only}
Development and evaluation of different versions of the decision
board for early breast cancer. Ongoing study April 2002.
Additional references
Bekker 1999
Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J,
Robinson MB, et al.Informed decision making: an annotated
bibliography and systematic review. Health Technology Assessment
1999; Vol. 3, issue 1:1–156.
Bekker 2003
Bekker HL, Legare F, Stacey D, O’Connor A, Lemyre L. Is anxiety
a suitable measure of decision aid effectiveness: A systematic review.
Patient Education and Counselling 2003;50(3):255–62.
Briss 2004
Briss P, Rimer B, Reilley B, et al.Promoting informed decisions
about cancer screening in communities and healthcare systems.
American Journal of Preventive Medicine 2004;26(1):67–80.
Charles 1997
Charles C, Gafni A, Whelan T. Shared decision-making in the
medical encounter: what does it mean?. Social Science and Medicine
1997;44:681–92.
Deber 1994a
Deber RB. Physicians in health care management: 7. The patient-
physician partnership: Changing roles and the desire for
information. CMAJ 1994;151(2):171–176.
Deber 1994b
Deber RB. Physicians and health care management: 8. The
patient-physician partnership: Decision making, problem solving
and the desire to participate. CMAJ 1994;151(4):423–427.
Degner 1992
Degner LF, Sloan JA. Decision making during serious illness: what
role do patients really want to play. Journal of Clinical Epidemiology
1992;45:941–50.
Elwyn 2006
Elwyn G, O’Connor A, Stacey D, Volk R, Edwards A, Coulter A, et
al.Developing a quality criteria framework for patient decision aids:
online international Delphi consensus process. BMJ 2006;333
(7565):417.
Ende 1989
Ende J, Kazis L, Ash A, Moskowitz MA. Measuring patients’ desire
for autonomy: decision making and information-seeking
preferences among medical patients. Journal of General Internal
Medicine 1989;4:23–30.
Entwistle 1998
Entwistle VA, Sowden A, Watt I. Evaluating interventions to
promote patient involvement in decision-making: by what criteria
should effectiveness be judged?. Journal of Health Services Research
and Policy 1998;3:100–7.
Estabrooks 2000
Estabrooks CA, Goel V, Thiel E, Pinfold SP, Sawka C, Williams JI.
Consumer decision aids: where do we stand? A systematic review of
structured consumer decision aids. Technical Report, Institute for
Clinical Evaluative Sciences March 2000, issue 00–01–TR.
Gafni 1998
Gafni A, Charles C, Whelan T. The physician-patient encounter:
The physician as a perfect agent for the patient versus the informed
treatment decision-making model. Soc Sci Med 1998;47(3):
347–354.
Godlee 2005
Godlee F. Clinical Evidence. BMJ Publishing Group, 2005.
Gravel 2006
Gravel K, Legare F, Graham ID. Barriers and facilitators to
implementing shared decision-making in clinical practice: a
systematic review of health professionals’ perceptions.
Implementation Science 2006;1:16.
48Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gruppen 1994
Gruppen LD, Margolin J, Wisdom K, Grum CM. Outcome bias
and cognitive dissonance in evaluating treatment decisions.
Academic Medicine 1994;69((10 Suppl)):S57–9.
Hays 1993
Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item
Health Survey 1.0. Health Economics 1993;2:217–227.
IPDAS 2005a
International Patient Decision Aid Standards Collaboration.
Background Document. http://ipdas.ohri.ca/
IPDAS˙Background.pdf 2005.
IPDAS 2005b
International Patient Decision Aid Standards Collaboration.
IPDAS Voting Document - 2nd Round. http://ipdas.ohri.ca/
IPDAS˙Second˙Round.pdf April 11, 2005.
Jadad 1996
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,
Gavaghan DJ, et al.Assessing the quality of reports of randomized
clinical trials: is blinding necessary. Controlled Clinical Trials 1996;
17(1):1–12.
Llewellyn-Thomas’95
Llewellyn-Thomas H. Presidential Address. Medical Decision
Making 1995;15(2):101–6.
Makoul 2006
Makoul G, Clayman ML. An integrative model of shared decision
making in medical encounters. Patient Education & Counseling
2006;60(3):301–12.
Martin 2002
Martin S. ’Shared responsibility’ becoming the new medical buzz
phrase. CMAJ 2002;167(3):295.
Molenaar 2000
Molenaar S, Sprangers MAG, Postma-Schuit FCE, Rutgers EJ,
Noorlander J, Hendriks J, et al.Feasibility and effects of decision
aids. Medical Decision Making 2000;20(1):112–27.
Mulley 1995
Mulley A. Outcomes research: Implications for policy and practice.
In: Smith R &, Delamother T editor(s). Outcomes in Clinical
Practice. London: BMJ Publishing Group, 1995.
O’Connor 1995
O’Connor AM. Validation of a decisional conflict scale. Medical
Decision Making 1995;15(1):25–30.
O’Connor 1997a
O’Connor AM, Drake ER, Fiset VJ, Page J, Curtin D, Llewellyn-
Thomas HA. Annotated bibliography of studies evaluating decision
support interventions for patients. Canadian Journal of Nursing
Research 1997;29(3):113–20.
O’Connor 1997b
O’Connor AM, Llewellyn-Thomas HA, Sawka C, Pinfold SP, To T,
Harrison DE. Physicians’ opinions about decision aids for patients
considering systemic adjuvant therapy for axillary-node negative
breast cancer. Patient Education and Counseling 1997;30(2):
143–53.
O’Connor 1998b
O’Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E,
Hollingworth G, et al.A decision aid for women considering
hormone therapy after menopause: decision support framework
and evaluation. Patient Education and Counselling 1998;33(3):
267–79.
O’Connor 1999c
O’Connor AM, Fiset V, DeGrasse C, Graham ID, Evans W, Stacey
D, et al.Decision aids for patients considering options affecting
cancer outcomes: evidence of efficacy and policy implications.
Monograph of the National Cancer Institute 1999;25:67–80.
O’Connor 2001a
O’Connor AM, Wells G, Jacobsen MJ, Elmslie T, Tugwell P.
Validation of a decision regret scale. Medical Decision Making 2001;
21(6):545.
O’Connor 2003a
O’Connor AM, Drake ER, Wells GA, Tugwell P, Laupacis A,
Elmslie T. A survey of the decision-making needs of Canadians
faced with complex health decisions. Health Expectations 2003;6
(2):97–109.
O’Connor 2007
O’Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA,
Moulton BW, Sepucha KR, et al.Toward the ’tipping point’:
decision aids and informed patient choice. Health Affairs 2007;26
(3):716–25.
Radloff 1977
Radloff L. The CES-D scale: a self-report depression scale for
research in the general population. Applied Psychological
Measurement 1977;3:385–401.
Ratliff 1999
Ratliff A, Angell M, Dow RW, Kuppermann M, Nease RF Jr, Fisher
R, et al.What is a good decision?. Eff Clin Pract 1999;2(4):185–97.
Roland 1983
Roland M, Morris R. A study of the natural history of back pain.
Part I: development of a reliable and sensitive measure of disability
in low-back pain. SPINE 1983;8(2):141–4.
Rothert 1987
Rothert M, Talarcyzk GJ. Patient compliance and the decision
making process of clinicians and patients. Journal of Compliance in
Health Care 1987;2:55–71.
RTI 1997
Research Triangle Institute. The effects of informatics tools and
decision aids to support shared patient decision making about medical
screening and treatment. Report to the Agency for Health Care
Policy Research, 1997.
Ruland 2002
Ruland C, Bakken S. Developing, implementing, and evaluating
decision support systems for shared decision making in patient care:
a conceptual model and case illustration. Journal of Biomedical
Informatics 2002;35:313–21.
Sepucha 2004
Sepucha KR, Fowler FJ Jr, Mulley AG Jr. Policy support for patient-
centered care: the need for measureable improvements in decision
quality. Health Affairs 2004;Suppl Web Exclusive:VAR54–62.
Spielberger 1970
Spielberger CD, Gorsuch RL, Lushene RE. Manual for the state-
trait anxiety inventory (Self-evaluations questionnaire). Palo Alto,
CA: Consulting Psychologists Press, 1970.
49Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stacey 2007
Stacey D, Murray MA, Legare F, Menard P, O’Connor A. Decision
Coaching to support shared decision making: A framework,
evidence, and implications for nursing practice, education, and
policy. Worldviews on Evidence-Based Nursing 2007;Dec:In press.
Stewart 1992
Stewart AL, Ware JE Jr (eds). Measuring functioning and well-being:
the medical outcomes study approach. Durham NC: Duke University
Press, 1992.
Whelan 2002
Whelan TM, O’Brien MA, Villasis-Keever M, Robinson P, Skye A,
Gafni A, et al.Impact of cancer-related decision aids. Evidence Report /
Technology Assessment Number 46. Rockville, MD: Agency for
Healthcare Research and Quality, July 2002.
Whitney 2003
Whitney SN. A new model of medical decisions: exploring the
limits of shared decision making. Medical Decision Making 2003;
23:275–80.
References to other published versions of this review
O’Connor 1999b
O’Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-
Thomas H, et al.Decision aids for patients facing health treatment
or screening decisions: systematic review. BMJ 1999;319:731–4.
O’Connor 2001b
O’Connor AM, Stacey D, Rovner D, Holmes-Rovner M, Tetroe J,
Llewellyn-Thomas H, et al.Decision aids for people facing health
treatment or screening decisions. Cochrane Database of Systematic
Reviews 2001, Issue 3.[Art. No.: CD001431. DOI: 10.1002/
14651858.CD001431.pub2]
O’Connor 2003b
O’Connor AM, Stacey D, Rovner D, Holmes-Rovner M, Tetroe J,
Llewellyn-Thomas H, et al.Decision aids for people facing health
treatment or screening decisions. Cochrane Database of Systematic
Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001431]
∗ Indicates the major publication for the study
50Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Auvinen 2004
Methods Pamphlet vs usual care
Participants 103 + 100 men newly diagnosed with prostate cancer
Interventions DA: pamphlet patient decision aid created for trial on options’ outcomes, outcome probability
COMPARE: standard care by clinical guideline
Outcomes Uptake of options, participation in decision making
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Barry 1997
Methods Interactive video disc vs general information
Participants 104 + 123 patients considering benign prostatic hyperplasia treatment
Interventions DA: interactive videodisc on options’ outcomes, clinical problem, outcome probability, others’ opinion
COMPARE: general information on the clinical problem
Outcomes uptake of option; knowledge; satisfaction with DM process; satisfaction with decision; interest in DM;
general health outcomes; condition specific health outcomes
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Bekker 2004
Methods Decision analysis + routine consultation vs routine consultation
Participants 59 + 58 pregnant women who have received a maternal serum screening positive test result for Down
syndrome
Interventions DA: decision analysis plus routine consultation on options’ outcomes, outcome probability, values clari-
fication
COMPARE: routine consultation on options’ outcomes, outcome probability
Outcomes uptake of option; knowledge; decisional conflict; anxiety; informed decision making; satisfaction with
consultation; consultation length
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Bernstein 1998
Methods Video vs usual care
Participants 61 + 48 patients with coronary artery disease considering revascularization surgery
Interventions DA: video on options’ outcomes, clinical problem, others’ opinion
COMPARE: usual care
Outcomes uptake of option, knowledge, satisfaction with care, satisfaction with decision making process, general
health outcomes, condition specific health outcomes
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Clancy 1988
Methods Pamphlet + personal decision analysis vs usual care
Participants 753 + 264 + 263 Health physicians considering Hep B vaccine
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Clancy 1988 (Continued)
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probability, values clarification, guidance/
coaching
COMPARE: usual care
Outcomes uptake of option
Notes Quality = 2
r=2 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Davison 1997
Methods Written + audiotaped consultation vs pamphlets
Participants 30 + 30 men with prostate cancer considering treatment
Interventions DA: written + audiotape consultation of options’ outcomes, clinical problem, outcome probability, others’
opinion
COMPARE: general information pamphlets on clinical problem
Outcomes role in decision making, anxiety, depression
Notes Quality = 2
r=2 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Deschamps 2004
Methods Audiotape booklet vs pharmacist consultation
Participants 67 + 61 women considering hormone replacement therapy
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probabilities, values clarification,
others’ opinions, guidance/coaching
COMPARE: 40-minute pharmacist consultation on options’ outcomes, outcome probability
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Deschamps 2004 (Continued)
Outcomes preferred option, decisional conflict, role in decision making, satisfaction with preparation for decision
making, satisfaction with decision, adherence
Notes Quality = 1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Deyo 2000
Methods Interactive videodisc vs pamphlet
Participants 190 + 203 adults with herniated disc or spinal stenosis considering back surgery
Interventions DA: interactive videodisc on options’ outcomes, clinical problem, outcome probability, other’s opinions
COMPARE: simple DA pamphlet with clinical problem, options outcomes.
Outcomes uptake of option, satisfaction with DM process, satisfaction with care, condition specific health outcomes
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Dodin 2001
Methods Audiotape booklet vs pamphlet
Participants 52 + 49 women considering hormone replacement therapy
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability, values clarification,
others’ opinions, guidance/coaching
COMPARE: simple decision aid pamphlet with options’ outcomes, clinical problem
Outcomes preferred option, knowledge, decisional conflict, realistic expectations, congruence between values and
choice
Notes Quality = 2
r=1 b=0 f=1
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Dodin 2001 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Dolan 2002
Methods Computer + pamphlet vs pamphlet (usual care)
Participants 50 + 47 average risk for colorectal cancer considering screening
Interventions DA: computer with analytic hierarchy process on options’ outcomes, clinical problem, outcome proba-
bility, values clarification, guidance/coaching
COMPARE: usual care with information on options, clinical problem.
Outcomes uptake of option, decisional conflict, role in decision making
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Dunn 1998
Methods Video + pamphlet vs pamphlet
Participants 143 + 144 parents of infants considering polio vaccine schedules
Interventions DA: video + pamphlet on options’ outcomes, clinical problem, outcome probability, others’ opinions
COMPARE: general information on clinical problem
Outcomes knowledge
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
55Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Frosch 2003
Methods Video vs website
Participants 112 + 114 men considering PSA testing
Interventions DA: video on options’ outcomes, clinical problem, outcome probability, others’ opinions
COMPARE: Internet presentation mirroring content of video decision aid
Outcomes preferred option, knowledge
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Gattellari 2003
Methods Decision aid vs general information leaflet
Participants 126 + 122 men considering PSA testing
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probability, values clarification
COMPARE: brief information on screening test and chances of false-positive results
Outcomes preferred option, knowledge, decisional conflict, realistic expectation of outcomes, perceived ability to
make an informed choice
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Gattellari 2005
Methods Booklet decision aid vs video decision aid vs general information leaflet
Participants 140 + 141 + 140 men considering PSA testing
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probability, values clarification
COMPARE: video on clinical problem, outcome probability, others’ opinion
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Gattellari 2005 (Continued)
COMPARE: brief information on screening test and chances of false-positive results
Outcomes preferred option, knowledge, decisional conflict, perceived ability to make an informed choice
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Goel 2001
Methods Audiotape booklet vs pamphlet
Participants 86 + 50 women considering surgery for breast cancer
Interventions DA: audiotape + booklet on options’ outcomes, clinical problem, outcome probability, values clarification,
other’s opinions, coaching/guidance
COMPARE: simple DA pamphlet with clinical problem, options outcomes
Outcomes knowledge, decisional conflict, decisional regret, anxiety
Notes Quality =3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Green 2001a
Methods Computer + counselling vs counselling vs usual care
Participants 29 + 14 women with a first degree relative with breast cancer interested in learning about genetic testing
Interventions DA: CD-ROM plus counselling on options’ outcomes, clinical problem, others’ opinions
COMPARE: Usual care
Outcomes knowledge, preferred options
Notes Quality = 1
r=1 b=0 f=0
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Green 2001a (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Green 2004
Methods Computer-based decision aid plus genetic counselling vs usual care
Participants 106 + 105 women with first degree relative with breast cancer considering genetic testing
Interventions DA: CD-ROM plus counselling on options’ outcomes, clinical problem, others’ opinions
COMPARE: genetic counselling
Outcomes preferred option, knowledge, decisional conflict, satisfaction with decision, anxiety, counsellor/participant
rating of effectiveness of counselling session, consultation length
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Herrera 1983
Methods Pamphlet + discussion vs usual care
Participants 56 + 47 parent(s) considering circumcision for male newborns
Interventions DA: pamphlet + discussion on options’ outcomes, clinical problem, outcome probability, others’ opinions,
guidance/coaching
COMPARE: usual care
Outcomes uptake of option
Notes Quality = 0
r=0 b=0 f=0
Risk of bias
Item Authors’ judgement Description
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Herrera 1983 (Continued)
Allocation concealment? No C - Inadequate
Hunter 2005
Methods Patient decision aid with option to speak to genetic counsellor vs individual genetic counselling vs group
counselling
Participants 116 + 126 + 110 women of advanced maternal age considering prenatal diagnostic testing
Interventions DA: audiotapeworkbookonoptions’ outcomes, clinical problem, outcomeprobability, values clarification,
others’ opinions, guidance/coaching
COMPARE: individual counselling session on options’ outcomes, outcome probability, values clarifica-
tion
COMPARE: group counselling session on options’ outcomes, outcome probability, others’ opinions
Outcomes uptake of option, knowledge, decisional conflict, satisfaction with decision making process, anxiety
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Johnson 2006
Methods Decision board vs usual care
Participants 32 + 35 patients considering endodontic treatment options
Interventions DA: decision board on options’ outcomes, clinical problem, outcome probability
COMPARE: usual care
Outcomes knowledge, satisfaction, anxiety
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Kennedy 2002
Methods Video + booklet + coaching vs video + pamphlet vs usual care
Participants 215 + 206 + 204 women considering treatment for menorrhagia
Interventions DA: video + booklet on options’ outcomes, clinical problem, outcome probabilities, values clarification,
others’ opinions, guidance/coaching
COACHING: ~20 minute coaching, in making a decision, with a registered nurse prior to see physician
COMPARE: usual care
Outcomes uptake of option, satisfaction, general quality of life, menorrhagia severity, cost effectiveness
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Lalonde 2006
Methods Booklet and personal worksheet + pharmacist consultation vs personal risk profile + pharmacist consulta-
tion
Participants 13 + 13 patients considering lifestyle changes and drug therapy to improve cardiovascular health
Interventions DA: booklet and worksheet on options’ outcomes, clinical problem, outcome probability, values clarifi-
cation, others’ opinion, guidance/coaching
COMPARE: personal risk profile with clinical problem, outcome probabilities
Outcomes knowledge, risk perception, decisional conflict, satisfaction with decision making process
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Laupacis 2006
Methods Decision aid vs usual care
Participants 60 + 60 patients undergoing elective open heart surgery considering pre-operative autologous blood
donation
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Laupacis 2006 (Continued)
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability, values clarification,
others’ opinions, guidance/coaching
COMPARE: usual care
Outcomes uptake of option, knowledge, decisional conflict, satisfaction with decision making process, satisfaction
with decision, realistic expectations
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Legare 2003
Methods Decision aid vs general information pamphlet
Participants 97 + 87 post-menopausal women considering hormone replacement therapy
Interventions DA: audiotape, booklet and worksheet on options’ outcomes, clinical problem, outcome probabilities,
values clarification, others’ opinions, guidance/coaching
COMPARE: general information pamphlet on risks, benefits and side-effects of HRT
Outcomes decisional conflict, satisfaction with decision making process, agreement between physicians’ and patients’
decisional conflict
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lerman 1997
Methods Discussion + counselling vs waiting list control
Participants 122 + 114 + 164 women considering BRCA1 gene testing
Interventions DA: Education and counselling on options’ outcomes, clinical problem, outcome probability, values
clarification, others’ opinions, guidance/coaching
COMPARE: no intervention
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Lerman 1997 (Continued)
Outcomes preferred option, knowledge, realistic expectations, perceived personal risk / benefits / limitations, agree-
ment between values and choice
Notes Quality =1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Leung 2004
Methods Interactive multimedia decision aid vs video and leaflet
Participants 100 + 101 women considering prenatal diagnostic testing
Interventions DA: interactive multimedia decision aid on options’ outcomes, clinical problem, outcome probability,
implicit values clarification, guidance/coaching
COMPARE: video and leaflet on options’ outcomes, clinical problem, outcome probability
Outcomes Preferred option, proportion remaining undecided, uptake of option
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Man-Son-Hing 1999
Methods Audiotape booklet vs usual care
Participants 139 + 148 patients on atrial fibrillation trial considering continuing on aspirin vs change to Warfarin
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability, values clarification,
others’ opinions, guidance/coaching
COMPARE: usual care
Outcomes uptake of options, help with making a decision, knowledge, realistic expectations, decisional conflict,
satisfaction with decision making process, role in decision making, adherence
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Man-Son-Hing 1999 (Continued)
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
McAlister 2005
Methods Audiotape booklet vs usual care
Participants 219 + 215 patients considering antithrombotic therapy for nonvalvular atrial fibrillation
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probabilities, values clarification,
others’ opinions, guidance/coaching
COMPARE: usual care
Outcomes uptake of (appropriate)option, knowledge, decisional conflict, realistic expectations
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
McBride 2002
Methods Pamphlet vs usual care
Participants 289 + 292 peri-menopausal women considering hormone replacement therapy
Interventions DA: options’ outcomes, clinical problem, outcome probability, values clarification, others’ opinions, guid-
ance/coaching
COMPARE: delayed intervention
Outcomes realistic expectations, satisfaction with decision, confidence with knowledge&making/discussing decision
Notes Quality = 1
r=1 b=0 f=0
Risk of bias
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McBride 2002 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Miller 2005
Methods Enhanced educational intervention vs standard care
Participants 279 women considering BRCA1 BRCA2 gene testing
Interventions DA: educational intervention on options’ outcomes, clinical condition, personal family cancer history
COMPARE: provision of general information about cancer risk
Outcomes Preferred option, knowledge, perceived risk, satisfaction
Notes Quality = 2
r=2 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Montgomery 2003
Methods Decision analysis + information video and leaflet vs decision analysis vs information video and leaflet vs
usual care
Participants 51 + 52 + 55 + 59 newly diagnosed hypertensive patients considering drug therapy for blood pressure
Interventions DA: Decision analysis plus information video and leaflet on options’ outcomes, clinical problem, outcome
probability, values clarification
COMPARE: Decision analysis on options’ outcomes, outcome probability, values clarification
COMPARE: Video and leaflet on options’ outcomes, clinical problem
COMPARE: usual care
Outcomes uptake of option, knowledge, decisional conflict, anxiety
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
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Montgomery 2003 (Continued)
Allocation concealment? Yes A - Adequate
Morgan 2000
Methods Interactive videodisc vs usual care
Participants 120 + 120 patients with Ischemic heart disease considering revascularization surgery
Interventions DA: interactive videodisc on options’ outcomes, clinical problem, outcome probability, others’ opinions
COMPARE: usual care
Outcomes uptake of option, knowledge
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Murray 2001a
Methods Interactive videodisc versus usual care
Participants 57 + 55 men considering treatment for benign prostatic hypertrophy
Interventions DA: interactive videodisc on options, outcomes, clinical problem, outcome probability, others’ opinions
COMPARE: usual care
Outcomes uptake of option, decisional conflict, role in decision making, prostate symptoms, costs, anxiety, general
health status, utility
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Murray 2001b
Methods Interactive videodisc versus usual care
Participants 102 + 102 women considering hormone replacement therapy
Interventions DA: interactive videodisc on options outcomes, clinical problem, outcome probability, other’s opinion
COMPARE: usual care
Outcomes preferred option, help with making a decision, decisional conflict, role in decision making
anxiety, menopausal symptoms, costs, utility, general health status
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Myers 2005a
Methods Booklet + education session vs booklet
Participants 121 + 121 African-American men considering prostate cancer screening
Interventions DA: information booklet on clinical problem, options’ outcomes + decision education session with values
clarification, guidance/coaching
COMPARE: information booklet on clinical problem, options’ outcomes
Outcomes uptake of option
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
O’Connor 1999a
Methods Audiotape booklet with values clarification vs audiotape booklet
Participants 101 +100 women considering long term hormone therapy
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O’Connor 1999a (Continued)
Interventions DA: audiotape booklet on options outcomes, clinical problem, outcome probabilities, values clarification,
others’ opinion, guidance/coaching
COMPARE: options outcomes, clinical problem, outcome probabilities, guidance/coaching.
Outcomes decisional conflict, congruence with values
Notes Quality = 3
r = 2, b=0, f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
O’Connor 1998a
Methods Audiotape booklet vs pamphlet
Participants 81 + 84 women considering long term hormone therapy
Interventions DA: audiotape booklet on options outcomes, clinical problem, outcome probability, values clarification,
others’ opinion, guidance/coaching
COMPARE: simple DA pamphlet.
Outcomes preferred option, knowledge, decisional conflict, realistic expectations
Notes Quality = 1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Oakley 2006
Methods Decision aid vs usual care
Participants 16 + 17 postmenopausal women with osteoporosis considering treatment options to prevent further bone
loss
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability, values clarification,
others’ opinions, guidance/coaching
COMPARE: usual care
67Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Oakley 2006 (Continued)
Outcomes satisfaction with information, decisional conflict (intervention group only), improvement in adherence
Notes Quality = 1
r=1 b=0 b=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Partin 2004
Methods Video vs pamphlet vs usual care
Participants 384 + 384 + 384 men considering PSA testing
Interventions DA: FIMDM video on options’ outcomes, clinical problem, outcome probability, others’ opinions
COMPARE: pamphlet on options’ outcomes, clinical problem, outcome probability
COMPARE: usual care
Outcomes preferred option, help with making a decision, knowledge, decisional conflict
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Phillips 1995
Methods video imaging + standard case presentation vs usual care
Participants 37 + 37 patients considering dental orthognathic surgery
Interventions DA: video imaging of facial reconstruction including options outcomes, clinical problem, guidance/
coaching
COMPARE: usual care
Outcomes preferred option, expectations
Notes Quality = 0
r=0 b=0 f=0
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Phillips 1995 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Pignone 2000
Methods Video vs usual care
Participants 125 + 124 adults considering colon cancer screening
Interventions DA: video of options’ outcomes, clinical problem, others’ opinion
COMPARE: video on car safety
Outcomes uptake of options
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Rostom 2002
Methods Computer program vs audiotape booklet
Participants 25 + 26 women considering hormone replacement therapy
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probabilities, values clarification,
others’ opinions, guidance/coaching
COMPARE: computer version of same information with feedback to reinforce and correct participant
knowledge
Outcomes knowledge, realistic expectations, satisfaction with decision aid
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
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Rostom 2002 (Continued)
Allocation concealment? Yes A - Adequate
Rothert 1997
Methods Lecture + personal decision exercise vs pamphlet
Participants 83 + 89 peri-menopausal women considering hormone replacement therapy
Interventions DA: lecture with personal decision exercise on options’ outcomes, clinical problem, outcome probability,
values clarification, others’ opinions, guidance/coaching
COMPARE: simple DA pamphlet with clinical problem, options’ outcomes
Outcomes knowledge, decisional conflict, satisfaction with decision, satisfaction with provider, self-efficacy, adher-
ence, likelihood to take HRT, consistency with values
Notes Quality = 1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Schapira 2000
Methods Booklet vs pamphlet
Participants 122 + 135 men considering PSA testing
Interventions DA: booklet on options’ outcomes, clinical problem, outcome probability
COMPARE: simple DA pamphlet with clinical problem, options’ outcomes
Outcomes uptake of option, knowledge, realistic expectations
Notes Qualtiy = 1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Schwartz 2001
Methods Booklet vs general information on breast cancer
Participants 181 + 190 Ashkenazi Jewish women considering genetic testing
Interventions DA: 16-page booklet on genetic testing with options’ outcomes, clinical problem
COMPARE: general information on breast cancer
Outcomes preferred option, knowledge, realistic expectations
Notes Quality = 2
r=2 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Shorten 2005
Methods decision aid booklet vs usual care
Participants 85 + 84 pregnant women who have experienced previous cesarean section considering birthing options
Interventions DA: decision aid booklet on options’ outcomes, clinical problem, outcome probabilities, values clarifica-
tion, coaching/guidance
COMPARE: usual care
Outcomes preferred option, help with making a decision, knowledge, decisional conflict
Notes Quality = 2
r=2 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Street 1995
Methods Interactive multimedia vs pamphlet
Participants 30 + 30 women considering breast cancer surgery
Interventions DA: interactive multimedia on options’ outcomes, clinical problem, others’ opinion, guidance/coaching
COMPARE: simple DA pamphlet with clinical problem, options’ outcomes
71Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Street 1995 (Continued)
Outcomes uptake of option, knowledge, optimism
Notes Quality = 1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
vanRoosmalen 2004
Methods Video and pamphlet plus decision analysis vs video and pamphlet
Participants 44 + 44 women diagnosed with BRCA 1/2 mutation considering prophylactic surgery
Interventions DA: video and brochure patient decision with decision analysis on options’ outcomes, clinical problem,
outcome probability, values clarification, guidance/coaching
COMPARE: same video and brochure on options’ outcomes, clinical problem, outcome probability,
guidance/coaching
Outcomes decision uncertainty, perceived weighing pros/cons, perceived participation, anxiety, health outcomes
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Volk 1999
Methods Video + pamphlet vs usual care
Participants 80 + 80 men considering PSA testing
Interventions DA: videotape and brochure on options’ outcomes, clinical problem, outcome probability, others’ opinion
COMPARE: usual care
Outcomes preferred option, knowledge, uptake of option, satisfaction with decision
Notes Quality = 3
r=2 b=0 f=1
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Volk 1999 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Vuorma 2003
Methods Information booklet vs usual care
Participants 184 + 179 women considering treatment for menorrhagia
Interventions DA: booklet on options’ outcomes, clinical problem, outcome probability
COMPARE: usual care
Outcomes uptake of option, knowledge, proportion remaining undecided, anxiety, satisfaction, health outcomes,
use and cost of healthcare services
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Whelan 2003
Methods Decision board and booklet vs standard care and booklet
Participants 82 + 93 women with node negative breast cancer considering adjuvant chemotherapy
Interventions DA: Decision board and booklet on options’ outcomes, clinical problem, outcome probability
COMPARE: booklet on clinical problem
Outcomes preferred option, knowledge, anxiety, realistic expectations, satisfaction of patient, participation in decision
making
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
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Whelan 2003 (Continued)
Allocation concealment? Yes A - Adequate
Whelan 2004
Methods Decision board vs standard care
Participants 94 + 107 women with Stage 1 or 2 breast cancer considering surgery
Interventions DA: Decision board on options’ outcomes, outcome probability
COMPARE: usual care
Outcomes preferred option, knowledge, realistic expectations, decisional conflict, anxiety, satisfaction
Notes Quality = 3
r=2 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Wolf 1996
Methods Script vs single sentence
Participants 103 + 102 men considering PSA testing
Interventions DA: script of options’ outcomes, clinical problem, outcome probability, others’ opinions
COMPARE: usual care
Outcomes preferred option
Notes Quality = 2
r=1 b=0 f=1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Wolf 2000
Methods Script vs 5 sentences
Participants 266 + 133 elderly (65+) considering colorectal cancer screening
Interventions DA: script of options’ outcomes, clinical problem, outcome probabilities
COMPARE: usual care
Outcomes preferred option, realistic expectations
Notes Quality = 1
r=1 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Wong 2006
Methods Decision aid leaflet vs placebo control leaflet
Participants 162 + 164 women referred for pregnancy termination
Interventions DA: simple decision aid leaflet on options’ outcomes, clinical problem, outcome probability, values clari-
fication
COMPARE: placebo leaflet on contraception use post pregnancy termination
Outcomes uptake of option, knowledge, decisional conflict, anxiety
Notes Quality = 2
r=2 b=0 f=0
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Characteristics of excluded studies [ordered by study ID]
Adab 2003 Hypothetical decision
Armstrong 2005 Unable to ascertain whether intervention meets criteria to qualify as a patient decision aid. Additional
information requested from author but not provided.
Brown 2004 No specific decision to be made
Brundage 2001 Non-RCT design
Chadwick 1991 Non-RCT design, decision support minimal
Chewning 1999 Non-RCT design
Colella 2004 Describes model of care
Coulter 2003 Editorial
Crang-Svalenius 1996 Non-RCT design
Davison 1999 Unable to ascertain whether intervention meets criteria (values clarification) to qualify as a patient decision
aid.
Flood 1996 Non-randomized allocation; waiting list control
Frosch 2001 Non-RCT design
Graham 2000 General information with no focused decision
Green 2001b Educational intervention
Greenfield 1985 Intervention to increase patient involvement in care; no focused decision
Gruppen 1994 No decision aid
Healton 1999 No specific decision; No decision aid; education to promote compliance
Hewison 2001 Not a decision aid; no values clarification
Hickish 1995 Letter
Hochlehnert 2006 General information; no values clarification
Holloway 2003 Promotes complying with a recommended option
Hunt 2005 Promotes complying with a recommended option
Hunter 1999 Not focused on specific decision
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(Continued)
Jorm 2003 Not at point of decision making - community sample asked to evaluate information booklet on depression
LaCroix 1999 Secondary report of pilot study
Lazcano Ponce 2000 No values clarification
Lewis 2003 Hypothetical decision
Maisels 1983 No values clarification
Manns 2005 Promotes complying with a recommended option
Markham 2003 Review of patient information pamphlets (pre-operative fasting)
Maslin 1998 Insufficient outcome data provided in publication. Requested from author but not provided.
Mazur 1994 Hypothetical decision
McGinley 2002 No values clarification
McInerney-Leo 2004 No risk/benefit information; no values clarification
Michie 1997 Unable to ascertain whether intervention meets criteria (values clarification) to qualify as a patient decision
aid. Additional information requested but author was unable to provide the intervention.
Molenaar 2001 Non-RCT design
Mulley 2006 Editorial
Myers 2005b Editorial
Newton 2001 Non-RCT design
O’Cathain 2002 Suite of 8 decision aids (not an efficacy trial)
O’Connor 1996 No patient decision aid - framing effects
Pearson2005 Focus on provision of information
Peele 2005 Decision aid only supplies mortality risk information; no risk info; no values clarification
Proctor 2006 General patient education resource
Rimer 2001 Promotes complying with a recommended option
Rimer 2002 Promotes complying with a recommended option
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(Continued)
Rovner 2004 Non-RCT design
Ryser 2004 Promotes complying with a recommended option
Sheridan 2004 Non-RCT design
Sorenson 2004 Non-RCT design
Steiner 2003 Only effectiveness not cons of options; not at point of decision making
Street 1998 Promotes complying with a recommended option
Tabak 1995 No decision aid; non-RCT design
Thomson 2006 Non-RCT design; not at point of decision making
Thornton 1995 Unable to ascertain whether intervention meets criteria to qualify as a patient decision aid. Additional
information requested from author but not provided.
Valdez 2001 Non-RCT; complying with a recommended option
Wagner 1995 Non-RCT
Wallston 1991 No decision aid - patient preference study
Wang 2004 Intent of intervention to facilitate genetic counselling process, no focused decision.
Willemsen 2006 Lifestyle change
Wroe 2005 Promotes complying with a recommended option
Zapka 2004 Promotes complying with a recommendation
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Characteristics of ongoing studies [ordered by study ID]
Connelly
Trial name or title Alternative approaches to support HRT decision making
Methods
Participants Peri & post menopausal women considering HRT
Interventions discussion with practitioner versus audio-guided booklet + visit versus video + visit
Outcomes satisfaction with menopausal care, knowledge, decisional conflict, likelihood to use HRT
Starting date Trial complete
Contact information Maureen Connelly, maureen˙connelly@hphc.org
Notes Paper being published
Cranny osteoporosis
Trial name or title Osteoporosis treatment options decision aid
Methods
Participants Women considering treatment for osteoporosis
Interventions Decision aid versus usual care controls
Outcomes Knowledge, realistic expectations, preference for outcomes, decision, persistence with decision, physician
perception of preference, decisional conflict, satisfaction with decision making process, preferred role in
decision making, preparation for decision making, decision self-efficacy, decision regret, health promotion
plans, SF-12, OPTQoL
Starting date May 2001
Contact information Ann Cranney
University of Ottawa, Ottawa Health Research Institute
C4 Ottawa Hospital
1053 Carling Ave
Ottawa, K1Y 4E9
acranney@ohri.ca
Notes
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Hamm/Volk prostate
Trial name or title Prostate cancer screening
Methods
Participants Men considering prostate cancer screening
Interventions Decision aid balance sheet versus NCI pamphlets on prostate cancer screening
Outcomes
Starting date Ongoing
Contact information Robert-Hamm@ouhsc.edu
Notes
Krist/Woolf prostate
Trial name or title Prostate cancer screening
Methods
Participants Men considering screening options for prostate cancer
Interventions Decision aid via Internet versus ?
Outcomes
Starting date Ongoing
Contact information ahkrist@vcu.edu
Notes
Kupperman prenatal
Trial name or title Prenatal diagnostic testing
Methods
Participants Couples considering prenatal diagnostic testing
Interventions Decision aid computer program versus ?
Outcomes
Starting date Ongoing
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Kupperman prenatal (Continued)
Contact information kuppermannm@obgyn.ucsf.edu
Notes
Leigh breast mets
Trial name or title Breast Cancer Metastatic Decision Aid
Methods
Participants Women with metastatic breast cancer considering treatment options
Interventions Decision aid versus usual care
Outcomes Treatment decision; satisfaction with decision; knowledge; anxiety; decisional conflict; physician satisfaction
with decision-making
Starting date Sept. 2002
Contact information Natasha Leighl, Princess Margaret Hospital, 5-222 610 University Avenue, Toronto, Ontario M5G 2M9,
Canada; Telephone; 416-946-2399, Fax; 416-946-6546, email; natasha.leighl@uhn.on.ca
Notes
Leighl colon mets
Trial name or title Colon Cancer Metastatic Decision Aid
Methods
Participants Women and men with metastatic colon cancer considering treatment options
Interventions Decision board, booklet and audiotape versus usual care.
Outcomes Treatment decision; satisfaction with decision; knowledge; anxiety; decisional conflict; physician satisfaction
with decision-making
Starting date Dec. 2002
Contact information Natasha Leighl, Princess Margaret Hospital, 5-222 610 University Avenue, Toronto, Ontario M5G 2M9,
Canada; Telephone; 416-946-2399, Fax; 416-946-6546, email; natasha.leighl@uhn.on.ca
Notes
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Molewijk aneurysms
Trial name or title Asymptomatic aorta aneurysm decision aid
Methods
Participants Adults considering treatment for asymptomatic aortic aneurysm
Interventions Decision aid decision analysis with booklet versus ?
Outcomes
Starting date Ongoing
Contact information Bert Molewijk
A.C.Molewijk@lumc.nl
Notes
Nagle 2006
Trial name or title Evaluation of a decision aid for prenatal testing of fetal abnormalities: a cluster randomised trial
Methods
Participants Women considering prenatal diagnostic testing
Interventions Decision aid versus pamphlet
Outcomes Informed choice; decisional conflict; attitudes to fetus/neonate; depression; anxiety; satisfaction with decision
Starting date Protocol published April 2006
Contact information Cate Nagle - cate.nagle@mcri.edu.au
Notes
Schapira HRT
Trial name or title Menopause options
Methods
Participants Women considering menopause options
Interventions Decision aid CD-Rom versus pamphlet
Outcomes
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Schapira HRT (Continued)
Starting date Trial complete
Contact information mschap@mcw.edu
Notes
Scheid breastscreen
Trial name or title Breast screening decision aid
Methods
Participants Women considering breast screening
Interventions Decision aid computer balance sheets versus?
Outcomes
Starting date Ongoing
Contact information Dewey Scheid (Dewey-Scheid@ouhsc.edu)
Notes
Taylor prostate screening
Trial name or title Prostate cancer screening decision aid
Methods
Participants African American men considering prostate cancer screening
Interventions Decision aid videocassette versus ?
Outcomes
Starting date Ongoing
Contact information Katheryn Taylor (TAYLORKL@gunet.georgetown.edu)
Notes
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Tiller ovarian prevention
Trial name or title High risk ovarian cancer prevention
Methods
Participants Women at high risk for ovarian cancer
Interventions Decision aid booklet versus general education pamphlet
Outcomes
Starting date June 2001 to December 2003
Contact information k.tiller@unsw.edu.au
Notes
VanSteenkiste cholesterol
Trial name or title Decision aid to enhance implementation of cholesterol guideline in general practice
Methods
Participants 45 general practitioners (19 intervention, 26 controls) to recruit 20 patients each
Interventions Decision aid booklet, embedded in an extensive educational group session versus normal care (no booklet)
Outcomes Adherence to cholesterol guideline (GP), self-efficacy (GP), satisfaction with consultation (P), satisfaction
with the decision aid (P), self-reported lifestyle, risk perception (p), Weariness (P)
Starting date Trial complete
Contact information Ben VanSteenkiste
Centre of Quality of Care Research
Department of General Practice
Maastricht University
PO Box 616
6200 MDMaastricht
The Netherlands
Ben.vansteenkiste@hag.unimaas.nl
Notes
Whelan mixed formats
Trial name or title Development and evaluation of different versions of the decision board for early breast cancer
Methods
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Whelan mixed formats (Continued)
Participants Medical oncologists at the Hamilton Regional Cancer Centre and surgeons in Hamilton and surrounding
area
Interventions Standard version of the decision board versus computerized version of the decision board versus paper version
of the decision board
Outcomes Patient comprehension, usefulness of the decisionboard, patient satisfactionwith the decision board, physician
satisfaction and usefulness of the decision board
Starting date April 2002
Contact information Tim Whelan (Hamilton Regional Cancer Centre, tim.whelan@hrcc.on.ca) or Shelley Chambers (shel-
ley.chambers@hrcc.on.ca)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Decision aids (DA) versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Knowledge: DA vs usual care 18 3491 Mean Difference (IV, Random, 95% CI) 15.18 [11.66, 18.69]
2 Decisional conflict: DA vs usual
care
14 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Uncertainty subscale 12 2333 Mean Difference (IV, Random, 95% CI) -0.94 [-3.29, 1.40]
2.2 Uninformed subscale 10 1839 Mean Difference (IV, Random, 95% CI) -8.31 [-11.85, -4.78]
2.3 Unclear values subscale 8 1433 Mean Difference (IV, Random, 95% CI) -6.35 [-10.02, -2.67]
2.4 Unsupported subscale 8 1433 Mean Difference (IV, Random, 95% CI) -5.97 [-10.40, -1.55]
2.5 Ineffective choice subscale 11 2065 Mean Difference (IV, Random, 95% CI) -5.69 [-8.93, -2.46]
2.6 Total decisional conflict
score
10 1850 Mean Difference (IV, Random, 95% CI) -6.12 [-8.62, -3.63]
3 Participation in decision making:
DA vs usual care
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Patient controlled decision
making
7 1106 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.02, 2.65]
3.2 Shared decision making 7 1106 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.78, 1.25]
3.3 Practitioner controlled
decision making
8 1277 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.45, 0.82]
4 Satisfaction with the decision
making process: DA vs usual
care
3 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Satisfaction with the decision:
DA vs usual care
3 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Behaviour: Reduced proportion
remaining undecided, DA vs
usual care
4 1032 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.34, 0.75]
7 Choice: Surgery over
conservative option: DA vs
usual care
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 As treated analysis 8 1875 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.59, 0.94]
7.2 Intention to treat analysis 8 2069 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.60, 0.94]
8 Choice: PSA screening: DA vs
usual care
5 1442 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.66, 0.98]
9 Choice: Colon screening FOBT
+ sigmoid: DA vs usual care
3 735 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.70, 1.85]
10 Choice: Breast cancer genetic
testing: DA vs usual care
4 949 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.83, 1.22]
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Comparison 2. Detailed versus simple decision aids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Knowledge: Detailed vs simple
decision aids
9 1261 Mean Difference (IV, Random, 95% CI) 4.63 [3.02, 6.24]
2 Decisional conflict: Detailed vs
simple decision aid
9 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Uncertainty subscale 7 865 Mean Difference (IV, Random, 95% CI) -2.43 [-8.58, 3.72]
2.2 Uninformed subscale 5 612 Mean Difference (IV, Random, 95% CI) -1.32 [-5.27, 2.62]
2.3 Unclear values subscale 5 609 Mean Difference (IV, Random, 95% CI) -1.05 [-4.81, 2.70]
2.4 Unsupported subscale 5 614 Mean Difference (IV, Random, 95% CI) -0.80 [-3.77, 2.17]
2.5 Ineffective choice subscale 5 613 Mean Difference (IV, Random, 95% CI) -0.04 [-3.93, 3.86]
2.6 Total decisional conflict
score
7 1023 Mean Difference (IV, Random, 95% CI) -1.34 [-3.33, 0.64]
3 Participation in decision making:
Detailed vs simple decision aid
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Patient controlled decision
making
1 Risk Ratio (M-H, Random, 95% CI) Not estimable
3.2 Shared decision making 1 Risk Ratio (M-H, Random, 95% CI) Not estimable
3.3 Practitioner controlled
decision making
1 Risk Ratio (M-H, Random, 95% CI) Not estimable
4 Behaviour: Reduced proportion
remaining undecided: Detailed
vs simple decision aids
2 292 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.62]
5 Choice: Surgery over
conservative option: Detailed
vs simple decision aid
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 As treated analysis 2 404 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.55, 1.01]
5.2 Intention to treat analysis 2 453 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.57, 1.07]
6 Choice: PSA screening: Detailed
vs simple decision aid
3 677 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.17]
7 Choice: Hormone replacement
therapy: Detailed vs simple
decision aid
3 357 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.55, 0.98]
8 Choice: Prenatal diagnostic
testing: Detailed vs simple
decision aid
2 443 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.85, 1.04]
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Comparison 3. Accurate risk perceptions: Decision aid with outcome probabilities vs no outcome probability
information
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Accurate risk perceptions 11 2953 Risk Ratio (M-H, Random, 95% CI) 1.61 [1.35, 1.92]
2 Accurate risk perceptions -
numbers
8 2011 Risk Ratio (M-H, Random, 95% CI) 1.81 [1.43, 2.29]
3 Accurate risk perceptions - words 3 942 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.09, 1.48]
Analysis 1.1. Comparison 1 Decision aids (DA) versus usual care, Outcome 1 Knowledge: DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 1 Knowledge: DA vs usual care
Study or subgroup Decision Aid Usual Care Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Laupacis 2006 53 83 (19.5) 53 67.4 (17) 5.3 % 15.60 [ 8.64, 22.56 ]
Whelan 2003 82 80.2 (14.4) 93 71.7 (13.3) 6.2 % 8.50 [ 4.37, 12.63 ]
Gattellari 2005 131 57.2 (21.3) 136 42.2 (16.7) 6.0 % 15.00 [ 10.40, 19.60 ]
Bernstein 1998 61 83 (16) 48 58 (16) 5.6 % 25.00 [ 18.95, 31.05 ]
Gattellari 2003 106 50 (18.4) 108 45 (15.9) 6.0 % 5.00 [ 0.39, 9.61 ]
Morgan 2000 86 75 (32.04) 94 62 (32.04) 4.6 % 13.00 [ 3.63, 22.37 ]
Volk 1999 78 48 (21.6) 80 31 (18.8) 5.5 % 17.00 [ 10.68, 23.32 ]
Johnson 2006 32 92.6 (11) 35 85.2 (15.6) 5.5 % 7.40 [ 0.98, 13.82 ]
Montgomery 2003 50 75 (17) 58 60 (18) 5.4 % 15.00 [ 8.39, 21.61 ]
Man-Son-Hing 1999 137 75.91 (15.72) 136 66.46 (16.07) 6.2 % 9.45 [ 5.68, 13.22 ]
Shorten 2005 99 75.33 (15) 92 60.53 (17.07) 6.0 % 14.80 [ 10.23, 19.37 ]
Bekker 2004 50 74 (14.5) 56 71.5 (16) 5.7 % 2.50 [ -3.31, 8.31 ]
Barry 1997 104 75 (45) 123 54 (45) 3.8 % 21.00 [ 9.25, 32.75 ]
Wong 2006 154 85 (26.7) 159 60 (21.7) 5.8 % 25.00 [ 19.60, 30.40 ]
Schwartz 2001 191 65.71 (14.29) 190 57.14 (15.71) 6.4 % 8.57 [ 5.55, 11.59 ]
Dunn 1998 143 83.67 (23.13) 144 55.53 (22.8) 5.8 % 28.14 [ 22.83, 33.45 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Green 2001a 29 95 (7) 14 65 (21) 4.0 % 30.00 [ 18.71, 41.29 ]
Lerman 1997 122 68.9 (19) 164 49 (21.7) 6.0 % 19.90 [ 15.17, 24.63 ]
Total (95% CI) 1708 1783 100.0 % 15.18 [ 11.66, 18.69 ]
Heterogeneity: Tau2 = 47.70; Chi2 = 130.35, df = 17 (P<0.00001); I2 =87%
Test for overall effect: Z = 8.47 (P < 0.00001)
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Analysis 1.2. Comparison 1 Decision aids (DA) versus usual care, Outcome 2 Decisional conflict: DA vs
usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 2 Decisional conflict: DA vs usual care
Study or subgroup Decision Aid Usual Care Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Uncertainty subscale
Gattellari 2003 106 42.5 (20) 108 42.5 (33.33) 7.5 % 0.0 [ -7.35, 7.35 ]
Morgan 2000 86 35 (13) 94 32.5 (13) 10.8 % 2.50 [ -1.30, 6.30 ]
Man-Son-Hing 1999 139 21 (21) 148 19.75 (19) 10.0 % 1.25 [ -3.39, 5.89 ]
Murray 2001b 94 52.5 (25) 96 60 (27.5) 7.4 % -7.50 [ -14.97, -0.03 ]
McAlister 2005 205 20 (20) 202 17.5 (17.5) 10.9 % 2.50 [ -1.15, 6.15 ]
Murray 2001a 57 35 (20) 48 42.5 (20) 7.3 % -7.50 [ -15.18, 0.18 ]
Gattellari 2005 131 30.83 (19.25) 136 29.17 (15) 10.5 % 1.66 [ -2.49, 5.81 ]
Laupacis 2006 54 20.5 (18.75) 55 23 (21) 7.4 % -2.50 [ -9.97, 4.97 ]
Montgomery 2003 50 35.5 (20.47) 58 47.99 (25.14) 6.5 % -12.49 [ -21.10, -3.88 ]
Dolan 2002 41 27 (19.25) 37 26 (24.25) 5.7 % 1.00 [ -8.79, 10.79 ]
Bekker 2004 50 45 (20.83) 56 45 (25.83) 6.3 % 0.0 [ -8.89, 8.89 ]
Wong 2006 136 38.25 (22.5) 146 40 (20.83) 9.6 % -1.75 [ -6.82, 3.32 ]
Subtotal (95% CI) 1149 1184 100.0 % -0.94 [ -3.29, 1.40 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 7.43; Chi2 = 20.91, df = 11 (P = 0.03); I2 =47%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Uninformed subscale
Murray 2001b 93 29.93 (17.26) 93 38.89 (22.53) 9.6 % -8.96 [ -14.73, -3.19 ]
Murray 2001a 52 27.56 (10.51) 45 38.88 (20.02) 8.9 % -11.32 [ -17.83, -4.81 ]
Man-Son-Hing 1999 139 15.75 (13.25) 148 21 (14.75) 12.1 % -5.25 [ -8.49, -2.01 ]
Montgomery 2003 50 22.17 (9.47) 58 49.14 (25.4) 8.4 % -26.97 [ -34.01, -19.93 ]
Laupacis 2006 54 16.25 (13.75) 54 27.25 (15) 10.0 % -11.00 [ -16.43, -5.57 ]
Morgan 2000 86 20 (21.5) 94 27.5 (21.5) 9.1 % -7.50 [ -13.79, -1.21 ]
McAlister 2005 205 15 (12.5) 202 20 (15) 12.6 % -5.00 [ -7.68, -2.32 ]
Dolan 2002 41 15.75 (13) 37 24.5 (21.25) 7.6 % -8.75 [ -16.67, -0.83 ]
Bekker 2004 50 32.5 (15) 56 31.67 (14.17) 9.8 % 0.83 [ -4.74, 6.40 ]
Wong 2006 136 21.75 (15) 146 25.75 (15) 11.9 % -4.00 [ -7.50, -0.50 ]
Subtotal (95% CI) 906 933 100.0 % -8.31 [ -11.85, -4.78 ]
Heterogeneity: Tau2 = 24.79; Chi2 = 48.65, df = 9 (P<0.00001); I2 =81%
Test for overall effect: Z = 4.61 (P < 0.00001)
3 Unclear values subscale
Laupacis 2006 54 18.75 (16.5) 55 30 (17) 11.1 % -11.25 [ -17.54, -4.96 ]
Murray 2001a 53 35.38 (12.33) 45 40.56 (16.44) 11.6 % -5.18 [ -11.02, 0.66 ]
Man-Son-Hing 1999 139 16.25 (12.5) 148 19 (14.75) 14.8 % -2.75 [ -5.91, 0.41 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 15.3 % -2.50 [ -5.18, 0.18 ]
Murray 2001b 82 37.5 (15) 84 42.85 (16.57) 12.9 % -5.35 [ -10.16, -0.54 ]
Montgomery 2003 50 28.5 (12.5) 58 51.29 (25.73) 9.7 % -22.79 [ -30.26, -15.32 ]
Morgan 2000 86 30 (3.25) 94 30 (3.25) 16.5 % 0.0 [ -0.95, 0.95 ]
Dolan 2002 41 19.75 (15.75) 37 29.25 (24) 8.1 % -9.50 [ -18.61, -0.39 ]
Subtotal (95% CI) 710 723 100.0 % -6.35 [ -10.02, -2.67 ]
Heterogeneity: Tau2 = 21.26; Chi2 = 57.65, df = 7 (P<0.00001); I2 =88%
Test for overall effect: Z = 3.39 (P = 0.00071)
4 Unsupported subscale
Murray 2001a 53 32.7 (12.75) 45 40.56 (17.1) 11.7 % -7.86 [ -13.92, -1.80 ]
Murray 2001b 85 36.47 (14.43) 82 48.68 (15.46) 13.7 % -12.21 [ -16.75, -7.67 ]
Morgan 2000 86 30 (24.75) 94 32.5 (24.75) 10.3 % -2.50 [ -9.74, 4.74 ]
Man-Son-Hing 1999 139 16.25 (13) 148 16.5 (14) 15.4 % -0.25 [ -3.37, 2.87 ]
Laupacis 2006 53 17.25 (15.75) 55 24 (17.25) 11.5 % -6.75 [ -12.98, -0.52 ]
Montgomery 2003 50 23.67 (10.96) 58 40.52 (19.83) 11.9 % -16.85 [ -22.79, -10.91 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McAlister 2005 205 15 (15) 202 15 (15) 15.6 % 0.0 [ -2.91, 2.91 ]
Dolan 2002 41 21 (13.5) 37 23.25 (20) 9.9 % -2.25 [ -9.91, 5.41 ]
Subtotal (95% CI) 712 721 100.0 % -5.97 [ -10.40, -1.55 ]
Heterogeneity: Tau2 = 32.77; Chi2 = 45.99, df = 7 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.65 (P = 0.0081)
5 Ineffective choice subscale
Murray 2001a 57 25 (10) 48 30 (15) 9.2 % -5.00 [ -9.97, -0.03 ]
Man-Son-Hing 1999 139 13.5 (13) 148 15.5 (14.75) 10.7 % -2.00 [ -5.21, 1.21 ]
Montgomery 2003 50 26 (11.11) 58 35.13 (17.2) 8.8 % -9.13 [ -14.52, -3.74 ]
Morgan 2000 86 20 (32) 94 22.5 (32) 5.7 % -2.50 [ -11.86, 6.86 ]
Laupacis 2006 53 15 (14.5) 55 21.25 (16) 8.5 % -6.25 [ -12.00, -0.50 ]
Murray 2001b 94 30 (15) 96 37.5 (17.5) 9.5 % -7.50 [ -12.13, -2.87 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 11.1 % -2.50 [ -5.18, 0.18 ]
Dolan 2002 41 20.5 (14.5) 37 25.75 (21) 6.6 % -5.25 [ -13.34, 2.84 ]
Whelan 2004 94 12.5 (12) 107 17 (13) 10.5 % -4.50 [ -7.96, -1.04 ]
Wong 2006 136 19.38 (13.13) 159 36.67 (19.17) 10.3 % -17.29 [ -21.00, -13.58 ]
Bekker 2004 50 22.5 (13.75) 56 21.88 (14.38) 8.9 % 0.62 [ -4.74, 5.98 ]
Subtotal (95% CI) 1005 1060 100.0 % -5.69 [ -8.93, -2.46 ]
Heterogeneity: Tau2 = 23.04; Chi2 = 56.49, df = 10 (P<0.00001); I2 =82%
Test for overall effect: Z = 3.45 (P = 0.00056)
6 Total decisional conflict score
Murray 2001b 94 37.5 (12.5) 96 45 (15) 11.1 % -7.50 [ -11.42, -3.58 ]
Morgan 2000 86 27.5 (37.5) 94 27.5 (37.5) 5.2 % 0.0 [ -10.97, 10.97 ]
Murray 2001a 57 32.5 (10) 48 40 (12.5) 10.6 % -7.50 [ -11.89, -3.11 ]
Montgomery 2003 50 27.1 (10) 58 44.2 (19.3) 9.4 % -17.10 [ -22.79, -11.41 ]
Laupacis 2006 53 17.5 (13.75) 54 25.25 (14.25) 9.7 % -7.75 [ -13.06, -2.44 ]
McAlister 2005 205 15 (12.5) 202 17.5 (12.5) 12.3 % -2.50 [ -4.93, -0.07 ]
Man-Son-Hing 1999 139 16.25 (11.25) 148 18.5 (13.5) 12.0 % -2.25 [ -5.12, 0.62 ]
Dolan 2002 41 20.75 (13) 37 25.75 (20.25) 7.6 % -5.00 [ -12.64, 2.64 ]
Whelan 2004 94 10 (12) 107 15.5 (12.9) 11.5 % -5.50 [ -8.94, -2.06 ]
Shorten 2005 99 23.5 (12.5) 88 29.5 (18.25) 10.5 % -6.00 [ -10.54, -1.46 ]
Subtotal (95% CI) 918 932 100.0 % -6.12 [ -8.62, -3.63 ]
Heterogeneity: Tau2 = 10.17; Chi2 = 29.87, df = 9 (P = 0.00046); I2 =70%
Test for overall effect: Z = 4.81 (P < 0.00001)
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Analysis 1.3. Comparison 1 Decision aids (DA) versus usual care, Outcome 3 Participation in decision
making: DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 3 Participation in decision making: DA vs usual care
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Patient controlled decision making
Murray 2001b 49/94 53/95 20.8 % 0.93 [ 0.72, 1.22 ]
Morgan 2000 17/86 14/94 14.1 % 1.33 [ 0.70, 2.53 ]
Auvinen 2004 44/103 9/100 13.8 % 4.75 [ 2.45, 9.20 ]
Davison 1997 17/30 5/30 10.9 % 3.40 [ 1.44, 8.03 ]
Dolan 2002 9/43 15/43 13.0 % 0.60 [ 0.29, 1.22 ]
Murray 2001a 18/57 2/48 5.7 % 7.58 [ 1.85, 31.03 ]
Man-Son-Hing 1999 85/137 80/146 21.7 % 1.13 [ 0.93, 1.38 ]
Subtotal (95% CI) 550 556 100.0 % 1.65 [ 1.02, 2.65 ]
Total events: 239 (Decision Aid), 178 (Usual Care)
Heterogeneity: Tau2 = 0.30; Chi2 = 40.59, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.06 (P = 0.039)
2 Shared decision making
Man-Son-Hing 1999 36/137 43/146 14.7 % 0.89 [ 0.61, 1.30 ]
Davison 1997 10/30 15/30 11.3 % 0.67 [ 0.36, 1.24 ]
Morgan 2000 42/86 38/94 15.4 % 1.21 [ 0.87, 1.68 ]
Murray 2001a 34/57 42/48 16.5 % 0.68 [ 0.54, 0.87 ]
Murray 2001b 40/94 36/95 15.1 % 1.12 [ 0.79, 1.59 ]
Dolan 2002 27/43 22/43 14.8 % 1.23 [ 0.85, 1.78 ]
Auvinen 2004 25/103 17/100 12.2 % 1.43 [ 0.82, 2.48 ]
Subtotal (95% CI) 550 556 100.0 % 0.99 [ 0.78, 1.25 ]
Total events: 214 (Decision Aid), 213 (Usual Care)
Heterogeneity: Tau2 = 0.06; Chi2 = 16.40, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Practitioner controlled decision making
Davison 1997 3/30 10/30 7.8 % 0.30 [ 0.09, 0.98 ]
Whelan 2003 6/80 12/91 10.6 % 0.57 [ 0.22, 1.45 ]
Morgan 2000 25/86 39/94 19.5 % 0.70 [ 0.47, 1.05 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Murray 2001a 5/57 4/48 7.2 % 1.05 [ 0.30, 3.70 ]
Dolan 2002 7/43 6/43 9.7 % 1.17 [ 0.43, 3.19 ]
Murray 2001b 5/94 6/95 8.1 % 0.84 [ 0.27, 2.67 ]
Man-Son-Hing 1999 16/137 23/146 15.9 % 0.74 [ 0.41, 1.34 ]
Auvinen 2004 31/103 73/100 21.2 % 0.41 [ 0.30, 0.57 ]
Subtotal (95% CI) 630 647 100.0 % 0.61 [ 0.45, 0.82 ]
Total events: 98 (Decision Aid), 173 (Usual Care)
Heterogeneity: Tau2 = 0.05; Chi2 = 10.22, df = 7 (P = 0.18); I2 =32%
Test for overall effect: Z = 3.32 (P = 0.00089)
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Analysis 1.4. Comparison 1 Decision aids (DA) versus usual care, Outcome 4 Satisfaction with the decision
making process: DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 4 Satisfaction with the decision making process: DA vs usual care
Study or subgroup Decision Aid Usual Care Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bernstein 1998 61 73.1 (20.6) 48 76.5 (17.6) -3.40 [ -10.58, 3.78 ]
Morgan 2000 86 72 (19.88) 94 70 (19.88) 2.00 [ -3.81, 7.81 ]
Barry 1997 104 76.38 (16.5) 117 71.07 (18.4) 5.31 [ 0.71, 9.91 ]
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Analysis 1.5. Comparison 1 Decision aids (DA) versus usual care, Outcome 5 Satisfaction with the decision:
DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 5 Satisfaction with the decision: DA vs usual care
Study or subgroup Decision Aid Usual Care Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Morgan 2000 86 80 (26) 94 77.5 (26) 2.50 [ -5.10, 10.10 ]
Bernstein 1998 61 73.1 (20.9) 48 77.7 (20.5) -4.60 [ -12.42, 3.22 ]
Barry 1997 104 75.89 (17.2) 117 73.9 (18) 1.99 [ -2.65, 6.63 ]
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Analysis 1.6. Comparison 1 Decision aids (DA) versus usual care, Outcome 6 Behaviour: Reduced
proportion remaining undecided, DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 6 Behaviour: Reduced proportion remaining undecided, DA vs usual care
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Man-Son-Hing 1999 1/139 9/148 3.6 % 0.12 [ 0.02, 0.92 ]
Vuorma 2003 8/184 20/179 22.8 % 0.39 [ 0.18, 0.86 ]
Murray 2001b 13/94 25/96 37.7 % 0.53 [ 0.29, 0.97 ]
Shorten 2005 14/99 20/93 36.0 % 0.66 [ 0.35, 1.22 ]
Total (95% CI) 516 516 100.0 % 0.51 [ 0.34, 0.75 ]
Total events: 36 (Decision Aid), 74 (Usual Care)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.15, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 3.43 (P = 0.00060)
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Analysis 1.7. Comparison 1 Decision aids (DA) versus usual care, Outcome 7 Choice: Surgery over
conservative option: DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 7 Choice: Surgery over conservative option: DA vs usual care
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 As treated analysis
Kennedy 2002 82/253 101/244 18.2 % 0.78 [ 0.62, 0.99 ]
Bernstein 1998 25/61 28/48 13.3 % 0.70 [ 0.48, 1.03 ]
Vuorma 2003 98/184 88/179 19.2 % 1.08 [ 0.89, 1.32 ]
Murray 2001a 6/54 1/48 1.0 % 5.33 [ 0.67, 42.73 ]
Morgan 2000 45/86 63/95 17.7 % 0.79 [ 0.62, 1.01 ]
Whelan 2004 6/94 26/107 5.1 % 0.26 [ 0.11, 0.61 ]
Barry 1997 8/103 16/116 5.4 % 0.56 [ 0.25, 1.26 ]
Auvinen 2004 60/103 91/100 20.1 % 0.64 [ 0.54, 0.76 ]
Subtotal (95% CI) 938 937 100.0 % 0.75 [ 0.59, 0.94 ]
Total events: 330 (Decision Aid), 414 (Usual Care)
Heterogeneity: Tau2 = 0.06; Chi2 = 25.77, df = 7 (P = 0.00055); I2 =73%
Test for overall effect: Z = 2.52 (P = 0.012)
2 Intention to treat analysis
Vuorma 2003 98/184 88/179 19.7 % 1.08 [ 0.89, 1.32 ]
Murray 2001a 6/57 1/55 1.0 % 5.79 [ 0.72, 46.54 ]
Morgan 2000 45/120 63/120 16.8 % 0.71 [ 0.54, 0.95 ]
Kennedy 2002 82/300 101/298 18.3 % 0.81 [ 0.63, 1.03 ]
Bernstein 1998 25/65 28/53 13.2 % 0.73 [ 0.49, 1.09 ]
Auvinen 2004 60/104 91/106 20.3 % 0.67 [ 0.56, 0.81 ]
Barry 1997 8/104 16/123 5.5 % 0.59 [ 0.26, 1.33 ]
Whelan 2004 6/94 26/107 5.2 % 0.26 [ 0.11, 0.61 ]
Subtotal (95% CI) 1028 1041 100.0 % 0.75 [ 0.60, 0.94 ]
Total events: 330 (Decision Aid), 414 (Usual Care)
Heterogeneity: Tau2 = 0.06; Chi2 = 23.71, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 2.45 (P = 0.014)
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Analysis 1.8. Comparison 1 Decision aids (DA) versus usual care, Outcome 8 Choice: PSA screening: DA vs
usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 8 Choice: PSA screening: DA vs usual care
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Gattellari 2003 27/106 25/108 11.6 % 1.10 [ 0.69, 1.77 ]
Gattellari 2005 37/131 42/136 16.0 % 0.91 [ 0.63, 1.33 ]
Volk 1999 48/78 64/80 27.3 % 0.77 [ 0.63, 0.95 ]
Partin 2004 83/308 87/290 23.4 % 0.90 [ 0.70, 1.16 ]
Wolf 1996 40/103 68/102 21.7 % 0.58 [ 0.44, 0.77 ]
Total (95% CI) 726 716 100.0 % 0.80 [ 0.66, 0.98 ]
Total events: 235 (Decision Aid), 286 (Usual Care)
Heterogeneity: Tau2 = 0.02; Chi2 = 8.35, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 2.22 (P = 0.027)
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Analysis 1.9. Comparison 1 Decision aids (DA) versus usual care, Outcome 9 Choice: Colon screening
FOBT + sigmoid: DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 9 Choice: Colon screening FOBT + sigmoid: DA vs usual care
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Pignone 2000 46/124 28/124 39.9 % 1.64 [ 1.10, 2.45 ]
Dolan 2002 2/45 7/43 8.6 % 0.27 [ 0.06, 1.24 ]
Wolf 2000 173/266 79/133 51.5 % 1.09 [ 0.93, 1.29 ]
Total (95% CI) 435 300 100.0 % 1.14 [ 0.70, 1.85 ]
Total events: 221 (Decision Aid), 114 (Usual Care)
Heterogeneity: Tau2 = 0.11; Chi2 = 6.91, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.54 (P = 0.59)
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Analysis 1.10. Comparison 1 Decision aids (DA) versus usual care, Outcome 10 Choice: Breast cancer
genetic testing: DA vs usual care.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Decision aids (DA) versus usual care
Outcome: 10 Choice: Breast cancer genetic testing: DA vs usual care
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Green 2004 65/106 64/105 35.2 % 1.01 [ 0.81, 1.25 ]
Schwartz 2001 35/191 49/190 17.9 % 0.71 [ 0.48, 1.04 ]
Green 2001a 13/29 16/42 10.0 % 1.18 [ 0.67, 2.06 ]
Lerman 1997 74/122 87/164 37.0 % 1.14 [ 0.93, 1.40 ]
Total (95% CI) 448 501 100.0 % 1.01 [ 0.83, 1.22 ]
Total events: 187 (Decision Aid), 216 (Usual Care)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.10, df = 3 (P = 0.16); I2 =41%
Test for overall effect: Z = 0.07 (P = 0.94)
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Analysis 2.1. Comparison 2 Detailed versus simple decision aids, Outcome 1 Knowledge: Detailed vs simple
decision aids.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 1 Knowledge: Detailed vs simple decision aids
Study or subgroup Detailed DA Simple DA Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Deyo 2000 41 71.76 (17.06) 49 62.35 (23.53) 3.7 % 9.41 [ 1.00, 17.82 ]
Rostom 2002 25 93.8 (9) 26 87.1 (11.8) 7.8 % 6.70 [ 0.95, 12.45 ]
Goel 2001 77 81.67 (11.11) 48 80 (12.22) 14.3 % 1.67 [ -2.59, 5.93 ]
Dodin 2001 52 71.04 (15.45) 49 61.2 (17.9) 6.1 % 9.84 [ 3.30, 16.38 ]
Hunter 2005 116 64.53 (19.61) 126 60.13 (19) 10.9 % 4.40 [ -0.47, 9.27 ]
Street 1995 30 82.6 (11.6) 30 76.4 (13.8) 6.2 % 6.20 [ -0.25, 12.65 ]
O’Connor 1998a 81 75 (20) 84 71 (21) 6.6 % 4.00 [ -2.26, 10.26 ]
Schapira 2000 122 83.33 (12.78) 135 78.33 (15) 22.4 % 5.00 [ 1.60, 8.40 ]
Rothert 1997 83 86.79 (11.34) 87 83.75 (11.54) 21.9 % 3.04 [ -0.40, 6.48 ]
Total (95% CI) 627 634 100.0 % 4.63 [ 3.02, 6.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.18, df = 8 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 5.63 (P < 0.00001)
-100 -50 0 50 100
Favours Simple Favours Detailed
98Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Detailed versus simple decision aids, Outcome 2 Decisional conflict: Detailed vs
simple decision aid.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 2 Decisional conflict: Detailed vs simple decision aid
Study or subgroup Detailed DA Simple DA Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Uncertainty subscale
vanRoosmalen 2004 38 27.5 (22.5) 42 32.5 (25) 11.2 % -5.00 [ -15.41, 5.41 ]
O’Connor 1999a 101 40 (30) 100 32.5 (30) 15.7 % 7.50 [ -0.79, 15.79 ]
Goel 2001 76 35.25 (25.75) 46 41.75 (26) 12.9 % -6.50 [ -15.99, 2.99 ]
Dodin 2001 52 45 (28) 49 34 (25) 11.3 % 11.00 [ 0.66, 21.34 ]
Lalonde 2006 12 27 (7) 12 36.75 (12) 16.9 % -9.75 [ -17.61, -1.89 ]
Rothert 1997 83 40 (24.5) 89 50 (25) 18.3 % -10.00 [ -17.40, -2.60 ]
O’Connor 1998a 81 42.5 (30) 84 45 (30) 13.6 % -2.50 [ -11.66, 6.66 ]
Subtotal (95% CI) 443 422 100.0 % -2.43 [ -8.58, 3.72 ]
Heterogeneity: Tau2 = 47.90; Chi2 = 20.14, df = 6 (P = 0.003); I2 =70%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Uninformed subscale
O’Connor 1999a 101 22.5 (17.5) 100 20 (17.5) 24.1 % 2.50 [ -2.34, 7.34 ]
Goel 2001 76 20.75 (10.75) 45 24 (16) 22.3 % -3.25 [ -8.51, 2.01 ]
Dodin 2001 52 17.5 (12.5) 49 22.25 (14.75) 21.9 % -4.75 [ -10.10, 0.60 ]
Lalonde 2006 12 38.25 (12) 12 31.25 (10.75) 11.3 % 7.00 [ -2.12, 16.12 ]
O’Connor 1998a 81 22.5 (17.5) 84 27.5 (20) 20.4 % -5.00 [ -10.73, 0.73 ]
Subtotal (95% CI) 322 290 100.0 % -1.32 [ -5.27, 2.62 ]
Heterogeneity: Tau2 = 11.22; Chi2 = 9.24, df = 4 (P = 0.06); I2 =57%
Test for overall effect: Z = 0.66 (P = 0.51)
3 Unclear values subscale
O’Connor 1999a 97 22.5 (15) 100 20 (15) 26.2 % 2.50 [ -1.69, 6.69 ]
Goel 2001 77 24 (12.5) 45 25.75 (15.75) 21.1 % -1.75 [ -7.13, 3.63 ]
Dodin 2001 52 25 (13.75) 49 24.75 (13.5) 21.3 % 0.25 [ -5.07, 5.57 ]
Lalonde 2006 12 39.5 (10.75) 12 37.5 (13) 10.2 % 2.00 [ -7.54, 11.54 ]
O’Connor 1998a 81 25 (17.5) 84 32.5 (17.5) 21.2 % -7.50 [ -12.84, -2.16 ]
Subtotal (95% CI) 319 290 100.0 % -1.05 [ -4.81, 2.70 ]
Heterogeneity: Tau2 = 9.89; Chi2 = 9.02, df = 4 (P = 0.06); I2 =56%
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(. . . Continued)
Study or subgroup Detailed DA Simple DA Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.55 (P = 0.58)
4 Unsupported subscale
O’Connor 1999a 101 27.5 (15) 100 25 (17.5) 25.4 % 2.50 [ -2.01, 7.01 ]
Goel 2001 78 24.75 (14.5) 45 24.5 (11) 25.2 % 0.25 [ -4.30, 4.80 ]
Dodin 2001 52 22.5 (16.5) 49 25.5 (17.75) 17.0 % -3.00 [ -9.69, 3.69 ]
Lalonde 2006 12 37.5 (14) 12 36 (12) 9.1 % 1.50 [ -8.93, 11.93 ]
O’Connor 1998a 81 27.5 (15) 84 32.5 (17.5) 23.3 % -5.00 [ -9.97, -0.03 ]
Subtotal (95% CI) 324 290 100.0 % -0.80 [ -3.77, 2.17 ]
Heterogeneity: Tau2 = 3.26; Chi2 = 5.61, df = 4 (P = 0.23); I2 =29%
Test for overall effect: Z = 0.53 (P = 0.60)
5 Ineffective choice subscale
Goel 2001 78 19.75 (14) 44 22.5 (14.75) 21.6 % -2.75 [ -8.10, 2.60 ]
O’Connor 1999a 101 25 (17.5) 100 20 (15) 25.2 % 5.00 [ 0.50, 9.50 ]
Dodin 2001 52 25 (17.75) 49 25.5 (17.75) 16.2 % -0.50 [ -7.43, 6.43 ]
Lalonde 2006 12 27.5 (5) 12 25 (10.75) 16.8 % 2.50 [ -4.21, 9.21 ]
O’Connor 1998a 81 25 (17.5) 84 30 (20) 20.1 % -5.00 [ -10.73, 0.73 ]
Subtotal (95% CI) 324 289 100.0 % -0.04 [ -3.93, 3.86 ]
Heterogeneity: Tau2 = 10.98; Chi2 = 9.18, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 0.02 (P = 0.99)
6 Total decisional conflict score
O’Connor 1999a 90 25 (12.5) 94 22.5 (15) 15.8 % 2.50 [ -1.48, 6.48 ]
Goel 2001 78 24.5 (13) 45 27 (11.5) 14.6 % -2.50 [ -6.93, 1.93 ]
Dodin 2001 52 27.25 (14) 49 26.25 (15) 11.6 % 1.00 [ -4.67, 6.67 ]
Lalonde 2006 12 34 (7.5) 12 33.25 (7.5) 10.9 % 0.75 [ -5.25, 6.75 ]
Legare 2003 97 28.5 (15) 87 30 (15) 14.8 % -1.50 [ -5.84, 2.84 ]
Hunter 2005 116 43.25 (12.5) 126 46.25 (12.5) 18.2 % -3.00 [ -6.15, 0.15 ]
O’Connor 1998a 81 27.5 (15) 84 32.5 (15) 14.2 % -5.00 [ -9.58, -0.42 ]
Subtotal (95% CI) 526 497 100.0 % -1.34 [ -3.33, 0.64 ]
Heterogeneity: Tau2 = 2.06; Chi2 = 8.47, df = 6 (P = 0.21); I2 =29%
Test for overall effect: Z = 1.33 (P = 0.19)
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Analysis 2.3. Comparison 2 Detailed versus simple decision aids, Outcome 3 Participation in decision
making: Detailed vs simple decision aid.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 3 Participation in decision making: Detailed vs simple decision aid
Study or subgroup Detailed DA Simple DA Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Patient controlled decision making
Deschamps 2004 25/48 16/43 1.40 [ 0.87, 2.25 ]
2 Shared decision making
Deschamps 2004 22/48 24/43 0.82 [ 0.55, 1.23 ]
3 Practitioner controlled decision making
Deschamps 2004 1/48 2/43 0.45 [ 0.04, 4.77 ]
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Analysis 2.4. Comparison 2 Detailed versus simple decision aids, Outcome 4 Behaviour: Reduced
proportion remaining undecided: Detailed vs simple decision aids.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 4 Behaviour: Reduced proportion remaining undecided: Detailed vs simple decision aids
Study or subgroup Detailed DA Simple DA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Leung 2004 5/100 8/101 16.6 % 0.63 [ 0.21, 1.86 ]
Deschamps 2004 23/48 18/43 83.4 % 1.14 [ 0.72, 1.81 ]
Total (95% CI) 148 144 100.0 % 1.04 [ 0.66, 1.62 ]
Total events: 28 (Detailed DA), 26 (Simple DA)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 2.5. Comparison 2 Detailed versus simple decision aids, Outcome 5 Choice: Surgery over
conservative option: Detailed vs simple decision aid.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 5 Choice: Surgery over conservative option: Detailed vs simple decision aid
Study or subgroup Detailed DA Simple DA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 As treated analysis
Deyo 2000 44/171 57/173 84.8 % 0.78 [ 0.56, 1.09 ]
Street 1995 7/30 12/30 15.2 % 0.58 [ 0.27, 1.28 ]
Subtotal (95% CI) 201 203 100.0 % 0.75 [ 0.55, 1.01 ]
Total events: 51 (Detailed DA), 69 (Simple DA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
2 Intention to treat analysis
Deyo 2000 44/190 57/203 84.1 % 0.82 [ 0.59, 1.16 ]
Street 1995 7/30 12/30 15.9 % 0.58 [ 0.27, 1.28 ]
Subtotal (95% CI) 220 233 100.0 % 0.78 [ 0.57, 1.07 ]
Total events: 51 (Detailed DA), 69 (Simple DA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
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Analysis 2.6. Comparison 2 Detailed versus simple decision aids, Outcome 6 Choice: PSA screening:
Detailed vs simple decision aid.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 6 Choice: PSA screening: Detailed vs simple decision aid
Study or subgroup Detailed DA Simple DA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Frosch 2003 86/106 86/94 46.9 % 0.89 [ 0.79, 0.99 ]
Myers 2005a 20/108 11/112 6.3 % 1.89 [ 0.95, 3.75 ]
Schapira 2000 100/122 113/135 46.8 % 0.98 [ 0.88, 1.09 ]
Total (95% CI) 336 341 100.0 % 0.97 [ 0.81, 1.17 ]
Total events: 206 (Detailed DA), 210 (Simple DA)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.96, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.28 (P = 0.78)
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Analysis 2.7. Comparison 2 Detailed versus simple decision aids, Outcome 7 Choice: Hormone
replacement therapy: Detailed vs simple decision aid.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 7 Choice: Hormone replacement therapy: Detailed vs simple decision aid
Study or subgroup Detailed DA Simple DA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Dodin 2001 21/52 31/49 53.7 % 0.64 [ 0.43, 0.95 ]
Deschamps 2004 16/48 19/43 30.4 % 0.75 [ 0.45, 1.27 ]
O’Connor 1998a 13/81 12/84 15.9 % 1.12 [ 0.55, 2.31 ]
Total (95% CI) 181 176 100.0 % 0.73 [ 0.55, 0.98 ]
Total events: 50 (Detailed DA), 62 (Simple DA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
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Analysis 2.8. Comparison 2 Detailed versus simple decision aids, Outcome 8 Choice: Prenatal diagnostic
testing: Detailed vs simple decision aid.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Detailed versus simple decision aids
Outcome: 8 Choice: Prenatal diagnostic testing: Detailed vs simple decision aid
Study or subgroup Detailed DA Simple DA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leung 2004 94/100 98/101 56.9 % 0.97 [ 0.91, 1.03 ]
Hunter 2005 64/116 77/126 43.1 % 0.90 [ 0.73, 1.12 ]
Total (95% CI) 216 227 100.0 % 0.94 [ 0.85, 1.04 ]
Total events: 158 (Detailed DA), 175 (Simple DA)
Heterogeneity: Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.24 (P = 0.22)
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Analysis 3.1. Comparison 3 Accurate risk perceptions: Decision aid with outcome probabilities vs no
outcome probability information, Outcome 1 Accurate risk perceptions.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Accurate risk perceptions: Decision aid with outcome probabilities vs no outcome probability information
Outcome: 1 Accurate risk perceptions
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Man-Son-Hing 1999 88/139 40/148 9.1 % 2.34 [ 1.75, 3.14 ]
Whelan 2003 47/82 34/92 8.6 % 1.55 [ 1.12, 2.15 ]
McAlister 2005 66/175 25/155 7.3 % 2.34 [ 1.56, 3.51 ]
Gattellari 2003 57/106 11/108 5.1 % 5.28 [ 2.93, 9.50 ]
Whelan 2004 73/94 62/107 10.6 % 1.34 [ 1.10, 1.63 ]
Dodin 2001 33/52 21/49 7.7 % 1.48 [ 1.01, 2.17 ]
Lerman 1997 90/122 108/164 11.1 % 1.12 [ 0.96, 1.31 ]
Schapira 2000 82/122 62/135 10.2 % 1.46 [ 1.17, 1.83 ]
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(. . . Continued)
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
O’Connor 1998a 58/81 39/84 9.5 % 1.54 [ 1.18, 2.02 ]
Wolf 2000 189/266 72/133 10.8 % 1.31 [ 1.10, 1.56 ]
McBride 2002 109/265 82/274 10.0 % 1.37 [ 1.09, 1.73 ]
Total (95% CI) 1504 1449 100.0 % 1.61 [ 1.35, 1.92 ]
Total events: 892 (Decision Aid), 556 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 52.16, df = 10 (P<0.00001); I2 =81%
Test for overall effect: Z = 5.34 (P < 0.00001)
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Analysis 3.2. Comparison 3 Accurate risk perceptions: Decision aid with outcome probabilities vs no
outcome probability information, Outcome 2 Accurate risk perceptions - numbers.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Accurate risk perceptions: Decision aid with outcome probabilities vs no outcome probability information
Outcome: 2 Accurate risk perceptions - numbers
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Man-Son-Hing 1999 88/139 40/148 13.3 % 2.34 [ 1.75, 3.14 ]
Whelan 2003 47/82 34/92 12.7 % 1.55 [ 1.12, 2.15 ]
McAlister 2005 66/175 25/155 11.1 % 2.34 [ 1.56, 3.51 ]
Gattellari 2003 57/106 11/108 8.2 % 5.28 [ 2.93, 9.50 ]
Whelan 2004 73/94 62/107 15.0 % 1.34 [ 1.10, 1.63 ]
Dodin 2001 33/52 21/49 11.6 % 1.48 [ 1.01, 2.17 ]
O’Connor 1998a 58/81 39/84 13.8 % 1.54 [ 1.18, 2.02 ]
McBride 2002 109/265 82/274 14.4 % 1.37 [ 1.09, 1.73 ]
Total (95% CI) 994 1017 100.0 % 1.81 [ 1.43, 2.29 ]
Total events: 531 (Decision Aid), 314 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 33.16, df = 7 (P = 0.00002); I2 =79%
Test for overall effect: Z = 4.96 (P < 0.00001)
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Analysis 3.3. Comparison 3 Accurate risk perceptions: Decision aid with outcome probabilities vs no
outcome probability information, Outcome 3 Accurate risk perceptions - words.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Accurate risk perceptions: Decision aid with outcome probabilities vs no outcome probability information
Outcome: 3 Accurate risk perceptions - words
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Wolf 2000 189/266 72/133 34.5 % 1.31 [ 1.10, 1.56 ]
Schapira 2000 82/122 62/135 27.2 % 1.46 [ 1.17, 1.83 ]
Lerman 1997 90/122 108/164 38.4 % 1.12 [ 0.96, 1.31 ]
Total (95% CI) 510 432 100.0 % 1.27 [ 1.09, 1.48 ]
Total events: 361 (Decision Aid), 242 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.38, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 3.06 (P = 0.0022)
0.1 0.2 0.5 1 2 5 10
Favours control Favours Decision Aid
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE,1966 to July 2006, OVID platform
001 choice behavior/
002 decision making/
003 exp decision support techniques/
004 Educational Technology/
005 decision$.tw.
006 (choic$ or preference$).tw.
007 communication package.tw.
008 or/1-7
009 exp health education/
010 Health knowledge, Attitudes, Practice/
011 informed consent.tw,hw.
012 patient.tw,hw.
013 consumer.tw,hw.
014 or/9-13
015 8 and 14
016 ((patient$ or consumer$) adj1 (decision$ or choice or preference or participation)).tw.
017 ((women or men) adj1 (decision$ or choice or preference or participation)).tw.
018 (parent$ adj1 (decision$ or choice or preferenc$ or participat$)).tw.
019 ((personal or interpersonal or individual) adj (decision$ or choice or preference$ or participat$)).tw.
020 shared decision making.tw.
021 decision aid$.tw.
022 informed choice.tw.
106Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
023 or/16-22
024 15 or 23
025 clinical trial.pt.
026 randomised controlled trial.pt.
027 random$.tw.
028 (double adj blind$).tw.
029 double-blind method/
030 or/25-29
031 24 and 30
Appendix 2. CENTRAL search strategy
CENTRAL, The Cochrane Library, Issue 2 2006
001 choice behavior/
002 decision making/
003 exp decision support techniques/
004 Educational Technology/
005 decision$.tw.
006 (choic$ or preference$).tw.
007 communication package.tw.
008 or/1-7
009 exp health education/
010 Health knowledge, Attitudes, Practice/
011 informed consent.tw,hw.
012 patient.tw,hw.
013 consumer.tw,hw.
014 or/9-13
015 8 and 14
016 ((patient$ or consumer$) adj1 (decision$ or choice or preference or participation)).tw.
017 ((women or men) adj1 (decision$ or choice or preference or participation)).tw.
018 (parent$ adj1 (decision$ or choice or preferenc$ or participat$)).tw.
019 ((personal or interpersonal or individual) adj (decision$ or choice or preference$ or participat$)).tw.
020 shared decision making.tw.
021 decision aid$.tw.
022 informed choice.tw.
023 or/16-22
024 15 or 23
Appendix 3. CINAHL search strategy
CINAHL, 1982 to July 2006, OVID platform
001 exp Decision Making/
002 information seeking behavior/
003 Help Seeking Behavior/
004 (choic$ or preference$).tw.
005 decision$.tw.
006 Educational Technology/
007 or/1-6
008 exp Health Behavior/
009 consumer participation/
010 exp Health Education/
011 health knowledge/ or exp professional knowledge/
012 exp Consent/
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013 informed consent.tw.
014 patient.tw,hw.
015 consumer.tw,sh.
016 or/8-15
017 7 and 16
018 ((patient$ or consumer$) adj1 (decision$ or choice or preference or participation)).tw.
019 ((women or men) adj1 (decision$ or choice or preference or participation)).tw.
020 (parent$ adj1 (decision$ or choice or preferenc$ or participati$)).tw.
021 ((personal or interpersonal or individual) adj (decision$ or choice or preference$ or participat$)).tw.
022 shared decision making.tw.
023 decision aid$.tw.
024 informed choice.tw.
025 or/18-24
026 17 or 25
027 exp clinical trials/
028 Clinical trial.pt.
029 (clinic$ adj trial$1).tw.
030 random$.tw.
031 Random assignment/
032 placebo$.tw,sh.
033 Quantitative studies/
034 Allocat$ random$.tw.
035 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$3)).tw.
036 or/27-35
037 26 and 36
Appendix 4. EMBASE search strategy
EMBASE,1980 to July 2006, OVID platform
001 decision making/
002 decision theory/
003 decision$.tw.
004 Educational Technology/
005 or/1-4
006 exp health behavior/
007 exp Patient Attitude/
008 exp health education/
009 informed consent.tw,sh.
010 patient.tw,sh.
011 consumer.tw,sh.
012 or/6-11
013 5 and 12
014 ((patient$ or consumer$) adj1 (decision$ or choice or preference or participation)).tw.
015 ((women or men) adj1 (decision$ or choice or preference or participation)).tw.
016 (parent$ adj1 (decision$ or choice or preferenc$ or participat$)).tw.
017 ((personal or interpersonal or individual) adj (decision$ or choice or preference$ or participat$)).tw.
018 shared decision making.tw.
019 decision aid$.tw.
020 informed choice.tw.
021 or/14-20
022 13 or 21
023 Controlled Study/
024 Randomized Controlled Trial/
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025 Clinical Study/
026 Clinical Trial/
027 Major Clinical Study/
028 Prospective Study/
029 Multicenter Study/
030 Randomization/
031 Double Blind Procedure/
032 Single Blind Procedure/
033 Crossover Procedure/
034 Placebo.tw,sh.
035 random$.tw.
036 (double adj blind$).tw.
037 or/23-36
038 22 and 37
Appendix 5. PsycINFO search strategy
PsycINFO, 1806 to July 2006, OVID platform
001 decision$.tw.
002 (choic$ or preference$).tw.
003 exp decision making/
004 computer assisted instruction/
005 or/1-4
006 exp health education/
007 exp health personnel attitudes/
008 informed consent.tw,sh.
009 patient.tw,hw.
010 consumer.tw,hw.
011 exp health behavior/
012 or/6-11
013 5 and 12
014 ((patient$ or consumer$) adj1 (decision$ or choice or preference or participation)).tw
015 ((women or men) adj1 (decision$ or choice or preference or participation)).tw
016 (parent$ adj1 (decision$ or choice or preferenc$ or participat$)).tw
017 ((personal or interpersonal or individual) adj (decision$ or choice or preference$ or participat$)).tw
018 shared decision making.tw.
019 decision aid$.tw.
020 informed choice.tw.
021 or/14-20
016 13 or 21
017 random$.tw.
018 (double adj blind$).tw.
019 placebo$.tw,hw.
020 or/23-25
021 22 and 26
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WH A T ’ S N E W
Last assessed as up-to-date: 30 June 2006.
29 April 2009 New citation required and conclusions have changed A substantially updated version of this review was published
on issue 1 2009 of The Cochrane Library. The changes are
outlined in the ’History’ (date 28 July 2006). The updated
review ought to have had a new citation to reflect the new
authorship and substantial changes to the review and its
conclusions; however because of a technical error this new
citation was not given to the updated review.
The new citation for this review for issue 3 2009 reflects the
updated review contents as actually published from issue 1
2009 onwards.
29 April 2009 New search has been performed See above, and the ’History’ item dated 28 July 2006.
28 April 2009 Amended Corrected mislabelled table ’Summary of pooled outcomes’.
H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 3, 2001
17 July 2008 Amended Converted to new review format.
28 July 2006 New search has been performed Changes for the 2006 update (first published on issue 1 2009 of The Cochrane
Library):
• Outcomes focus on the new effectiveness criteria of the International
Patient Decision Aids Standards (IPDAS) Collaboration
• There are now 55 randomised controlled trials evaluating decision aids
in the review. Twenty-five new randomised controlled trials have been
added for this update. Four trials that were previously included were
excluded from this review as the decision support intervention was not
available to determine whether it met the inclusion criteria - a requirement
for this update in light of the new IPDAS standards.There are an additional
15 trials in progress.
• The number of included countries has doubled from the last update.
We now have results from 7 countries (AU, CA, China, Finland,
Netherlands, US, UK).
Findings from the 2006 update (*new to this update):
• * Thirty-eight trials used at least one measure that mapped onto an
IPDAS effectiveness criteria. No trials evaluated the extent to which patient
decision aids achieve the IPDAS decision process criteria: helped patients to
recognize that a decision needs to be made, understand that values affect the
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(Continued)
decision, or discuss values with their practitioner.
• * Exposure to a decision aid with probabilities resulted in a higher
proportion of people with accurate risk perceptions; the effect was stronger
when probabilities were measure quantitatively rather than qualitatively.
• Compared to usual care, exposure to decision aids improved
knowledge, decreased decisional conflict, reduced the proportion of people
who were passive in decision making, reduced the proportion who
remained undecided, and reduced rates of elective invasive surgery.
• Detailed decision aids (compared to simpler decision aids) improved
knowledge and reduced the uptake of hormone replacement therapy.
• * Compared to usual care, exposure to decision aids reduced PSA
screening.
• There are too few studies to comment on the effects of decision aids
on length of the consult, patient-practitioner communication, persistence
with chosen option, costs, and resource use.
21 February 2003 New search has been performed For the 2002 update (O’Connor 2003b), the following changes were made:
• There are now 221 decision aids (increased from 87) that have been
identified for the inventory with 131 available and up-to-date: many of
which are available on the Internet. However few have undergone any form
of evaluation for impact on decision making.
• There are now 35 randomized controlled trials evaluating decision aids
in the review. Eleven new randomized controlled trials have been added for
this update including 1 large scale trial that evaluated a suite of 8 decision
aids in a number of health services.
• There are an additional 6 trials pending publication and 24 trials in
progress.
• In conjunction with the benefits reported in the earlier reports, there is
now evidence that decision aids compared to usual care also help with
making actual choices and there is a statistically significant reduction in
major elective surgery by a quarter. Detailed compared to simple decision
aids also show an improved agreement between values and actual choice.
• There continues to be too few studies to comment on the effects of
decision aids on persistence with chosen therapy, costs, resource use, or
efficacy of dissemination.
C O N T R I B U T I O N S O F A U T H O R S
1999 Review (O’Connor 1999b):
AO, AR, VF, JT, VE, HLT, MHR, VF, MB, JJ contributed to the design of the protocol, the interpretation of results, and the revision
and final approval of the final paper.
AO led the team, JT coordinated the project.
AO, MH-R, AR, VF, and JT pilot tested the data extraction forms.
AR, VF, JT screened studies and extracted data.
AR, JT, and AO analysed results.
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2001 Review (O’Connor 2001b):
AO, DS, DR, MHR, HLT, VE, MB, JT, VF, AR contributed to the interpretation of results, and the revision and final approval of the
final paper.
AO lead the team and DS coordinated the update.
AO, DR, MHR, HLT, JT, DS, JP screened studies and extracted data.
DS, JP evaluated decision aids using the CREDIBLE criteria.
AO and DS analysed the results.
2002 Review (O’Connor 2003b):
AO, DS, DR, MHR, HLT, VE, MB, JT, VF contributed to the interpretation of results, and the revision and final approval of the
paper.
AO lead the team and DS coordinated the update.
DS, JP, VT, JT screened studies and extracted data.
DS, JP, VT, SK evaluated decision aids using the CREDIBLE criteria.
AO and DS analysed the results.
2006 (current) Review:
AO, CB, DS, MB, NC, KE, VE, VF, MHR, SK, HLT, DR, contributed to the interpretation of results, and the revision and final
approval of the paper.
AO led the team and CB coordinated the update.
CB, SK, DS, AO, VF screened studies and extracted data.
AO and CB analysed the results.
D E C L A R A T I O N S O F I N T E R E S T
Several of the investigators have developed patient decision aids (AO, DS, HL, MH, MB, NC, KE), but none reviewed their own
studies. Three investigators (AO, HL, MB) receive support from the not-for-profit Foundation for InformedMedical Decision Making
(FIMDM). FIMDM has a licensing agreement with Health Dialog (a commercial firm) that distributes and promotes patient decision
aids. NC is co-founder of Strategic Health Decisions, an organization devoted to the development and dissemination of interactive
patient decision aids.
S O U R C E S O F S U P P O R T
Internal sources
• Agency for Healthcare Research and Quality, USA.
KE is currently directing patient decision aid development for the John M. Eisenberg Clinical Decisions and Communications
Science Center funded by the Agency for Healthcare Research and Quality (HHSA29020050013C) and located at Oregon Health &
Science University in Portland, Oregon.
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External sources
• Canadian Institutes of Health Research, Canada.
Group Grant in Decision Support Tools for Clinicians and Patients (MGC 42668) provided salary (CB, SK) and material (systematic
review software) support.
• Canada Research Chair Program, Canada.
AO holds a Tier 1 Canada Research Chair in Health Care Consumer Decision Support.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Decision Support Techniques; ∗Patient Participation; Patient Education as Topic [∗methods]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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